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Tregs that accumulate in the encephalomyocarditis virus-infected mouse brain: 
Origin, compartmentalization, function, and gene signature 
Sarah Puhr 
It is well recognized that regulatory T cells (Tregs) are immunosuppressive, by 
which they prevent systemic autoimmunity throughout life. Beyond this stereotypical 
function, however, a growing body of evidence demonstrates that Tregs in distinct 
tissues, including the visceral adipose tissue, dystrophic muscle, the flu-infected lung, 
and wounded skin can acquire unique functions directed by their local environment. 
Tregs in these tissues can employ a wide variety of mechanisms to accumulate and 
acquire tissue-specific function, including conversion from conventional T cells, 
canonical T cell receptor (TCR)-dependent expansion and non-canonical, TCR-
independent, cytokine-dependent expansion. Intriguingly, the niche-specific function of 
tissue Tregs can be independent of, and mutually exclusive of, their immunosuppressive 
capacity. Together, this recent literature reveals that Tregs can accumulate in discrete 
tissue sites through non-canonical mechanisms, and in response to niche-specific cues 
can acquire distinct functions, which distinguish them from their peripheral, lymphoid 
Treg counterparts. Other tissue Treg populations remain to be identified and 
characterized. Moreover, it is unknown whether other tissue Tregs rely on non-canonical 
mechanisms of accumulation, and exhibit functions distinct from the typical Treg 
immunosuppressive role.  
Tregs are known to accumulate in the CNS during infection, injury and 
inflammation. The CNS is an organ with distinctive architecture that maintains a 
regulated interaction with the peripheral immune system due to its critical function and 
poor regenerative capacity. While it is known that Tregs broadly protect against 
excessive tissue pathology in the diseased CNS, the origin, localization, function, 
mechanism of accumulation, and gene signature of CNS-infiltrating Tregs have not been 
studied, likely due to the challenge of isolating these rare cells and distinguishing them 
from circulating cells left over after perfusion.  
Here, we establish a safe model of CNS infection using encephalomyocarditis 
virus and employ a series of methods to locate, monitor and isolate CNS-infiltrating 
Tregs free from contamination from the circulation. We show that a distinct population of 
thymus-derived Tregs accumulates within the cerebrospinal fluid (CSF) of the EMCV-
infected CNS, independently of lymph node priming. Tregs function in this unique niche 
to limit excessive tissue pathology. While CNS Tregs maintain expression of core Treg 
signature genes, including FoxP3, their global transcriptome is more similar to that of 
conventional T cells (Tcons) harvested from the infected CNS than to that of peripheral 
Tregs. Bioinformatics analysis reveals that genes shared by CNS Tcons and CNS Tregs 
are also shared by Tregs and Tcons from injured muscle and from the visceral adipose 
tissue of aged mice, indicating that tissue inflammation and injury, rather than viral 
infection per se, contribute to CNS Treg accumulation, function and phenotype.  
Additionally, we observe that CNS Treg accumulation during infection is 
associated with a simultaneous increase in meningeal/choroid plexus dendritic cells 
(m/chDCs), which are professional antigen presenting cells that localize to the gates of
the CNS. Splenic cDC and peripheral lymphoid Treg homeostasis are linked, and both 
populations can be artificially increased by treatment with the DC-poietin and adjuvant, 
Ftlt3L. Therefore, we hypothesized that CNS Tregs and m/chDCs may also be linked and 
could also be manipulated by Flt3L treatment. Indeed, treatment with Flt3L in 
conjunction with EMCV infection results in enhanced CNS Treg and m/chDC 
accumulation, independent of Flt3 receptor expression on Tregs. In an effort to determine 
if dendritic cells mediate CNS Treg increase during infection, we turned to a DC-ablative 
mouse model in which all CD11c-expressing cells express the catalytic subunit of 
diphtheria toxin and are depleted. Surprisingly, while splenic cDCs are completely 
abrogated in these mice, a portion of m/chDCs persists, unaffected. Moreover, CNS 
Tregs accumulate normally in these mice during infection. This data suggests an 
unappreciated heterogeneity in m/chDCs, and indicates that those that remain unaffected 
in these mice may mediate CNS Treg accumulation during infection. While 
characterizing m/chDC heterogeneity, we found that m/chDCs comprise three distinct 
subsets with unknown potential. Whereas m/chDCs were previously considered to be a 
homogeneous, CD45hiB220-CD11c+MHCII+ population, we have found them to contain 
three subsets, distinguishable by IRF8 and FcR-γ expression. This finding paves the way 
for further study of the origin, localization, and division of labor between these three 
m/chDC subsets.  
In summary, our studies clarify the distinct compartmentalization, lymph node-
independent accumulation, and inflammation-associated gene signature of CNS Tregs. 
Most importantly, these findings have implications for neuro-immune cross-talk, 
particularly at the interface of the CSF and brain parenchyma. That is, neural progenitors 
extend their apical domains into the CSF of the ventricles, and therefore may be subject 
to regulation by CSF-borne Tregs. Further, while many studies have focused on the 
differences between tissue Treg subsets, we find a core set of genes expressed by CNS 
Tregs, injured muscle Tregs and VAT Tregs. This data suggests that common 
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Chapter I. Introduction 
Our bodies are protected from infection throughout life by cellular and molecular 
components of the two arms of the immune system—the innate immune system and the 
adaptive immune system. Innate immune responses are always available to provide 
immediate protection against a wide range of pathogens but they do not lead to lasting 
immunity and are not specific for any individual pathogen. In contrast, adaptive immune 
responses or acquired immune responses, which take days rather than hours to develop, 
are specific to a single pathogen, adapt to fight an infection, and can lead to life-long 
protection against reinfection with the same pathogen (i.e. immunological memory). 
Adaptive immune responses are specific to vertebrates and are carried out by 
lymphocytes—T cells and B cells.  
T cell receptors expressed on the surface of T cells, and B cell receptors expressed 
on the surface of T cells recognize specific peptides known as antigens, which derive 
from self or pathogen proteins that are processed and presented on the cell surface of 
antigen presenting cells (APCs). The enormous and diverse repertoire of antigen 
receptors on lymphocytes, resultant from germline rearrangements during lymphocyte 
development, allows the recognition of near infinite numbers of antigens. Naïve T cells, 
which are generated in the thymus after antigen receptor development, migrate through 
circulation to seed lymphoid sites such as spleen and peripheral lymph nodes where they 
are educated by APCs. After antigen presentation by activated APCs and antigen 
recognition by T cells expressing the cognate T cell receptor, these antigen-specific T 
cells become activated, expand by proliferation, and generate a large pool of effector T 
cells. Effector T cells can be heterogeneous in phenotype and function, allowing for a 
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tailor-made, pathogen-specific immune response. A portion of those lymphocytes that 
have expanded during an adaptive immune response persist after pathogen clearance so 
that a second exposure to the same pathogen is faster and greater in magnitude, thereby 
creating immunological memory.  
During these complex immune responses, the immune system must be carefully 
regulated so that body tissues are not damaged. One mechanism of immune tolerance is 
the deletion of self-reactive T cells in the thymus during T cell development in a process 
known as clonal deletion. However, some auto-reactive T cells escape clonal deletion. 
These T cells can cause damage in the periphery if they encounter their auto-antigen on 
an APC and become activated. Early studies suggested a cellular mechanism by which 
these self-reactive T cells are regulated. While the existence and identity of this cellular 
mediator of immune tolerance were initially controversial, it is now widely accepted that 
a subset of CD4+ T cells, termed regulatory T cells, is responsible for regulating self-
reactive T cells and maintaining immune homeostasis.  
 
1. Regulatory T cells: seminal findings revealed their canonical immunosuppressive 
role  
Early studies show that suppressive function is contained within CD25+CD4+ T cells 
Regulatory T cells (Tregs) are an essential subset of CD4+ αβ T cells that 
maintain immune and tissue homeostasis throughout adult life (reviewed in (1)). Even 
early experiments hinted at the existence of an immunosuppressive population of T cells. 
These experiments demonstrated that neonatal thymectomy of wild-type (WT) mice 
between two and four days after birth resulted in the autoimmune destruction of ovarian 
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tissue (2), thyroiditis, orchitis, prostatitis, and sialadenitis, that correlated with the 
detection of tissue-specific autoantibodies in the circulation (3). This phenotype was not 
only restricted to neonatal thymectomized mice, as adult rats that underwent thymectomy 
followed by sublethal irradiation also acquired autoimmune thyroiditis (4) and type 1 
diabetes (5). Adoptive transfer of WT T cells into neonatal thymectomized mice 
ameliorated disease symptoms (6, 7), implicating a population of T cells in the control of 
tissue homeostasis. In particular, adoptive transfer of CD4+ T cells inhibited autoimmune 
disease in thymectomized mice (6). Furthermore, adoptive transfer of CD4+ T cells 
harvested from thymectomized mice into T cell-deficient, athymic, BALB/c nude mice 
induced autoimmunity in recipient mice (8). Together these experiments demonstrated 
that CD4+ T cells include at least two subsets: one capable of suppressing autoimmunity 
and one that mediated autoimmune disease. 
These early experiments prompted the search for a marker that would distinguish 
these two subsets of CD4+ T cells. While several markers were initially put forth, such as 
CD5 (9), CD45RB (10, 11), and CD45RC (12), their singular expression was not 
sufficient to define the immunosuppressive T cell subset. Instead, suppressive capacity 
was found to be restricted to IL-2 receptor α-expressing (CD25)-expressing CD4+ cells. 
As evidence, T cell-deficient, athymic, BALB/c nude mice receiving adoptive transfers of 
CD25-depleted, CD4+ T cells quickly succumbed to a variety of autoimmune diseases 
while co-transfer of CD25+ cells protected against autoimmunity (13). The presence of 
CD25 and other activation markers, such as CTLA4, on these cells, led some to postulate 
that they were a set of chronically activated T cells, mediating immunosuppression by 
depriving other cells types of critical resources, rather than a dedicated, 
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immunosuppressive T cell type (14). However, transfer of CD25+ cells into WT, neonatal 
mice thymectomized three days after birth, protected against multi-organ inflammation, 
demonstrating that suppressor function exists in a long-lasting, thymically derived 
population (15). Moreover, while lack of proliferation in vitro in the presence of IL-2 
suggested that CD4+CD25+ T cells were chronically activated and anergic, adoptive 
transfer of CD4+CD25+ T cells into lymphopenic mice lead to their robust proliferation 
and increased suppressive capacity despite reduction in CD25 expression (16, 17). 
Therefore, suppressive CD4+CD25+ T cells represent a distinct, immune-modulatory 
subset rather than population of constitutively activated, anergic cells. The observations 
that these suppressive CD4+CD25+ T cells constituted a distinct subset prompted the 
search for the molecular mechanism underlying their identity and their function.  
 
The transcription factor, Foxp3, controls Treg development, maintenance, and function 
Human patients and scurfy mice with loss-of-function mutations in the X-
chromosome-encoded transcription factor, Forkhead Box P3 (FoxP3) suffered from fatal, 
early-onset, multi-organ, T cell-dependent autoimmunity at an early age, mirroring the 
phenotype mediated by CD25-depleted, CD4+ T cell transfer into lymphopenic mice (18-
24). These data suggested that FoxP3 was the functional marker of Tregs. Indeed, 
CD4+CD25+ T cells were shown to be enriched for FoxP3 mRNA and protein expression, 
and forced expression of FoxP3 using retroviral vectors imbued CD4+CD25- T cells with 
suppressive capacity (25-27). Additionally, analysis of knock-in mice expressing 
fluorescent reporter protein under control of the endogenous FoxP3 regulatory elements, 
revealed that FoxP3 protein expression is concentrated predominantly in suppressive 
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CD4+ T cells (28, 29). Furthermore, CD25hi and CD25lo FoxP3+CD4+ T cells shared a 
regulatory gene signature (17, 30), distinct from CD25hiFoxP3- cells, arguing that FoxP3 
expression, and not CD25 expression, specifies a regulatory gene signature (28).  
Conclusive evidence that FoxP3 controls the development and function of Tregs 
was facilitated by the generation of additional mouse models such as FoxP3fl/fl mice, 
which allowed constitutive depletion of FoxP3-expressing cells when crossed to a Cre 
deleter strain (FoxP3ko) (25, 28), as well as FoxP3DTR and FoxP3-DTR-eGFP BAC 
(DEREG) mice (31, 32), which could be conditionally depleted of FoxP3-expressing T 
cells after diphtheria toxin (Dtx) treatment. These models demonstrated that loss of 
FoxP3, whether from birth (25, 31) or conditionally in adulthood (31), resulted in loss of 
CD4+CD25+ cells (25) and a corresponding lymphoproliferative disorder, 
lymphadenopathy and splenomegaly, wasting disease characterized by weight loss, 
failure to thrive and reduced mobility, and severe conjunctivitis (31). Adoptive transfer of 
CD4+CD25+ cells back into one- to two-day-old Treg-deficient mice recovered myelo- 
and lymphoproliferative syndrome, together indicating a cell-intrinsic requirement for 
FoxP3 in the suppressive function of CD4+CD25+ cells (25, 33). As further evidence that 
FoxP3 is required for Treg suppressor function, experimental attenuation of FoxP3 levels 
using a targeted knock-in results in impaired suppressor function in FoxP3+ Tregs (34). 
Additionally, ablating FoxP3 in CD4+ cells, including CD4+ T cells, using CD4-Cre x 
FoxP3fl/fl mice was phenotypically indistinguishable from the germ-line deletion, 
demonstrating that the lack of FoxP3+ in CD4+ cells was responsible for the systemic 
autoimmunity observed in FoxP3ko mice (28). Moreover, mixed adoptive transfer of WT 
and FoxP3ko bone marrow into congenic recipients demonstrated that FoxP3-deficient 
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cells cannot give rise to CD4+CD25+ Tregs, indicating that FoxP3 is also required for the 
generation of CD4+CD25+ Tregs (25). All together these studies demonstrated that 
expression of the transcription factor FoxP3 in CD4+ T cells is required for the generation 
of Tregs, the regulation of their suppressive function, and maintenance of tissue 
homeostasis throughout adult life. Armed with genetic tools to identify, track and deplete 
Tregs, numerous studies subsequently investigated the origin, homeostasis and 
mechanisms of function of Tregs. In this work, we refer to the broad group of TCRβ+ 
CD4+ FoxP3- cells as conventional T cells, or Tcons, based on nomenclature that has 
been commonly published in sources such as (35-40) and (41). While this group of cells 
includes distinct and important subsets of T cells, including naïve, effector and memory T 
cells, others and we use this nomenclature to distinguish the group of them from FoxP3-
expressing Tregs. 
 
Two types of Tregs exist in vivo, with similar suppressive capacity but distinct origin, 
distribution and antigen recognition 
The majority of Tregs are generated in the thymus (deemed natural, nTregs or 
thymic, tTregs) from immature T cell precursors at the double positive, CD4+CD8+ stage, 
or single positive, CD4+ stage, (28, 42-46). The induction of FoxP3 in the thymus 
generally occurs in the presence of IL-2, IL-7, and IL-15, in precursors that have high 
affinity for self-antigens, which are presented on medullary thymic epithelial cells 
(mTECs) (1, 47-53). In support of the fact that antigen presentation by mTECs promotes 
Treg development, the generation of influenza hemagglutinin (HA)-specific Tregs can be 
artificially forced by transgenic expression of influenza hemagglutinin in mTECS (49). 
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Additionally, the high affinity of Treg TCRs for self antigens  is demonstrated by the fact 
that Tregs consistently express higher levels of Nur77 than their conventional T cell 
(Tcon) counterparts; Nur77 is an indicator of TCR signal strength (54-56). Due to their 
selection on self antigens, the TCR repertoire of peripheral nTregs is biased towards self-
antigens (50). The self-antigen-biased TCR repertoire of Tregs was demonstrated by TCR 
sequencing of the TCRα chain of CD25+CD4+ cells in mice expressing variable TCRα 
chains and fixed TCRβ chains (50). Subsequently retroviral expression of TCRα genes 
enriched in CD25+CD4+ cells into TCR transgenic Rag1-/- T cells, followed by adoptive 
transfer of transgenic T cells into lymphopenic, Rag1-/- mice, resulted in a rapid 
expansion of adoptively transferred T cells, indicating that T cells expressing Treg TCRs 
recognize constitutively presented self antigens (50). However, TCR sequencing of the 
TCRα chain of CD25-CD4+ cells in the same study revealed that a fraction of the Tcon 
TCR repertoire overlaps with Treg TCR repertoire (50) indicating that Tregs are not 
necessarily more “self-reactive” than their Tcon counterparts.  
Tregs can also be generated in the periphery from naïve CD4+ T cells that up-
regulate FoxP3 and covert to FoxP3+CD4+ cells (termed induced, iTregs or peripheral, 
pTregs). The evidence that these Tregs are generated in the periphery and not the thymus 
came from observation that immunosuppressive, CD4+CD25+ T cells arose in 
thymectomized mice that received a chronic, low dose of antigen through osmotic pump 
(57). pTregs are generally dependent upon TGF-β (58, 59), and can be generated under a 
number of conditions including chronic exposure to low-dose antigen (57, 60), oral 
administration of antigen (61), exposure to commensals in the gut (62, 63) and during 
helminth infection (64). As such, compared to their frequencies in lymphoid organs, 
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pTregs are present in greater frequencies in tissues like the gut, lung airway, and skin 
where they are constantly exposed to foreign antigen and allergens (52, 65). It follows, 
then, the TCR repertoire of pTregs is predominantly specific for foreign antigens. That is 
not to say that pTregs are always specific for foreign antigens, however, as myelin basic 
protein (MBP)-TCR transgenic Rag1-/- mice Tregs are devoid of thymic nTregs but can 
generate Tregs in the periphery (66). Similarly, Tregs develop in the periphery and not 
the thymus of insulin-specific TCR transgenic mice (67). 
The recognition that at least two different types of Tregs exist in vivo led to a 
search for markers that would distinguish them from one another. Initially, gene 
expression analysis of CD4+CD25+ and CD4+CD25- T cells suggested that expression of 
Helios, an Ikaros family transcription factor, was restricted to natural, and not induced or 
in vitro generated, CD4+FoxP3+ cells (68). However, later studies demonstrated that 
Helios was also up-regulated in FoxP3- Th2 and follicular helper T (Tfh) cells (69), as 
well as in activated and proliferating Tregs (70), indicating that Helios expression is not 
exclusive to nTregs. Additional studies searching for a marker to define thymus-derived 
nTregs, turned to MBP-TCR transgenic Rag1-/- mice, where pTregs are spontaneously 
generated in the periphery. By comparing the gene expression of pTregs from MBP-TCR 
transgenic Rag1-/- mice to that of WT FoxP3+ Tregs, it was found that while expression of 
FoxP3 and CD25 did not differ between the two groups, nTregs up-regulated neuropilin-
1 (Nrp-1) and programmed cell death-1 (PD-1) compared to their pTreg counterparts 
(66). The expression of Nrp-1 and PD-1 in nTregs was corroborated by a separate study 
which used oral immunization of OVA-specific, TCR transgenic Rag1-/- mice with 
ovalbumin to generate pTregs in the gut and compare their gene expression to Tregs 
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harvested from the mesenteric lymph node (mLN) of WT mice (71). This study (71) also 
revealed that pTregs expressed higher levels of Dapl1 and Igfbp4 compared to their 
pTreg counterparts. However, Weiss et al (71) also found that Nrp-1 could also be up-
regulated on pTregs in the CNS during spontaneous autoimmune encephalomyelitis 
(EAE) and in the lungs of mice with chronic asthma (71), indicating that Nrp-1 
expression is not necessarily restricted to nTregs. In sum, nTregs and pTregs can 
generally be distinguished by Nrp-1, Dapl1 and Igfbp4, but these markers are not 
absolute. 
The recognition that at least two different types of Tregs exist in vivo also 
prompted the search for functional differences between nTregs and pTregs. While the 
division of labor between the two types is still relatively unstudied, pTregs are no less 
suppressive than nTregs (71-74). This similarity in functional capacity was demonstrated, 
in part, by submitting both CD4+Nrp-1- pTregs and CD4+Nrp-1+ nTregs to in vitro 
suppression assays and demonstrating that both populations equally suppressed naïve T 
cell proliferation in vitro (72). Interestingly, one study demonstrated that nTregs and 
pTregs can synergize in certain instances to protect tissues. That is, only the adoptive 
transfer of both pTregs and nTregs is sufficient to protect against colitis in Rag1-/- mice 
receiving adoptive transfer of CD4+ T cells that cannot induce FoxP3 (i.e. CD4+ T cells 
from FoxP3-deficient donors) (74). Such synergy is postulated to be due to distinct 
antigen-specificities of pTregs and nTregs (74), In total, two types of FoxP3-expressing 
Tregs can be generated in vivo with similar suppressive capacity but distinct tissue 
distribution and antigen recognition.  
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Mechanisms of Treg-mediated immunosuppression and regulation of related gene 
signature 
Tregs maintain immune homeostasis throughout adult life by suppressing a 
variety of cells, including CD4+ and CD8+ T cells (75-78), dendritic cells (79, 80), B cells 
(81), macrophages (82, 83), osteoblasts (84), mast cells (85), NK cells (86-88), and NKT 
cells (89) through contact-dependent (90) and contact-independent mechanisms (91), 
though they are best known for suppressing the proliferation of self-reactive T cells. 
Tregs mediate these functions through the expression of inhibitory cytokines such as IL-
10 (92, 93), TGF-β (90), and IL-35 (94, 95), competition for IL-2 resulting in Bim-
mediated apoptosis of other T cells (96), granzyme-mediated cytolysis of other T cells 
(86, 97), and expression of inhibitory cell surface molecules, such as Glatectin-1 (98, 99), 
CTLA4 (93, 100-102), LAG-3 (103), CD39 (104, 105), and Nrp-1 (106).  
The canonical immunosuppressive Treg gene program requires TCR engagement, 
since deletion of the TCR in FoxP3-cre mice results in down-regulation of ~59% of the 
putative Treg suppressor genes, correlating with a reduced capacity to prevent intestinal 
pathology in an adoptive transfer model of colitis (107-109). To elaborate, TCR-
deficiency in mature Tregs results in significant down-regulation of CD73, CTLA-4, 
GITR, IL-10, IL-10r, Nrp1 and Lag3 and the reduced expression of these molecules is 
associated with an inability to suppress autoimmunity (110, 111). In contrast, continuous 
TCR signaling is not required for the maintenance of FoxP3 expression, since deletion of 
the TCR in the same model does not result in loss of FoxP3 expression (108, 111).  
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Mechanisms of Treg homeostasis 
 The identification of Tregs as CD25 (IL-2Rα)-expressing T cells suggested an 
intrinsic requirement for IL-2 in their maintenance and/or function. While in vitro assays 
including standard IL-2 concentrations used to promote Tcon proliferation failed to 
stimulate the proliferation of Tregs, Treg populations in vivo are dependent upon Il-2. 
That is, IL-2- or IL2rα-deficient mice exhibit a severe lymphoproliferative syndrome, 
corresponding to ~50% reduction in Tregs (112-115). Adoptive transfer of IL2rα-
sufficient Tregs into IL2rα-deficient mice abrogates disease, together indicating that IL-2 
controls Treg homeostasis and IL-2 signaling in Tregs prevents lymphoproliferative 
disease (112, 115). Data suggest that IL-2 may work downstream of TCR stimulation to 
promote Treg survival. That is, Treg precursors that receive TCR stimulation up-regulate 
CD25, permitting them to respond to IL-2 and induce FoxP3 expression in a STAT-5-
dependent manner (113). Other common γ chain cytokines also play role in Treg 
homeostasis. That is, IL-7 and IL-15 contribute to Treg homeostasis but appear to play 
redundant roles (115). For example, only deficiency of IL-2, IL-7 and IL-15 is sufficient 
to completely abolish peripheral Treg populations (115).  
Treg homeostasis also depends on the cell surface molecule CD28. CD28 is a co-
stimulatory molecule constitutively expressed on the cell surface of naïve T cells, which 
is critical for optimal naïve T cell activation, cytokine production, proliferation, and 
survival (116, 117). CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins, 
which are up-regulated on activated antigen presenting cells (118). Engagement of the 
TCR:MHC complex that occurs in the absence of CD28:B7 co-stimulation results in T 
cell anergy (118, 119). Beyond its critical function in naïve T cell activation, cytokine 
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production, proliferation, and survival, CD28 is also critical for Treg homeostasis (120, 
121). Mice that lack CD28 or its ligands have significantly reduced numbers of nTregs 
and develop accelerated autoimmunity when bred to a NOD background (122). CD28 
binding to CD80/CD86 can be blocked by CTLA-4, an inhibitory molecule homologous 
to CD28 that is constitutively expressed on Tregs but only up-regulated in conventional T 
cells after activation (123, 124). CTLA-4 has higher affinity for CD80/CD86 than CD28, 
so it can out-compete CD28 for its ligands (125, 126). In support of the role of CD28 in 
Treg homeostasis, blockade of CD28 by CTLA-4Ig results in a rapid decrease of thymic 
and peripheral Tregs (120, 122). To conclusively determine the CD28-mediated 
mechanism of Treg homeostasis, mice lacking CD28 specifically in Tregs were generated 
by crossing FoxP3-Cre mice to CD28fl/fl mice (127). FoxP3-Cre+ CD28fl/fl+ mice develop 
systemic autoimmunity reminiscent of that observed in Treg-deficient mice despite 
maintenance of normal Treg numbers (127), which can be prevented by adoptive transfer 
of CD28-sufficient Tregs, indicating that CD28 expression is critical for Treg-mediated 
maintenance of immune homeostasis. The impaired capacity of CD28-deficient Tregs to 
maintain immune homeostasis correlates with reduced expression of CTLA-4, PD-1, and 
CCR6 (127), among which CTLA-4 is known to be required for Treg suppressive 
function and PD-1 is known to regulate the development of pTregs (128). Additionally, 
CD28-deficient Tregs also demonstrate survival/proliferation deficits, evidenced by the 
fact that CD28-deficient Tregs cannot fill the Treg niche after competitive adoptive 
transfer (127). In sum CD28 is required for Treg proliferation, survival and maintenance 
of CTLA-4-mediated immune homeostasis.  
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Treg homeostasis not only depends on cytokine signaling and CD28 signaling, but 
also depends on interactions with other immune cell types. For example, dendritic cells 
(DCs) and Tregs in the periphery are inextricably linked. Classical dendritic cells (DCs) 
are a small population of specialized antigen-presenting cells of the mammalian immune 
system, which constantly sample their environments for extracellular antigens to present 
to T lymphocytes (129-131). DCs are required for the persistence of natural, thymically 
derived Tregs (nTregs). The complex feedback loop between dendritic cell and nTreg 
populations is evidenced by DC-ablated, Dtx-treated, CD11c-DTR mice, wherein the loss 
of DCs leads to a loss of regulatory T cells (132-135). In a compensatory way, 
conditional depletion of Tregs induces an expansion in dendritic cell populations (31). 
Moreover, the expansion of dendritic cells with Flt3L treatment is commensurate with an 
increase in peripheral, lymphoid Tregs (136). Additionally, DCs have the capacity to 
promote Treg proliferation in vitro (137-140). The relationship between DCs and Tregs 
critically depends on MHCII expression on DCs, as Dtx treated, mixed bone marrow 
chimeras reconstituted with CD11c-DTR and MHCII-/- cells demonstrate significantly 
reduced Treg populations compared to Dtx treated, mixed bone marrow chimeras 
reconstituted with CD11c-DTR and WT cells (135). Therefore, dendritic cell and 
peripheral Treg populations are linked and Treg populations can be manipulated in vivo 
by ablating or increasing DCs.  
In sum, Tregs are FoxP3+CD4+ T cells that arise in two ways and are 
immunosuppressive, relying on TCR-dependent genes to mediate diverse mechanisms of 
immune suppression. Treg homeostasis is maintained, in part, by cytokine signaling and 
by Flt3L-dependent dendritic cells.  
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2. Tissue Tregs, directed by their niche, can perform functions independent and 
mutually exclusive of their canonical immunosuppressive role 
Tissue-infiltrating Tregs can play typical roles in maintaining tissue homeostasis  
Beyond the distinction between nTregs and pTregs, greater heterogeneity within 
Tregs has recently become appreciated. That is, tissue-specific Tregs have been found in 
numerous tissues of mice and humans, including, but not limited to the bone marrow 
(141, 142), skin (143-150), intestinal mucosa (151), lung (152), adipose tissue (35, 36, 
39, 40, 153, 154), placenta (155-159), and injured muscle (38, 160). Homing to these 
distinct sites is requisite for tissue-specific Treg function because Treg suppression relies 
on direct cell-to-cell contact with T cells or APCs (77, 106, 161-163). As such, tissue-
specific Treg populations depend on distinct homing molecules, chemokine receptors and 
transcription factors that guide them to their niches (164). To illustrate, skin and lung-
tropic Tregs uniquely express CD103 and CCR4, which are induced after stimulation by 
their cognate antigen in draining lymph nodes during inflammatory settings (165). In the 
absence of CCR4, there is an impaired accumulation of CD103+ Tregs in the skin and 
airways, and the lack of CCR4 on Tregs alone results in a T cell-dependent wasting 
disease characterized by inflammation of the skin, lung and liver (165). This study 
demonstrates that site-specific Tregs maintain tissue homeostasis through canonical 
immunosuppression.  
Not only do tissue-infiltrating Tregs mediate tissue homeostasis through canonical 
means, but they can also exert functions separate from their stereotypical role in 
suppressing autoimmunity. Specifically, several populations of Tregs with unique 
localization, mechanisms of accumulation and tissue-specific functions have been 
 15
identified and characterized including Tregs that enter the visceral adipose tissue of aged 
mice (VAT Tregs), Tregs that infiltrate injured muscle (muscle Tregs), Tregs that enter 
the lung during acute influenza infection (lung Tregs) and Tregs that accumulate in the 
skin during cutaneous injury (skin Tregs).  
 
A case study: VAT Tregs, which seed their niche at an early age, regulate metabolic 
indices in response to antigen-dependent and cytokine-mediated signaling  
The most well studied tissue-specific nTreg population is that which accumulates 
in the VAT of aged mice (35, 36, 39, 40, 153, 154). Thymic-derived Tregs seed the VAT 
early in development (39), where they are maintained by antigen-dependent and IL-33-
dependent mechanisms and regulate VAT inflammation and metabolic indices (35). 
These Tregs accumulate in the VAT near “crowns” of inflammatory macrophages and 
dying adipocytes. In mouse models of obesity and insulin resistance, VAT Tregs are 
markedly decreased or absent, but their expansion using IL-2 anti-IL2 treatment results in 
VAT Tregs recovery and increased insulin sensitivity (154). Conversely, systemic Treg 
depletion in Dtx-treated, aged FoxP3-DTR-eGFP BAC mice results in decreased insulin 
sensitivity despite increased insulin production, both associated with increased 
inflammatory cytokines produced in the fat (35). VAT Tregs are bona fide Tregs but 
display a site-specific gene signature, including up-regulation of homing molecules like 
CCR2, CCR9, Il1lr1 (St2/IL33r) and ItgaV, up-regulation of anti-inflammatory IL-10, 
decreased Th1-associated genes such as IFN-γ and Tbet, and up-regulated PPAR-γ (35, 
36). Expression of PPAR-γ is suggestion of niche-specific specification, as PPAR-γ is a 
transcription stereotypically used to regulate adipogenesis (166). The co-retroviral 
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transduction of naïve CD4+CD25- T cells with PPAR-γ and FoxP3 induces expression of 
genes characteristic of VAT Tregs, indicating that PPAR-γ may, in part, drive their niche 
specific gene expression (36). Indeed, Treg-specific deletion of PPAR-γ depletes VAT 
Tregs and conversely, PPAR-γ agonist treatment of high-fat diet-fed mice results in 
specific increase of VAT Tregs and recovery of insulin sensitivity (36). The PPAR-γ 
program is initiated by BATF and IRF4 signaling downstream of TCR cross-linking 
because BATF-/- and IRF4-/- mice recapitulate the VAT Treg deficiency observed in 
PPAR-γ-deficient mice (153). In sum, VAT Tregs are integral for maintaining metabolic 
indices; they traffic to their niche due to a unique combination of integrins, chemokine 
and cytokine receptors, and function within their niche due to a distinct transcriptional 
program regulated by BATF and IRF4 and driven by PPAR-γ. It is of interest, then, 
where VAT Tregs acquire their niche-specific program.  
At least a portion of VAT Tregs are first activated in the lymph nodes, after which 
they undergo a few rounds of division. This is supported by fact that 2-4% of Tregs 
within the lymph node include clonal TCR sequences that overlap with TCR sequences 
from VAT Tregs (35). Such clonally expanded Tregs likely respond to VAT-specific 
antigens, because these TCR sequences are only found within lymph node and VAT 
Tregs, but are not found in thymic Tregs. Indeed, confirming the importance of antigen 
recognition in the development and maintenance of VAT Tregs, MHCII-deficient mice 
lack VAT Tregs (39). Division also appears to prompt the expression of a VAT-specific 
transcriptional program, which drives up-regulation of homing molecules distinct for the 
VAT such as St2. To illustrate, TCR cross-linking and co-stimulation of naïve splenic 
Tregs in the presence of IL-2 induces robust proliferation, the induction of PPAR-γ and 
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the up-regulation of St2 on a fraction of cells (153). PPAR-γ and St2 expression are 
abrogated in stimulated IRF4-/- or BATF-/- cells, indicating that PPAR-γ induction and 
St2 expression occur downstream of IRF4 and BATF.  
Next, primed Tregs are recruited to and proliferate within the VAT due to site-
specific IL-33 cytokine signaling (39). IL-33 may be produced by adipocytes, myeloid 
cells or VAT epithelial cells in aged mice. St2 or IL33 deficiency severely reduces VAT 
Treg accumulation (VAT Tregs comprise 35% of CD4+ T cells in WT mice and 10.5% 
and 6.2% of CD4+ T cells in St2-/- and IL-33-/- mice, respectively). Moreover, St2-/- Tregs 
comprise only ~25% of VAT Tregs within WT and St2-/- bone marrow chimeras, 
indicating that the requirement for St2 is cell intrinsic and suggesting that IL-33 signaling 
also drives proliferation within the VAT. If St2 was only required for VAT Treg 
recruitment to the VAT, then St2 deficiency would completely abrogate VAT Treg 
accumulation. However, St2-deficient animals maintain a small portion of VAT Tregs, 
indicating St2-deficient Tregs can reach the niche but do not expand further once there. 
Indeed, treatment of VAT Tregs with IL-33 in vitro, even in the absence of TCR 
stimulation, results in dramatic Treg proliferation. To elaborate, VAT Tregs cultured in 
IL-33 without TCR stimulation undergo an average of three to four divisions whereas 
those cultured in the presence of IL-2 undergo only two divisions (153). Relatedly, 
injection of IL-33 in vivo increases expression of St2 on the surface of VAT Tregs 
indicating IL-33 signaling may prime Tregs for further response to IL-33. Further, in 
vitro TCR stimulation of naïve splenic Tregs in the presence of IL-2 and IL-33 maintains 
PPAR-γ, FoxP3 and Gata3 expression, indicating that IL-33 maintains the VAT-Treg 
specific transcriptional program. Other evidence to support that VAT Tregs proliferate 
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within the niche is the fact that TCR clones observed in VAT Tregs that are shared by 
lymph node Tregs occur at increased frequency within the VAT compared to the lymph 
node. One CDR3α sequence, CAARPNTGGLSGKLTF, is found in 0.3% of lymph node 
Tregs but found in 3.1% of VAT Tregs, indicating enrichment in the VAT (35). In 
support of antigen encounter inside the niche, VAT Tregs exist in close proximity to 
CD11b- CD11c+ cDCs and CD11b+CD11c+ macrophages within the VAT (39).  
After proliferation within the tissue, VAT Tregs may adopt additional 
specialization. This is inferred because transduction of naïve CD4+ CD25- T cells with 
PPAR-γ and FoxP3 induces expression of only some genes characteristic of VAT Tregs 
(36). Therefore, site-specific signaling, independent of PPAR-γ, must further prompt 
niche specific functions within VAT Tregs. In sum, thymus-derived Tregs seed the VAT 
at an early age and are maintained in this niche by antigen-specific interactions, IL-33 
and a molecular program driven by PPAR-γ. Though they appear to be primed in the 
lymph node, they specify further within the VAT, uniquely responding respond to fatty 
acids and regulating metabolic indices.  
 
Tregs are recruited to injured muscle by IL-33, where they ameliorate muscle repair  
A second population of tissue-specific Tregs (muscle Tregs) infiltrates injured or 
dystrophic muscle in great numbers after macrophages entering the same site switch from 
a pro-inflammatory to anti-inflammatory phenotype (160). Muscle Tregs are recruited to 
the muscle during injury and dystrophy by IL-33 produced by fibro/adipogenic 
progenitor cells (38). Indeed, age-related deficits in IL-33 production by fibro/adipogenic 
progenitor cells are correlated with impaired capacity to recruit Tregs to injured muscle 
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and impaired muscle repair (38). Entry into the injured muscle results in Treg 
specification i.e. the gene signature of injured muscle Tregs is distinct from their 
peripheral counterparts and includes dramatic induction of amphiregulin, a member of the 
epidermal growth factor family whose receptor (Egfr) is expressed on muscle satellite 
cells and who ameliorates muscle repair after wounding (160). Treg-deficient mice show 
impaired muscle healing after injury (37). Additionally, supplemental Areg treatment in 
Treg-sufficient or -deficient mice results in improved muscle repair, suggesting a role for 
Tregs and Areg in muscle repair, though the requirement for the Treg-specific expression 
of Areg in muscle repair has not been assessed (160). Muscle Tregs, like VAT Tregs, also 
display a unique TCR repertoire. A substantial portion (20-40%) of muscle Tregs share 
the same TCR sequence as other muscle Treg cells, indicating clonal expansion of several 
sequences (37). Strikingly, one particular TCR clone was enriched in nine separate mice 
(37), strongly implying that muscle Tregs recognize a specific antigen though, again, 
where muscle Tregs encounter this antigen is unclear—in the lymph node or in situ or 
both.  
 
Tregs are recruited to the flu-infected lungs by Il-18 and regulate lung barrier function 
through amphiregulin production 
Tregs are recruited to the lung during influenza infection by IL-18 in the 
bronchoalveolar lavage (BAL) fluid and also produce amphiregulin (152). Here, Treg-
specific deletion of Areg results in exacerbated lung pathology and reduced blood oxygen 
saturation, indicative of impaired lung barrier function (152). Interestingly, Treg-specific 
Areg deficiency has no effects on Treg suppressive capacity in this model, indicating that 
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this tissue reparative function is independent of Treg suppressive capacity (152). Further, 
Areg production by lung Tregs is independent of TCR engagement as lung Tregs 
incubated with alarmins, IL-33 and IL-18, produce Areg without TCR stimulation and 
TCR-deficient lung Tregs isolated from flu-infected mice still showed robust Areg 
production (152). Therefore, lung Tregs repair tissue during viral infection independently 
of their canonical, TCR-dependent suppressive function.  
 
Skin Tregs promote wound repair, in part due to Egfr-dependent suppression of 
inflammatory macrophages 
Activated (CD25+CTLA-4+ICOS+) Tregs accumulate robustly in the skin during 
cutaneous injury and Treg ablation using Dtx-treated, FoxP3DTR mice significantly 
impairs wound closure and healing, especially when Tregs are ablated early after 
wounding (150). Impaired wound healing in Treg-depleted animals is associated with 
increased accumulation of IFN-γ-producing T cells and pro-inflammatory 
(CD45+CD11bhiF4-80+Ly6ChiLy6GloCD206lo) macrophages at the wound site (150). 
Moreover, upon wounding, skin-infiltrating Tregs demonstrate a dramatic up-regulation 
in epidermal growth factor receptor (Egfr) compared to their counterparts in the draining 
lymph node (150). The specific expression of Egfr in skin Tregs indicates that skin Tregs 
acquire a niche-specific signature, including Egfr expression, after entry into the skin. 
Treg-specific loss of Egfr results in delayed wound closing, partial loss of skin Tregs, 
impaired activation of remaining skin Tregs, and an increase in pro-inflammatory 
macrophages in the wounded skin (150). Importantly, treatment of wounded mice with 
FTY720, a sphingosine-1-phosphate receptor modulator that sequesters T cells in the 
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lymph nodes (167), results in a significant reduction in skin Treg accumulation (150). 
These data demonstrate that skin Tregs are primed in the lymph node prior to entry into 
the wounded tissue. Therefore, skin Tregs facilitate wound repair due to production of 
Egfr, a pro-reparative growth factor. Skin Tregs are primed in the lymph node to enter 
their tissue niche, and acquire niche-specific gene signature after entry into the wounded 
skin.   
In sum, tissue specific Tregs appear to employ unique mechanisms to accumulate 
and function within their respective niches. While lung Tregs definitively function in a 
TCR-independent manner, the expansion of distinct TCR clones within VAT and muscle 
Tregs suggests that distinct antigens drive their expansion. Additionally, while it is 
known that VAT Tregs localize in close proximity to CD11b- CD11c+ cDCs and 
CD11b+CD11c+ macrophages (39), it is unclear if other tissue Tregs rely on interactions 
with cDCs inside their tissue niche. Therefore, it is unclear whether all tissue Tregs 
function in a TCR-independent manner and if not, if they are primed in the periphery, 
like skin Tregs, or if they encounter their cognate antigens only within their tissue niche. 
Moreover, the accumulation and function of many tissue Treg populations atypically 
depends on alarmins, which are molecules such as IL-33 or IL-18, that are released by 
dying cells in response to injury, infection and inflammation(168). However, it is 
unknown if other alarmins beyond IL-18 and IL-33 mediate the expansion and 
specification of other tissue Treg populations.  
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3. Tregs accumulate in the central nervous system—a unique organ with distinct 
architecture that counteracts the passage of immune cells in the steady state 
The CNS is considered immune privilege due to its delayed response to exogenous 
antigens delivered to the brain parenchyma 
One tissue where Tregs have been reported to accumulate during infection and 
injury is the central nervous system (CNS), including the optic nerve, brain and spinal 
cord. The CNS is an organ with distinctive architecture that maintains a unique 
interaction with the immune system due to its critical function and poor regenerative 
capacity. The CNS is encased in bone (skull or vertebral column) and a three-fold 
membranous covering—the outermost dural membrane, the intermediate arachnoid 
membrane and the innermost pial membrane—that together forms the meninges. The 
brain and spinal cord are suspended in neutral buoyancy in cerebrospinal fluid (CSF), 
which not only provides a protective padding for the delicate tissue but also carries 
critical nutrients into, and waste out of, the CNS. CSF is generated in the ventricles, of 
which there are four, by the choroid plexus, a highly vascularized secretory tissue 
consisting of cuboidal epithelial cells that surround a stromal core of vasculature and 
connective tissue (Figure 1.1).  
As early as 1921, experiments demonstrated that the CNS is unique in its response 
to exogenous antigens (169, 170). Rat tumor cells injected directly into the mouse brain 
parenchyma fail to result in tumor rejection. However, an adaptive immune response can 
be prompted when antigens are delivered to the brain ventricles, choroid plexus, or 
meninges (170, 171). Adaptive immune response to antigens delivered to the 
parenchyma, typified by antigen-specific T cell entry into the CNS, can also be provoked 
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Figure 1.1: CSF-mediated drainage of interstitial fluid and CNS antigens to deep 
cervical lymph nodes. From Ransohoff and Engelhardt, 2012 (170). (A) human head in 
midline sagittal section, showing revelant anatomical structures (namely the ventricle, 
choroid plexus, central nervous system (CNS) parenchyma, lymphatics and deep cervical 
lymph nodes (DCLNs) in schematic form. (B) Arachnoid granulations in relation to the 
subarachnoid space and brain parenchyma. (C) Subpial vasculature in relation to 
subarachnoid space and brain parenchyma, indicating the anatomy discussed in the main 
text. The inset shows the cellular components of cerebral capillaries, the glia limitans and 
the basement membranes in relation to the perivascular space. CSF, cerebrospinal fluid. 
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after peripheral immunization (172). Finally, while adaptive immune response is 
significantly delayed in the brain parenchyma, autologous tissue grafts can be rejected 
eventually (173). Together, these studies show that the immune privilege of the CNS is 
due to a separation between the CNS and systemic immune system but that this privilege 
is not absolute (170). Separation between the CNS and systemic immune system derives, 
in part, from the absence of a potent antigen-presenting cell within the parenchyma. 
However, brain-derived antigens can be carried to the draining cervical lymph nodes 
(dCLNs) through cerebrospinal fluid (CSF) (Figure 1.1), explaining why adaptive 
immune responses can be initiated when antigen is delivered to circulating CSF within 
the brain ventricles, choroid plexus, or meninges.  
 
Misconceptions about the role of the BBB in CNS immune response 
The second obstacle to initiating adaptive immune response inside the CNS, 
beyond the challenge of antigen delivery, is the fact that the healthy brain parenchyma is  
devoid of leukocytes and barriers limit the entry of leukocytes into the brain. However, 
imprecise interpretation of data has led to the common misconception that the blood-
brain barrier (BBB) is the sole impediment to lymphocyte entry into the brain 
parenchyma (174). The BBB is formed by highly specialized endothelial cells, which 
inhibit transcellular molecular traffic owing to low pinocytotic activity, and restrict 
paracellular diffusion of hydrophilic molecules because of an elaborate network of 
complex intra-endothelial tight junctions (175). The BBB allows precise regulation of 
osmolarity within the brain parenchyma, necessary to support proper neuronal function. 
However, the impermeable qualities of BBB, including intraepithelial tight junctions, are 
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present primarily at the capillary level and therefore cannot wholly explain the limited 
passage of cells into the brain parenchyma because immune cells are too large to circulate 
through capillaries. In other words, whereas solute diffusion is regulated at the capillary 
level by the BBB, leukocyte transmigration occurs preferentially at post-capillary 
venules, where endothelial cell permeability is increased (Figure 1.2). At post-capillary 
segments, however, the vessel wall is boundaried by the perivascular space and a second 
barrier erected by astrocytic end-feet—the glia limitans. Therefore, in spite of increased 
permeability at the post-capillary venules, lymphocyte entry into the parenchyma is 
further obstructed by the glia limitans. In sum, while the blood-brain barrier regulates 
solute concentration within the brain parenchyma, it does not fully explain restricted 
lymphocyte trafficking into the brain parenchyma 
 
Two barriers impede leukocyte entry into the brain parenchyma 
Leukocyte entry into the brain parenchyma at brain post-capillary venules is 
distinct from transmigration into other tissues (Figure 1.3). In other tissues, leukocytes 
can reach the tissue in one step, after endothelial transmigration. In the brain, however, 
cells must first cross the endothelial cells of the vasculature (step one), after which they 
are retained in a “moat” of CSF, and in order to reach the brain parenchyma must then 
penetrate the glia limitans, which is a barrier of astrocyte foot process associated with the 
parenchymal basement membrane (step two). 
While transmigration through brain post-capillary venules in the healthy brain is 
prevented by lack of adhesion molecules expressed on endothelial cells, tight junctions 
between endothelial cells, and immunosuppressive molecules, like IL-25 expressed by 
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Figure 1.2: Schematic of the difference between brain post-capillary venules, which 
are more permeable to leukocyte transmigration, and brain capillaries, where the 
glia limitans is fused with the endothelial cell basement membrane. Brain post-
capillary venules, unlike vasculature in body tissues, are sheathed by a “moat” of 


















endothelial cells, cells can enter the CNS during inflammation, injury and infection. 
Pathological conditions within the brain can result in recruitment of immune cells to the 
CNS via chemokines such as CCL2, CCL4, CCL9, CCL10, CCL11, and CCL20 (176). 
These chemokines, especially CCL2 (177), in conjunction with effector molecules 
secreted by leukocytes themselves, like IFN-γ produced by CD8+ T cells, result in 
increased permeability of brain endothelial cells and up-regulation of adhesion 
molecules. These changes at the endothelial level are required for the first step of 
leukocyte entry into the brain: transmigration of the endothelial cells. As in all tissues, 
leukocyte extravagation from the brain blood vessels involves chemoattraction, rolling 
adhesion, tight adhesion and transmigration. Leukocyte slowing at brain blood vessels 
depends on P-selctin/PSGL1 and ICAM1/LFA1 interactions (178). Adhesion depends on 
interactions between VCAM1/α4β1 (179, 180). As evidence, treatment with 
Natalizumab, a monoclonal antibody against human α4 integrin (181), inhibits leukocyte 
entry to the CNS at this first step and consequently protects against demyelination during 
multiple sclerosis. In CNS viral infection models, such as West Nile Virus infection, 
blocking leukocyte entry at the first step abrogates pathology at the cost of uncontrolled 
viral infection (182). 
After penetrating the endothelial cell layer, leukocytes are retained within a 
“moat” of CSF and interstitial fluid that sheaths the post-capillary venules between the 
endothelial basement membrane and the glial limitans, called the perivascular space. This 
CSF is the same CSF that originates from the choroid plexus of the ventricles, flows 
through the ventricles and is pulled down into the brain parenchyma by vessels that 
penetrate the arachnoid and pia layers of the meninges. Cells are actively held in the 
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perivascular space after crossing endothelial cells unless the necessary molecules are 
produced to initiate the second step of leukocyte migration into the brain parenchyma: 
penetration of the glia limitans. For example, CXCL12 expressed at the basolateral side 
of the epithelial cells retains CXCR4+ T cells in the perivascular space (176). If a CXCR4 
antagonist, which blocks binding of CXCL12 to CXCR4, is administered during West 
Nile Virus infection, these T cells are driven into the parenchyma and promote virus 
clearance (176). These data indicate that specific homing molecules are responsible for 
leukocyte trafficking from the blood into the perivascular space, and from the 
perivascular space into the brain parenchyma. 
Penetration of the glia limitans requires matrix metalloproteinase production, 
which generally only occurs in activated immune cells. Studies in animal models of 
multiple sclerosis (MS) indicate that matrix MMP-2 and MMP-9 are required for 
proteolytic cleave dystroglycan, which anchors astrocyte endfeet to the glia limitans 
basement membrane. T cell infiltration into the parenchyma is not detected in MMP-
2/MMP-9 double knockout mice during a model of MS, and this correlates with reduced 
disease severity (183). Neutrophils, macrophages and monocytes appear to be relevant 
producers of MMPs based on immunohistochemistry, and CCL2+F4-80+ cells appear to 
be required for lymphocyte migration through the glia limitans during viral encephalitis. 
Interestingly, the compartmentalization of immune cells in regards to the glia limitans 
affects disease outcome. If CD4+ T cells are retained in the perivascular space by 
manipulating MMP inhibitors during a model of neurotropic hepatitis virus (184), then 
paralysis is delayed at the cost of higher viral titer within the brain. This means that 
despite the fact that immunocytes are within the CNS, the outcome of immunopathology 
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and pathogen clearance is dependent upon passage through the second barrier. In sum, 
entry into the CNS and penetration of the brain parenchyma is an active process that 
uniquely requires passage through two barriers.  
Leukocytes can enter the brain through two routes, which converge upon the CSF 
Leukocytes can enter the brain parenchyma through two primary routes that converge 
upon the cerebrospinal fluid (CSF): 1) across the choroid plexus stroma and epithelium, 
from the blood to the CSF, into the brain parenchyma and 2) at post-capillary venules in 
the lepto-meningeal space, from the blood to the CSF-containing perivascular space to 
the brain parenchyma (185, 186) (Figure 1.3). The choroid plexus is a highly 
vascularized secretory tissue consisting of cuboidal epithelial cells that surround a 
stromal core of vasculature and connective tissue. Choroid plexuses are found in each of 
the four ventricles of the brain and are responsible for generating CSF. While cell 
trafficking through the blood endothelial cells at the lepto-meningeal space only occurs 
during pathological conditions, cells can enter the CSF through the choroid plexus 
infrequently and selectively in the steady state . Cells transmigrate through the choroid 
plexus stroma into the CSF due to signaling through P-selecting and P-selecting 
glycoprotein ligand-1 (187). However, this gate to the CNS is selective, illustrated by the 
distinct composition of leukocytes in the human CSF, which is comprised primarily of 
CD4 effector memory T cells, very little neutrophils and only a few monocytes (188). 
Memory T cells (CD4+CD45RO+CD27+) in human CSF express CXCR3 and CCR7, 
possibly responding to CCL19 expressed by choroid plexus endothelial cells (189). 
Together, selecting-mediated rolling and integrin-dependent adhesion on choroid vessels 
may mediate the slowing down of these CCR7+ lymphocytes, allowing them to sense  
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Figure 1.3: Schematic of barriers impeding leukocyte entry from the blood into 
peripheral tissues compared to those impeding leukocyte entry into the CNS at the 
lepto-meningeal space. Whereas leukocyte entry into peripheral tissues only requires 
transmigration through blood endothelial cells, leukocyte entry into the CNS at the post-
capillary venules requires passage through two barriers: the blood endothelial cells and 












CCL19, which further facilitates their trans endothelial migration.  
Cells also enter the CNS at the choroid plexus during pathological conditions and 
this may precede cell transmigration at post-capillary venules. That is, T cell entry 
through the choroid plexus appears to initiate the entry of T cells through post-capillary 
venules, because blocking T cell entry at the choroid plexus prevents T cell entry 
elsewhere and abrogates disease during experimental autoimmune encephalomyelitis 
(190). Further, distinct T cell subsets preferentially use different gates during 
inflammation; During EAE, Th17 cells only enter at the choroid plexus in a CCR6-
dependent manner, whereas Th1 cells enter the CNS through post-capillary venules 
(190).  
The convergence of both routes of leukocyte entry into the CNS on the CSF is 
important for two reasons: first, the circulation of CSF is crucial for metabolic waste 
removal from and solute delivery to the CNS. CNS antigens can be carried to draining 
cervical lymph nodes (dCLNs) via the nasal mucosa. Moreover, factors circulating in the 
CSF are critical for the proliferation and differentiation of neural progenitors that extend 
their apical domains into the CSF of the lateral ventricle (191, 192). Therefore, the CSF is 
fluid by which leukocytes can encounter antigen, where leukocytes can receive signals 
from resident brain cells and conversely a route through which molecules secreted by 
leukocytes can impact the function of resident brain cells. Second, the choroid plexus 
stroma is populated by resident dendritic cells, which have been shown to have superior 
antigen-presenting capacity compared to microglia (193). Therefore, the choroid plexus 
represents an area where T cells can encounter antigen during health and disease. As 
such, it is of interest which immune cell populations circulate in and traverse through the 
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CSF during CNS pathology, as this represents a critical niche for cross-talk between the 
CNS and peripheral immune system. 
 
4. Tregs accumulate in the central nervous system during infection, inflammation 
and injury but their origin, localization, mechanism of accumulation, and gene 
signature are undefined  
  Tregs have been shown to accumulate in the CNS during infection, inflammation 
and injury and broadly play CNS tissue protective roles (194-196). For instance, Treg 
accumulation inside the CNS (bulk brain) has been noted during glia tropic mouse 
hepatitis virus (MHV) infection (197). Depleting Tregs through diphtheria toxin (Dtx) 
treatment of FoxP3-DTR mice during MHV infection results in increased, non-virus-
specific T cell trafficking to the infected CNS, correlating with increased CNS tissue 
pathology, without resulting changes in virus-specific T cell response or viral titer (197). 
In that study, Tregs mediate effector T cell trafficking to the infected CNS by regulating 
CXCR3 expression on Tons in the draining cervical lymph node. Therefore, during MHV 
infection Tregs play a tissue protective role but perform this function in the periphery. A 
separate study demonstrated that activated Tregs accumulate in the CNS during West 
Nile Virus (WNV) infection (198, 199). Treg depletion during WNV infection increased 
IFN-γ production from effector T cells during peak response but impaired memory CD8+ 
T cell response (199), indicating that Tregs protect against overzealous immune response 
and promote CD8 memory T cell phenotype during WNV infection. Further, Tregs have 
been shown to be cerebroprotective in an IL-10-dependent manner and localize near brain 
vasculature during ischemia and brain injury (200-202). As such, Tregs can also enter the 
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CNS during sterile injury, without requiring priming by, or stimulation by, foreign 
antigens. 
 One animal model of CNS disease in which the role of Tregs has been well 
characterized is EAE. In this model, CNS demyelinating disease, meant to model 
multiple sclerosis, is induced by peripheral immunization with CNS antigens, such as 
myelin basic protein (MBP), myelin proteolipid protein (PLP), or myelin oligodendrocyte 
glycoprotein (MOG), often combined with an adjuvant (172, 203, 204). Alternatively, 
adoptive transfer of T cells specific for these CNS antigens can be used to drive disease 
(203-205). Only certain T helper cell phenotypes are capable of inducing EAE. That is, 
Th1-polarized myelin-specific T cells, hallmarked by their production of the 
inflammatory cytokine IFN-γ, Th9-polarized myelin-specific T cells, hallmarked by their 
production of IL-9 and IL-10, and Th17-polarized myelin-specific T cells, hallmarked by 
their production of IL- 17A, IL-17F, IL-21, and IL-22, are capable of inducing EAE (179, 
206-208). In contrast, Th2-polarized myelin-specific T cells, hallmarked by their 
production of IL-4, are not capable of promoting EAE (208), together indicating that 
CNS pathology is driven by T cells with specific effector functions. EAE-affected mice 
can suffer from a monophasic bout of EAE, a relapsing-remitting form, or chronic EAE, 
in which disease is typified by increasing severity of paralysis. Paralysis correlates with 
CNS pathology, characterized by meningeal and parenchymal mononuclear cell 
infiltrates predominantly in the white matter of the spinal cord, irrespective of T helper T 
cell phenotype (208).  
In addition to mononuclear cells and CD4+ T cells (205), Tregs have been shown 
to accumulate in the spinal cord during acute phases of disease (209-211). Several studies 
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have observed that the transfer of CD25+ Tregs ameliorates EAE disease (209, 211-213). 
As a more conclusive indication that Tregs play an important role during EAE, studies 
using monoclonal anti-CD25 antibodies to deplete Tregs showed that Treg deficiency 
during EAE exacerbates disease (209, 214, 215). Additionally, conditional depletion of 
Tregs in diphtheria toxin-treated FoxP3-DTR mice that were immunized with MOG 
peptide resulted in severe and fatal EAE (216). Mechanistically, it was proposed based on 
in vitro studies that Tregs suppress the severity of EAE by inhibiting the expression of 
IL-17 and IFNγ in an IL-10-dependent manner (217). However, little evidence suggested 
that Tregs perform their critical role during EAE in situ in the CNS until it was shown 
that conditional depletion of Tregs in diphtheria toxin-treated FoxP3-DTR mice that were 
immunized with MOG peptide results in increased effector T cell entry into and 
proliferation within the CNS (216). As such, Tregs critically dampen inflammatory 
effector T cell responses and CNS pathology during EAE by limiting effector T cell entry 
into and proliferation within the CNS.  
Defective Treg function has also been associated with CNS disease in humans. 
For example, humans who are symptomatic for WNV-induced fever have lower 
frequencies of Tregs in their peripheral blood (198). Additionally, Tregs are increased in 
the CSF of patients with MS (201). However Tregs isolated from MS patients are less 
suppressive than those harvested from healthy controls (196). Together these results 
suggest that Treg dysfunction can have an effect on human CNS disease. 
In sum, Tregs known to enter the infected and injured CNS play canonical 
immunosuppressive roles to protect delicate CNS tissue. Indeed, deficiencies in FoxP3+ 
Tregs during CNS immune perturbations have pathological consequences in mice and 
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humans. However, despite the recognition that Tregs enter the infected CNS, their origin, 
localization and mechanisms underlying their accumulation and function are not well 
defined. Moreover, whether Tregs play non-canonical roles in the inflamed CNS is 
unknown. These characteristics of CNS Tregs may have been unstudied due to the 
scarcity of Tregs that can be recovered from the bulk CNS. In particular, the scarcity of 
CNS Tregs may have impaired gene expression analysis of CNS Tregs. Further, 
contamination of blood cells remaining after perfusion during bulk brain tissue 
preparation makes it difficult to differentiate tissue-specific Treg response from systemic 
Treg response. 
 
5. Encephalomyocarditis virus exhibits CNS tropism and can result in lethal hind-
limb paralysis mediated by CD4+ T cells 
EMCV naturally infects rodents and is generally safe for laboratory use  
 Encephalomyocarditis virus (EMCV) is a cardiovirus of the Picornaviridae 
family; meaning small (pico), non-enveloped, single-strand RNA (rna) viruses. EMCV is 
a causative agent of myocarditis, encephalitis, and diabetes in some animal models. A 
related cardiovirus is Theiler’s murine encephalomyelitis virus, a common laboratory 
model of demyelinating disease. EMCV naturally infects a wide array of wild and 
domestic animals and has been isolated from squirrels, elephants, pigs, raccoons, 
antelope and several species of non-human primates, to name a few (218). Its natural 
reservoir is thought to be rodents, given that infections in rats are usually asymptomatic, 
though wild boars have also been suggested as a natural animal reservoir (218). Given the 
co-localization of some of these host species with humans, some have described EMCV 
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as a potential zoonotic disease, however, a conclusive link between animal hosts and 
disease occurrence in humans has not been demonstrated. Nonetheless, humans are 
susceptible to EMCV as hunters and those with occupational exposure to animals, such as 
zookeepers, have been shown to be seropositive for EMCV. Despite seropositivity, 
EMCV rarely results in anything more than a febrile illness in humans. In fact, EMCV 
infection may be quite common in humans but most cases are asymptomatic or go 
unrecognized. Given these qualities—the natural infection of rodents without need for 
intracranial injection and the low morbidity in humans—EMCV is a convenient 
laboratory model for myocarditis, encephalitis and diabetes. 
 
EMCV variants are divided into those that are dominantly neurotropic or 
cardiotropic/diabetogenic, and neurotropic strains differ in their CNS tropism   
Variants of EMCV have been isolated from wild animal species and have been 
tested for tropism in murine models. Distinct EMCV strains have differing tropism for 
the spleen, intestine, pancreas, heart, and central nervous system of the mouse (219, 220). 
Furthermore, distinct neurotropic strains also demonstrate varied tropism for different 
regions of the brain. For example, at least five neurotropic EMCV strains have been 
studied: EMCV 30/87 (221), EMCV-B (219), EMCV-D (222, 223), EMCV-K (220), and 
EMCV-MM (220). EMCV 30/87 infection results in pathology in the hippocampus, 
cerebral cortices, hypothalamus; EMCV-B results in pathology in Ammon’s horn of the 
hippocampus, but only after intracranial injection; EMCV-D results in pathology in 
hippocampal pyramidal neurons, in the amygdala, in the cerebellum and the anterior 
horn, the lateral funiculus and the ventral funiculus of the spinal cord; EMCV-K results 
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in pathology in Purkinje cells of the cerebellum, and in brainstem, and EMCV-MM 
results in pathology in the cerebrum (220). Despite the varied tropism for CNS tissue, 
however, these strains all cause paralysis. Therefore, paralysis is not a sufficient readout 
for discrete pathology during EMCV infection. Additionally, given the heterogeneity in 
CNS tropism between EMCV strains, any strain whose tropism has not been documented 
cannot be assumed to demonstrate pathology in certain regions of the brain.  
 
EMCV virulence in the CNS depends critically on age 
Age is one important factor dictating EMCV virulence in the CNS, which is 
critical to establishing a model of CNS disease in laboratory animals. The effect of host 
age has been investigated in vitro and in rats in vivo using the EMCV-D strain. In vitro, 
viral titers in EMCV-D infected hippocampal sections isolated from rats 1-, 4-, 7-, 14-, 
28- and 56-days-old decreased significantly as age increased (224). Moreover, 
neurodegeneration occurred in EMCV-D-infected hippocampal slices isolated from 1-, 7-
, and 28-day-old mice, but not in those isolated from 56-day-old mice, corresponding to a 
decrease in viral RNA and viral antigen distribution. These data were corroborated by a 
separate study, which indicated that decreased susceptibility to EMCV infection resulted 
from intrinsic differences in the aged neurons themselves rather that differences in 
immune response (225). In vivo, rats under 4 days of age died by 6 days post-infection 
with 104 pfu EMCV-D, administered intaperitoneally (226). Importantly, this study 
indicated that no viral titer was recoverable from any organ from 28- or 56-day-old rats 
that had been infected with either 104 or 107 pfu EMCV, i.p. While no study has 
definitively proved the mechanism of decreased susceptibility to EMCV infection with 
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age, these studies indicate that aged-related changes in neurons themselves prohibit 
EMCV replication in aged mice, an important consideration for experimental design. 
 
Adaptive immune response to neurotropic EMCV infection includes CD4+ T cells, 
though Tregs within CD4+ T cells have not been studied 
The main receptor for EMCV remains uncertain, though the sialoglycoprotein, 
VCAM-1, has been identified as a receptor for EMCV on vascular endothelial cells. 
Other sialoglycoproteins, such as an unknown 70KDa sialoglycoprotein on HeLa and 
K562 cells, as well as sialylated glycophorin A, expressed on red blood cells, have also 
been implicated in EMCV binding. As sialoglycoproteins are “sticky,” the binding of 
EMCV to these proteins may reflect promiscuous binding rather than dedicated receptors 
for EMCV. However, binding to cell-specific receptors does appear to play some role in 
EMCV tropism as mutation of a single amino acid (alanine 776) in the VP1 gene 
encoding the viral capsid protein renders a diabetogenic strain of EMCV non-
diabetogenic due to loss of capacity to bind to pancreatic β cells (227).  
After binding, absorption and uncoating, EMCV can be detected by the innate 
immune system via the cytosolic sensor, MDA5, leading to rapid production of type I 
interferon (228). Interferon is required for protection against EMCV, as IFN-α/β receptor 
knockout mice demonstrate impaired survival compared to infected, WT mice (228). 
EMCV can also it can bind CCR5 on macrophages and rapidly induce iNOS production, 
MAP kinase, cyclic AMP response element binding protein and the NF-κB cascade 
(229). Importantly, evidence demonstrates that these cascades are activated 
independently of cytosolic EMCV RNA accumulation, as empty capsids promote iNOS 
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production as efficiently as intact virions (229). Therefore, EMCV binding to CCR5, 
without subsequent infection, may be sufficient to initiate immune responses. 
Encephalitic strains of EMCV, including EMCV-D and EMCV-M, induce CNS 
pathology and paralysis due to innate and adaptive immune responses within the CNS. 
That is, infection with these strains of EMCV results in inflammation and lymphocyte 
accumulation in the cerebral cortices, hypothalami and hippocampi of the brain, 2 to 7 
days post-infection (219, 220, 222). Infection also induces perivascular cuffing around 
brain blood vessels, indicative of perivascular accumulation of leukocytes infiltrating the 
CNS from the peripheral blood. In mice infected with EMCV-M, infection-induced 
paralysis is partly due parenchymal infiltration of lymphocytes and CD11b+ cells (230). 
That is, treatment of mice with monoclonal antibodies against CD4, CD8 or CD11b prior 
to infection is sufficient to prevent paralysis and demyelination (218, 223). Further, 
treatment with anti-CD4 antibody results in a modest delay in viral clearance from the 
brain (223). Together these data suggest that effector T cell response is required to 
effectively eliminate EMCV infection at the expense of paralysis and damage to CNS 
tissue.  
Additionally, during EMCV-D infection, which causes a biphasic hind limb 
paralysis, CD4+ T cells are observed in the anterior horn of the spinal cord near dying 
motor neurons that stain positive for viral RNA (222). This peripheral adaptive immune 
response exacerbates paralysis as mice treated with anti-CD4, anti-CD8 or anti-Mac1 
antibodies exhibit a dramatic decrease in hind limb paralysis 7 dpi compared to mock-
treated controls (218, 223). Further, only treatment with anti-CD4 and not anti-CD8 
antibodies decreased the incidence of paralysis and spinal cord lesions (218, 223). These 
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data suggest that CD4+ T cells, which are recruited to virally infected neurons, promote 
lethal hind-limb paralysis due to demyelination. The effect on viral titer was not 
analyzed. 
Together these experiments suggest that CD4+ T cells facilitate viral clearance 
during EMCV-D infection, while CD4+, CD8+ and CD11b+ cells together exacerbate 
paralysis. However, the role of Tregs among CD4+ T cells in CNS tissue damage during 
EMCV infection has not been investigated. 
 
6. Summary and Research Goals 
A well-appreciated role of Tregs is the suppression of autoimmunity, i.e., Tregs 
suppress the proliferation of auto-reactive conventional T cells (Tcons), thereby 
maintaining tissue homeostasis. However, it has been recently demonstrated that Tregs 
can play unique roles separable from their canonical immunosuppressive function, 
especially when they enter distinct tissue niches. The mechanisms by which they 
accumulate in distinct tissues, where they acquire tissue-specific functions, are wide-
ranging and include TCR-dependent mechanisms (VAT) and TCR-independent, 
cytokine-dependent mechanisms (flu-infected lung). However, it is unclear where tissue 
Tregs are primed and acquire their tissue-specific function: are they are primed in the 
periphery, or do they specify in situ? Further, while lymphoid Treg homeostasis is known 
to depend on dendritic cells, the extent to which tissue-specific Treg populations interact 
with dendritic cells is relatively unstudied. 
Tregs are also detected inside the central nervous system (CNS) during infection, 
inflammation and injury. Although it is known that Tregs broadly play tissue protective 
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roles inside the infected, injured and inflamed CNS, their localization, origin, their 
mechanism of accumulation and the molecular mechanisms underlying their function are 
unclear. Further, a population of dendritic cells is known to localize to the meninges and 
choroid plexus of the healthy mouse brain. However, whether these dendritic cells are 
associated with CNS-infiltrating Tregs is unknown. These qualities of CNS Tregs may 
have remained unstudied due to the difficulty in isolating this rare population and 
differentiating contaminating, circulating Tregs from bona fide, CNS-infiltrating cells. 
Therefore, we aimed to overcome these difficulties by taking advantage of flow 
cytometric techniques that would allow us to distinguish contaminating, circulating Tregs 
from bona fide, CNS-infiltrating cells. Moreover, we adopted new techniques to isolate 
RNA from rare cell populations for the purpose of transcriptomic analysis. Using these 
methods, we characterized the localization, origin, mechanism of accumulation, and 










Chapter II: Materials and Methods 
1. Mice 
Foxp3EGFP (FoxP3-GFP) mice were generously provided by the Rudensky Lab 
(MSKCC) and subsequently bred at Columbia University Medical Center (CUMC). 
CD11c-Cre (Tg(Itgax-cre)1-1Reiz) mice were generously provided by the Reizis Lab 
(CUMC/NYU) or purchased from Jackson Laboratory and subsequently bred at CUMC. 
R26-STOPflox-DTA mice were generously provided by the Ivanov Lab (CUMC) and 
subsequently bred at CUMC. FoxP3DTR/GFP (FoxP3-DTR), Rag1tm1Mom/J (Rag1-/-, Rag1-
deficient or Rag1 knockout), and Ltatm1Dch (Lymphotoxin alpha knockout or Lta-/-) mice 
were obtained from Jackson Laboratory and subsequently bred at CUMC. C57BL/6 and 
C57Bl/6 CD45.1+ (B6.SLJ-Ptprca Pepcb/BoyJ), mice were purchased from the Jackson 
Laboratory or were bred at CUMC. All mice were maintained in specific pathogen-free 
barrier facilities at CUMC in accordance with IACUC-approved animal protocols.  
Infections were carried out in BSL-2 barrier facilities at CUMC according to IACUC-
approved animal protocols.  
 
2. Virus preparation and infection 
For virus propagation: an initial stock of EMCV-R (231) was a generous gift from 
the Racaniello Lab (CUMC) and was aliquoted and maintained at -80°C. In order to 
propagate the virus, we passaged this stock through HeLa cells grown in complete 
DMEM (CellGro/Mediatech 10-017-CV) with 10% FCS and penicillin/streptomycin 
(Invitrogen). To passage virus, we inoculated confluent monolayers of HeLa cells grown 
in 150cm tissue culture dishes with 300-500μL of 108 pfu/mL stock of EMCV-R. After 
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24 hours, cytopathic effect was obvious in infected HeLa monolayers as cells decreased 
in size, became rounded and detached from the bottom of the plate. We harvested 
supernantant and all cells and cell debris from these 150cm tissue culture dishes and froze 
collection tubes at -80°C. Collection tubes were frozen and thawed at room temperature 
for a total of three times. Freezing and thawing lyses cells and releases intracellular viral 
particles. After the third and final thaw, collection tubes were spun at 1500 rpm for 5 
minutes to pellet cell debris. The supernatant was isolated after spinning and was 
submitted to plaque assay to determine viral titer (see below). In order to prevent virus 
mutation, stocks were not continually passaged through HeLa cells. That is, the same 
frozen mother stock was aliquoted and used to generate all subsequent virus. In order to 
prevent changes in viral titer, stocks used for injection were aliquoted in small volumes 
and not frozen and thawed more than once. 
For infections: Six- to eight-week-old mice were inoculated intraperitoneally with 
107 pfu EMCV in 200μL sterile PBS according to approved animal protocols. Mice older 
than eight weeks are refractory to infection, so this age range is critical. This age-
dependent susceptibility to EMCV (EMCV-D) has been observed in vitro (232) and in 
vivo (233) and is attributed to both to the reduced capacity for viral replication in neurons 
in older mice and the reduced capacity for virus trafficking to the CNS of older mice. 
Virus was thawed and diluted immediately before injection and vortexed prior to each 
injection. Unless otherwise noted, mice were euthanized 4.5 to 5 days post-infection or 
were sacrificed and not analyzed if moribund prior to experiment endpoint.  
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3. Plaque assays 
Plaque assays were performed on two types of samples: cell lysates harvested 
from EMCV-infected HeLa cells (see virus preparation) and homogenized tissue samples 
harvested from EMCV-infected mice. For virus harvested from infected HeLa cells (see 
virus preparation): supernatant including virus was prepared as above and diluted in 10-
fold serial dilutions in sterile 1X dPBS including 0.01% BSA.  
For tissues: whole spleens, brains, and spinal cords were harvested from 
euthanized, EMCV-infected mice, weighed and added to 5 mL round-bottom culture 
tubes including 1 mL sterile 1X dPBS. 100μL blood was also harvested in transferred 
1.5mL Eppendorf tubes. Tissues were homogenized with a Brinkman Polytron 10/35 
Homogenizer and transferred to 1.5mL Eppendorf tubes. Sample tubes, including blood 
collection tubes, were frozen at -80°C and thawed at room temperature for a total of three 
times to release infectious virions from tissue cells. Sample tubes were spun in a tabletop 
Eppendorf centrifuge at max speed for 5 min and supernatant including virus was 
harvested and diluted in 10-fold serial dilutions in sterile dPBS including 0.01% BSA.  
Each virus dilution (100μL, whether from infected HeLa cells or homogenized 
tissue) was added to confluent HeLa monolayers in 6 well plates in duplicate and 
incubated at 37° for one hour. Every ten minutes, infected cells were rocked gently by 
hand to ensure complete coverage of the cell monolayer. Infected HeLa cells were 
covered with a solid overlay including 1.6% noble agar and a liquid DMEM overlay as in 
(234). 48 hours post-infection, HeLa cells were fixed with 10% trichloroacetic acid for 10 
min, solid overlay was rinsed off with tap water, plaqued cells were dyed with crystal 
violet (Sigma, V5265-250mL) (40 mL of 1% crystal violet + 80 mL ethanol + 300 mL 
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dH2O) for 10 to 15 min, crystal violet was rinsed off gently in running water and plaques 
were enumerated.  
 
4. Antibodies used  
The following antibodies were used for flow cytometry analysis: Biotin anti-
CD11b (Biolegend M1/70), Biotin anti-CD19 (eBioscience, eBio1D3), Biotin anti-B220 
(CD45R) (Biolegend, RA3-6B2) Biotin anti-Ly6G (Biolegend, 1A8), Biotin anti-NK1.1 
(eBioscience, PK136), APC anti-CD4 (Biolegend, GK1.5), APC anti-CD8α (BD, 53-6.7), 
APC anti-CD11b (eBioscience, M1/70), APC-Cy7 anti-CD4 (Biolegend, GK1.5), APC 
anti-Ki67 (Biolegend, 16A8), APC-Cy7 anti-CD11b (eBioscience, M1/70), APC-Cy7 
anti-CD45.1 (Biolegend, 104), APC-Cy7 anti-CD11c (eBioscience, N418), APC-Cy7 
anti-Ly6C (eBioscience, HK1.4), Alexa Fluor 700 anti-MHCII (IA/IE) (eBioscience, 
M5/114.15.2), FITC anti-CD3ε (eBioscience, 145-2 C11), FITC anti-CD8α (eBioscience, 
ebio1D3), FITC anti-CD45.1 (eBioscience, A20), FITC anti-B220 (eBioscience, H1524), 
FITC anti-CD45.2 (eBioscience, 1D4), Pacific Blue anti-CD19 (Biolegend, 6D5), Pacific 
Blue anti-B220 (eBioscience, RA3-6B2), Pacific Blue anti-Ter119 (Biolegend, TER119), 
Pacific Blue anti-Ly6G (Biolegend, 1A8), purified anti-CD16/32 (Biolegend, 93), Pacific 
Blue anti-FoxP3 (Biolegend, MF-14), PerCP-Cy5.5 anti-CD11c (Biolegend, N418), 
PerCP-Cy5.5 anti-CD45.1 (eBioscience, A20), PerCP-Cy5.5 anti-TCRβ (Biolegend, 
H57-597), PerCP-Cy5.5 Streptavidin (eBioscience), PerCP-Cy5.5 anti-Ly6C (Biolegend, 
HK1.4), PE-Cy7 anti-CD45 (eBioscience, 30-F11), PE-Cy7 anti-CD4 (Biolegend, 
GK1.5), PE-Cy7 anti-CD11b (eBioscience, M1/70), PE anti-CD8α (Biolegend, 53-6.7), 
PE anti-CD11c (Biolegend, N418), PE anti-CD45.2 (eBioscience, 104), PE anti-CD115 
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(Biolegend, AF598), PE anti-Ly6G (Biolegend, 1A8), PE anti-CCR5 (Biolegend, 
HMCCR5) and PE anti-FoxP3 (eBioscience, FJK-16s). 
 
5. Cell preparation, flow cytometry and sorting 
For flow cytometry experiments: six- to eight-week-old mice were injected 
intravenously with 100μL sterile PBS including 5μg Pacific Blue anti-mouse CD45 (30-
F11, Biolegend). Ten minutes after i.v. injection, mice were euthanized and intracardiac 
perfusion was performed slowly with 10 to 25mL ice cold PBS including heparin (1 USP 
unit/mL, National Drug Code #63323-540-11) until blanching of the liver was observed. 
For mice where blood was collected, blood was harvested from the top left atrium with a 
1mL syringe prior to perfusion. Spleens, lymph nodes and brain tissue including 
meninges were dissected. Dissected brain tissue was collected in Eppendorf tubes 
containing 500μL HBSS plus Ca++ and Mg++. Dissected spleens were collected in 6 well 
plates containing 5mL HBSS plus Ca++ and Mg++ and 250 mU/mL collagenase D 
(Roche). Lymph nodes were collected in 6 cm dishes including 5mL FACs buffer (2.0% 
(vol/vol) fetal calf serum in 1X dPBS).  
For spleen preparations: spleens were ballooned using 1mL syringes and then 
were homogenized by tweezing according to standard protocols. Homogenized spleens 
were incubated for 20 minutes at 37°C and collagenase was subsequently quenched with 
10mM EDTA (Corning, 46-034-Cl) for 5 min at 37°C. Undigested tissue was filtered 
through 50μM filters and filters were washed twice with FACs buffer. Cell suspensions 
were then spun at 1500 rpm for 5 min, followed by ACK lysis (Lonza, 10-548E), and two 
washes with FACs buffer. Cells were enumerated using hemacytometer or BD Accuri 
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cytometer. 2X106 spleen cells were incubated with 24G2 block in FACs buffer before 
cell surface marker antibody staining.  
For blood preparation: blood was harvested from the top left atrium prior to 
perfusion. 300-500μL of blood were added to 1X RBC Lysis Buffer (Biolegend, 
420301), vortexed and incubated on ice for 10 min, after which cell suspension was spun 
at 1500 rpm for 5 min. Blood leukocytes were washed with 15 mL FACs buffer, spun at 
1500 rpm for 5 min and incubated with 24G2 block in FACs buffer before cell surface 
marker antibody staining.  
For lymph node preparation: peripheral lymph nodes (or mesenteric lymph nodes, 
where indicated) were harvested and mashed on 50uM mesh filter using the flat back of a 
syringe. This filter was washed with 10-25mL of FACs buffer, the cell suspension was 
spun at 1500 rpm for 5 min and cells were incubated with 24G2 block in FACs buffer 
before cell surface marker antibody staining.  
For brain preparations: brains and meninges collected in Eppendorf tubes were 
minced into a slurry using scissors. The homogenate was poured into a six well plate 
including 4.5 mL HBSS plus Ca++ and Mg++ and 250 mU/mL collagenase D (Roche) and 
remaining tissue fragments were washed from the tube using 1mL HBSS from the 6 well 
plate. Tissue was homogenized further by pipetting up and down using a Pasteur pipette. 
Homogenized brains were incubated for 40 minutes at 37°C; every 10 to 15 minutes, 
brain slurry was pipetted up and down with a Pasteur pipette to ensure complete 
homogenization. Collagenase was subsequently quenched with 10mM EDTA for 5 min at 
37°C. Brain homogenate was passed through a 50μM filter and mashed completely 
through the filter using the flat end of a syringe. The filter was then washed twice with 
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ice-cold dPBS, for a total volume of 50mL. Ice cold PBS is critical to brain leukocyte 
harvest and greatly increases cell viability. Brain cells were spun at 1500 rpm for 10 min, 
washed with an additional 50mL ice-cold dPBS and resuspended in 35% Percoll (GE, 17-
0891-01). Percoll separation was performed by spinning at 2000 rpm for 20 min at 4°C, 
after which the upper layer of glial cells and middle layer of Percoll were aspirated. The 
leukocyte pellet was washed with 15mL ice-cold PBS at spun at 1500 rpm for 5 min. 
Total brain leukocytes were incubated with 24G2 block in FACs buffer before cell 
surface marker antibody staining.  
Brains, spleens, blood, and lymph nodes were stained with fixable live-dead blue 
(ThermoFisher, L23105) according to manufacturer’s protocols to exclude dead cells. 
Cells were subsequently stained on ice in FACs buffer with antibodies. LSR II (BD) was 
used for multiparameter flow cytometry of stained cell suspensions, followed by analysis 
with FlowJo software (Tree Star).  
To enumerate total cells per brain, we obtained 15μL of bulk brain preparation 
after collagenase digestion and prior to centrifugation and diluted this in 285μL FACs 
buffer including PE-Cy7 anti-CD45 (30-F11, eBioscience) and APC anti-CD11b (M1/70, 
Biolegend). We ran 50μL of this stained, bulk brain preparation on the BD LSRII flow 
cytometer and enumerated the number of microglia (MG, CD45int CD11bhi) using 
FlowJo. We then normalized cells stained after Percoll purification to MG and used the 
total number of MG from the same sample to calculate total cells/brain i.e. ((cell count of 
population of interest determined by FlowJo/cell count of MG determined by 
FlowJo)*total MG count=total cell count of population of interest). 
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For adoptive transfer experiments and sorting for RNAseq, cell suspensions were 
prepared from indicated tissues from FoxP3-GFP mice as above and stained with anti-
CD45, anti-CD11b, anti-CD19, anti-Ter119, anti-TCRβ, anti-CD4 and DAPI. Live 
CD45hi BL-CD45- (i.e. non-circulating) Ter119- CD19- TCRβ+ CD4+ GFP- (Tcons) or 
live CD45hi BL-CD45- (i.e. non-circulating) Ter119- CD19- TCRβ+ CD4+ GFP+ (Tregs) 
were sorted on a FACS Influx (BD) to >97% purity at the CCTI Flow Core (supported in 
part by the Office of the Director, National Institutes of Health under awards 
S10RR027050 and S10OD020056).  
 
6. CSF isolation and staining 
Six- to eight-week-old FoxP3-GFP mice were injected intravenously with 100μL 
sterile PBS including 5ug Pacific Blue anti-mouse CD45 (30-F11, Biolegend), euthanized 
10 minutes later, blood was harvested from the top left atrium and mice were perfused 
with 10-25mL ice-cold 1X dPBS, as above. Mice were then placed firmly into a Kopf 
stereotaxic frame (model 922) and were dissected to reveal the skin over the cisterna 
magna as in (235). The skin over the cisterna magna was punctured gently with a pulled, 
20μL calibrated pipet (Drummond Scientific, 2-000-020) and 1 to 10μL of CSF were 
obtained by mouth pipetting through a P1000 filter tip and rubber hose (included in 
purchase of Drummond Scientific calibrated pipets). Quality of CSF was confirmed by 
eye by lack of RBC contamination in the fluid withdrawn from the cisterna magna. 1μL 
of CSF was place in a microtiter tube, incubated with 24G2 Fc block and used for 
staining with 5μL FACs buffer including anti-CD45, anti-CD11b, anti-TCRβ, anti-CD4 
and anti-CD8α.  
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7. Adoptive transfers 
For adoptive transfers of FoxP3-DTR and C57BL/6 (WT) cells into Rag1-/- mice, 
total splenocytes were harvested sterilely from FoxP3-DTR or WT mice (see Cell 
Preparation) and 20X106 cells were transferred intravenously into Rag1-/- mice, aged 5-6 
weeks. 1.5 weeks post-transfer, Dtx treatment commenced (see Treg depletion).  
For adoptive transfer of GFP+ Tregs or GFP- Tcons from FoxP3-GFP mice into 
CD45.1 recipients, 2.5-5X105 sorted GFP+ Tregs or 1X106 sorted GFP- Tcons, isolated 
from naïve FoxP3-GFP mice as described above, were adoptively transferred 
intravenously into 6-8 week old congenic CD45.1 recipients. One day after transfer, mice 
were infected with EMCV and 4.5 to 5 days post infection, GFP expression in donor 
splenic, lymph node and brain CD4+ T cells was assessed by flow cytometry.  
 
8. Treg Depletion 
One and a half weeks after transfer, Rag1-/- mice receiving adoptive transfer of 
FoxP3-DTR or WT splenocytes were injected with Dtx (List Biological Laboratories, 
150) intraperitoneally (50ng/g bodyweight). Mice were injected with Dtx one day prior to 
infection and every day thereafter until experiment endpoint. 4.5 to 5 days post-infection, 
mice were euthanized and separated into two parallel groups. One group was used for 
FACS analysis of blood, spleen and brain to detect Treg depletion using anti-CD45, anti-
CD11b, anti-TCRβ, anti-CD4, anti-CD8α and anti-FoxP3. The second group was used for 
histological analysis; in this group peripheral blood was isolated to measure Treg 
depletion and brain and spinal cord were harvested for H&E staining as described below.  
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9. Flt3L treatment  
 In order to artificially increase Flt3L-dependent populations, six-week-old mice 
were injected intraperitoneally with Flt3L (Celldex) (10µg/200μL sterile 1X dPBS) every 
day for 7-10 days. Alternatively, 5.5-week-old mice were injected in the flank, 
subcutaneously, with 2-8X106 B16 Flt3L-producing tumor cells, 14 days prior to 
experiment endpoint. Five days prior to experiment endpoint, mice were infected with 
EMCV according to our standard protocol. 
 
10. Histology and immunofluorescence microscopy 
For histology and microscopy experiments: six- to eight-week old mice were 
euthanized and perfused with 25mL ice cold PBS followed by 25mL freshly-prepared, 
ice cold 4% paraformaldehyde (PFA) in PBS until blanching of the liver was observed 
and rigor was evident. Brain, including meninges, and whole spinal cords were dissected. 
For histology experiments, brain was roughly bisected sagittally into two symmetrical 
lobes using a razor. Then the bisected brain and whole spinal cords were preserved in 
25mL phosphate-buffered formalin for 48 hours prior to embedding, sectioning and H&E 
staining. For histology analysis, brains were sectioned sagittally and spinal cords were 
separated into the four main sections—cervical, thoracic, lumbar, and sacral—and 
sectioned coronally. Paraffin-embedding, sectioning and H&E staining of 8μM sections 
of sagittal brain and coronal spinal cord sections was performed by the CUMC Molecular 
Pathology core. H&E-stained slides were analyzed using a Zeiss Axio Imager 
microscope. Brain and spinal cord sections were graded for graded for the presence of 
inflammation, demyelination, and necrosis on a four-point scale as in (236). Scores were 
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assessed as follows: 0 = no pathology, 1 = minimal inflammation demonstrated by few 
distinct foci of increased cellularity and/or microglia, 2 = moderate inflammation with 
perivascular cuffing and parenchymal infiltration but no loss of tissue architecture, 3 = 
intense inflammation with definite parenchymal injury (loss of tissue architecture, cell 
death, Purkinje cell loss, neurophagia, neuronal vacuolation), and 4 = intense 
inflammation with obvious necrosis (complete loss of all tissue elements with associated 
cellular debris). 
For fluorescence microscopy experiments: whole brains and spinal cords were 
immersed in 25mL 4% PFA for 24 hours, washed with 1XdPBS, immersed in 30% 
sucrose until tissue pieces sunk, washed with PBS and frozen in OCT blocks. Brains were 
sectioned axially to enrich for PVS cross-sections and spinal cords were sectioned 
laterally. 40μM floating sections were prepared and placed in a 24 well plate, washed 
with 3X with 1mL PBS, permeabilized with 500µL 0.2% Triton-X-100 in PB for 1 hour, 
blocked with 500µL 0.2% Triton-X-100 in PB containing 5% goat serum for 1 hour, 
stained in 200µL blocking solution containing primary antibodies overnight at 4°C on a 
shaker, washed 3X with 1mL 0.2% Triton-X-100 in PB, stained with secondary 
antibodies at room temperature for 1 hour in 200µL in 0.2% Triton-X-100 in PB, stained 
with DAPI (1:1000) in 200µL PB for 10 min, washed 3X with 1mL PB and finally 
mounted on a Superfrost Plus slide with Aqua Poly/Mount (Polysciences, 18606). 
Sections were stained with Alexa 488 anti-GFP (Jackson Immuno, 200-542-037), anti-
Pan-laminin (Novus Biologicals, NB300-144), anti-CD31 (BD, MEC13.3), and/or PE 
anti-CD3 (Biolegend, 145-2C11) primary antibodies, goat anti-rabbit Alexa 647 
(Invitrogen) secondary, and DAPI (Invitrogen, D1306) and analyzed on a Zeiss LSM 710 
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Confocal microscope. Z-stack images were merged and analyzed using Image J and 
presented as de-speckled max intensity.  
 
11. Microarray 
 For microarray, RNA was purified using either RNEasy kit (for samples with 
>100,000 sorted cells i.e. LN and SP Tregs and Tcons)(Cat ID 74104) or Ambion 
RNAqueous Micro Kit (for rare CNS Tregs and CNS Tcons)(Invitrogen AM1931) 
according to manufacturers’ instructions. RNA was evaluated by Qubit (Invitrogen 
Q33216) and Bioanalyzer. RNA with RIN>8 was sent to the Rockefeller Genomics 
Resource Center for cDNA synthesis and amplification, and fragmentation and labeling 
using the NuGen Ovation kit and NuGen Encore Biotin Module, respectively. Labeled 
cDNA was run on an Illumina Mouse Ref8 v2.0 Expression BeadChip (no longer 
available for purchase) at the Rockefeller Genomics Resource Center. Data was imported 
into Genespring (Agilent Technologies) for expression analysis. 
 
12. RNAseq 
For RNAseq, RNA was purified, fragmented, converted to cDNA, labeled and 
amplified from sorted Tregs and Tcons using the Clonetech SMARTer Stranded RNAseq 
kit (634837) according to manufacturer’s instructions. We capped PCR amplification at 
20 cycles to avoid amplification of high molecular weight fragments and/or primer 
amplification. Resultant cDNA was analyzed by Qubit fluorometer (Invitrogen Q33216) 
for concentration and Bioanalyzer High Sensitivity DNA assay for quality. Bioanalyzer 
analysis was performed through the CUMC Molecular Pathology Core. Only cDNA with 
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RIN>8 was submitted for RNAseq. Sequencing was performed using the High Output, 
150 cycle Illumina NextSeq 500 v2 kit and NextSeq500 sequencer according to 
manufacturer’s instructions at the Columbia Genome Center. RNAseq reads were aligned 
and mapped and counted and three types of analysis were performed. R code used to 
perform the following analyses is available upon request from the Liu Lab. 
First, we performed an unsupervised analysis to determine the most significant 
variable genes in our data set. To do so, we calculated the variance and the mean of each 
gene across all samples. The line of best fit for the plot of log(variance) vs. log(mean) 
indicates the technical variability of an experiment, whereas genes that fall outside this 
line are genes with biological variability (Figure 3.13.A). Therefore, we plotted 
log(variance) vs. log(mean) for our data set, drew a line of best fit and calculated genes 
that fell outside line (95% COI) i.e. genes with the greatest biological variance. When we 
plotted the resultant gene list on a heat map (not shown), we observed that many of these 
genes were not expressed in any sample. Therefore, we further winsorized these 
significantly variable genes to remove spurious outliers. This analysis yielded 280 
significantly variable genes across all samples in our data set (Fig. 3.13.B). 
Second, we performed a comparison between all CNS samples and all peripheral 
samples, with Tregs and Tcons as covariates, using EdgeR. In other words, we grouped 
the CNS samples together and the peripheral samples together asked for the differences 
between them (FC>1, FDR<0.05), while ignoring any gene detected due to differences 
between Tregs and Tcons. EdgeR is preferable to DESeq2 in this instance because EdgeR 
allows addition of covariates and also uses generalized linear modeling to handle multi-
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factor experiments that have minimal biological replication. This analysis resulted in a 
list of 159 genes. 
Lastly, we performed pairwise comparisons to determine differentially expressed 
genes (DEG, FC>1.5, p<0.05) between all possible pairwise combinations of CNS Tregs, 
CNS Tcons, LN Tregs, LN Tcons, and SP Tregs using DESeq2. 
To generate the lists of injured muscle and VAT T cell-specific genes, we 
submitted publically available microarray data (Series GSE50096 for injured muscle 
Tregs (160) and Series GSE37535 for VAT Tregs (36)) to Genespring and used the 
software to perform a Venn diagram analysis on the intersection of genes differentially 
expressed by injured muscle Tregs compared to their peripheral counterparts and genes 
differentially expressed by injured muscle Tcons compared to their peripheral 
counterparts (FC>2, p<0.05). Similarly, we used Genespring to perform a Venn diagram 
analysis on the intersection of genes differentially expressed by VAT Tregs compared to 
their peripheral counterparts and genes differentially expressed by VAT Tcons compared 
to their peripheral counterparts (FC>2, p<0.05). We then converted Affymetrix probe 




Unless otherwise noted, data are presented as Mean ± SEM, with significance 
calculations determined by unpaired, two-tailed Student’s t test or ANOVA using Prism 
software (GraphPad). Significance calculations for Figure 3.4.A-B were determined by 
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paired Student’s t test. A value of p>0.05 was deemed not statistically significant; 
































Chapter III.  Elucidating the function, origin, localization, mechanism of 
accumulation and gene signature of regulatory T cells that accumulate in the CNS 













Regulatory T cells (Tregs) are an essential subset of CD4+ αβ+ T cells that 
maintain immune and tissue homeostasis throughout adult life (reviewed in (1)). Murine 
Tregs require the transcription factor FoxP3 for their development, maintenance and 
suppressive function  Tregs arise either in the thymus (28, 42-44), or in the periphery 
from naïve T cells who up-regulate FoxP3, generally after chronic exposure to low dose 
antigen (58-61) (62-64). Tregs maintain immune homeostasis by suppressing a variety of 
cells, including CD4+ and CD8+ T cells, dendritic cells, B cells, macrophages, 
osteoblasts, mast cells, NK cells, and NKT cells through contact-dependent and contact-
independent mechanisms, though they are best known for suppressing the proliferation of 
self-reactive T cells (reviewed in (1)). Tregs mediate these functions through the 
expression of TCR-dependent genes, including inhibitory cytokines, such as IL-10 and 
IL-35, competitive IL-2 consumption that results in Bim-mediated apoptosis of other T 
cells, granzyme-mediated cytolysis of other T cells, and expression of inhibitory cell 
surface molecules, such as Glatectin-1, CTLA4, LAG-3, CD39, and Nrp-1 (reviewed in 
(106)).  
While the immune-suppressive role of Tregs is well-established, recent data 
reveals that Tregs in distinct tissue niches can acquire novel functions that are tuned to 
their environments and that these distinct functions can be independent of and mutually 
exclusive of their suppressive capacity (35, 36, 38, 39, 152, 153, 160, 237). For instance, 
Tregs accumulate in the flu-infected lung in response to IL-18 in the BAL and produce 
Amphiregulin (Areg), which is essential for tissue repair and lung barrier function (152). 
In this model, Areg deficiency has no effect on lung Treg capacity to suppress effector T 
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cells and conversely, TCR-deficiency (requisite for Tregs suppressive capacity (111)) has 
no effect on lung Treg Areg production. Therefore, tissue Tregs can accumulate in non-
canonical ways and can play roles that are separable from their canonical immune-
suppressive function.  
One tissue niche in which Tregs have been shown to accumulate during injury, 
inflammation and infection is the CNS, together including the brain and spinal cord 
(194). The CNS is distinct from other tissue because CNS parenchymal tissue lacks 
leukocytes in the steady state (185, 238). Additionally, unlike leukocyte entry into other 
tissues, which requires passage through only one barrier, leukocyte entry into the 
pathological CNS is impeded by two barriers—the blood endothelial cell layer and the 
glia limitans (238). Moreover, leukocyte compartmentalization between these two 
barriers affects the outcome of disease. That is, if leukocytes are prohibited from passing 
through the second barrier during MHV infection using MMP inhibitors, CNS pathology 
is abrogated at the expense of pathogen clearance (184). Passage through each barrier is 
an active process, requiring specific adhesion molecules at the endothelial cell layer and 
production of matrix metalloproteinases at the glia limitans. 
Tregs broadly play tissue protective roles inside the injured, inflamed and infected 
CNS. For example, during MHV infection, Tregs accumulate in the bulk brain and 
protect against excessive pathology and excessive T cell infiltration into the CNS without 
effecting viral replication in the CNS (197). In this model, Tregs effect the accumulation 
of non-antigen-specific T cells within the CNS by down-regulating CXCR3 on T cells 
within the cervical lymph nodes. This was demonstrated by total in vivo depletion of 
Tregs using MHV-infected, Dtx-treated, FoxP3-DTR mice. While Tregs have been 
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shown to be broadly tissue protective in multiple models of CNS disease using in vivo 
Treg depletion models, much remains unknown about their role in this unique niche. That 
is, the precise localization of Tregs within the infected CNS, their origin, their 
mechanism of accumulation and their gene signature have not been studied. The 
elucidation of Treg localization within the pathological CNS is especially important 
given the affect localization can have on the outcome of disease, as described above. The 
study of CNS Treg phenotype by FACs has been limited by the fact that others have not 
differentiated between tissue-infiltrating cells and contaminating cells leftover after 
perfusion. Further, CNS Treg gene signature has likely remained unexplored due to the 
difficulty in obtaining sufficient numbers of CNS Tregs for transcriptome analysis.  
To evaluate these unknown qualities of CNS Tregs, we turned to a viral infection 
that could safely and naturally model CNS disease in the laboratory—
encephalomyocarditis virus (EMCV). EMCV is a picornavirus related to polio whose 
natural reservoir is small rodents (218, 239). The dominant target organs of EMCV are 
the CNS, the pancreas and the heart. EMCV variants are divided into those that are 
dominantly neurotropic or cardiotropic, among which are strains that are also 
diabetogenic (220). The most well characterized neurotropic strain, EMCV-D, results in 
biphasic hind-limb paralysis after i.p. injection in DBA2 mice due to viral replication and 
immune response in CNS organs (218, 223, 239). In particular, EMCV-D infects 
pyramidal neurons in the hippocampus, neurons in the cortical nucleus of the amygdala, 
neurons in the granule layer of the cerebellum and motor neurons in the anterior horn of 
lower thoracic and lumbar spinal cord (223). First phase paralysis involves macrophage 
and CD4+ T cell infiltration into the CNS while second phase paralysis is promoted 
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primarily by CD4+ T cells (223) as demonstrated by decreased paralysis in infected mice 
treated with anti-Mac1 (CD11b) or anti-CD4 antibodies. Therefore, EMCV-D results in 
paralysis due to viral replication and CD4+ T cell immune response in CNS organs. 
However, while EMCV causes CNS disease by natural route and induces CD4+ T cell 
response, the role of Tregs within CD4+ T cells during EMCV infection has not been 
investigated. Therefore, we set out to establish a model of CNS infection in our lab using 
a strain of EMCV highly homologous to the paralysis-inducing EMCV-D (221), EMCV-
R, to evaluate the role of Tregs during EMCV infection. 
Using flow cytometry, microscopy, and genetic models in combination with 
microarray and RNAseq transcriptome analysis, we overcame the difficulties presented 
by isolating rare, CNS-infiltrating Tregs and we investigated for the first time, the 
localization, origin, mechanism of accumulation and gene signature of CNS Tregs in the 
CNS infected by EMCV. 
 
2. Results 
EMCV induces CNS disease typified by lethal hind-limb paralysis, CNS tissue 
pathology and leukocyte accumulation near areas of pathology  
EMCV-infected mice succumb to lethal hind limb paralysis, correlating with viral 
replication in CNS organs 
Intra-peritoneal (i.p.) inoculation with EMCV-R induces CNS disease, 
manifesting in lethal hind limb paralysis in 45% of mice infected with 107 pfu by 5 DPI; 
onset and frequency of paralysis correlates with viral infection dose (Fig. 3.1.A). In 
accordance with symptoms of paralysis, which indicate neural involvement, viral titer is 
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recoverable from the brain and spinal cord, but not the spleen or blood, of infected mice 
(Fig. 3.1.B). Viral replication in CNS organs is also correlated with reproducible 
pathology in distinct regions of the brain and spinal cord—the granule (1) and molecular 
(2) layers of the cerebellum, the pons (3), and the lumbo-sacral spinal cord (4) (Fig. 
3.1.C).  
EMCV infection induces reproducible pathology in the cerebellum, pons, and lumbo-
sacral spinal cord 
In the healthy cerebellum, along the edge of the granule layer, Purkinje neurons—
cells that are responsible for integrating motor neuron output to finely tune movement 
(240)—are aligned at regular intervals (Fig. 3.1.D). In the infected brain, however, the 
regularity of Purkinje cell spacing is disrupted by empty sockets, indicating loss of 
Purkinje cells (Fig. 3.1.D). Further, in healthy mice, the molecular layer, bordering the 
granule layer, is comprised of regularly spaced, diverse glial cells (Fig. 3.1.D). In 
contrast, the same area of infected mice is characterized by an increase in cellularity and 
an increase in activated microglia, identifiable as cells with rod-shaped nuclei (Fig. 
3.1.D). 
Pathology is also detected in the region beneath the cerebellum and fourth 
ventricle in the EMCV-R-infected brain (Fig. 3.1.E). This area of the healthy brain is 
comprised of diverse glial cells, including intermittent clumps of neurons with medium to 
large cell bodies interspersed with microglia—small cells with dark nuclei (Fig. 3.1.E). 
In the infected brain, a dramatic increase of cellularity is observed in the same region 
(Fig. 3.1.E). Increased cellularity includes rosette clusters of microglia, or microglial 
nodules, comprised of phagocytic microglia with amoeboid-shaped nuclei and activated 
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microglia with rod shaped nuclei (Fig. 3.1.E). Such microglial nodules have been 
reported to be triggered by glia cell death (241). Moreover, layers of nuclei surround 
blood vessels in the infected pons (Fig. 3.1.E) but not vessels in the healthy pons, 
indicative of cell accumulation in the perivascular space. That is, cells entering the brain 
from the periphery pool in the perivascular space (PVS), an area of cerebrospinal fluid 
sandwiched between the blood endothelium and the glial limitans. 
Pathology is also observed in the spinal cord. In the healthy anterior horn—the 
region containing motor neurons that control hind limb movement—motor neurons with 
large cell bodies are found interspersed throughout the tissue (Fig. 3.1.F). In the infected 
spinal cord, however, spaces previously inhabited by motor neurons are filled with 
microglial nodules (Fig. 3.1.F) containing both microglia with visible cytoplasm 
(phagocytic microglia) (Fig. 3.1.F), and microglia with rod-shaped nuclei (activated 
microglia). The absence of large motor neurons concomitant with the presence of 
microglial nodules suggests neurophagia by phagocytic microglia.  
Pathology in these regions correlates with CD45+ cell infiltration into the CNS. 
The healthy brain and spinal cord are devoid of CD45+ staining (Fig. 3.1.G), consistent 
with the commonly observed immune privilege status of the healthy CNS. In contrast, 
distinct clusters of CD45+ cells are observed in the infected cerebellum, concentrated 
primarily around blood vessel-like structures, and in the lumbosacral spinal cord, near 
microglial nodule-like structures (Fig. 3.1.G). Together these data indicate that EMCV 
induces leukocyte infiltration into areas where pathology is observed.  
In sum, EMCV-R infects the CNS and results in loss of tissue integrity and 
leukocyte infiltration in the cerebellum, pons and lumbo-sacral spinal cord, regions which 
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are involved in initiating (cerebellum and midbrain) and carrying out (spinal cord) 
voluntary muscle contraction. As such, EMCV-R causes lethal hind limb paralysis, like 
EMCV-D, but demonstrates tropism for different regions of the brain. While EMCV-D 
infects the pyramidal neurons of the hippocampus, we observe no pathology in this 
region during infection with EMCV-R. Thus EMCV-R infection induces specific local 
pathology, correlating with local increase of leukocytes, concentrated in regions that 
affect motor control.  
EMCV infection induces a CNS-specific accumulation of dendritic cells, Ly6Chi 
monocytes, and T cells—including a certain accumulation of FoxP3+ Tregs—within the 
infected CNS 
To determine the composition of CNS-infiltrating leukocytes, we used multi-color 
flow cytometry. To distinguish CNS-resident or CNS-infiltrating leukocytes from 
contaminating circulating blood cells that remain after perfusion, we injected anti-CD45 
intravenously (i.v.) ten minutes prior to euthanasia; this method labels circulating blood 
cells while leaving tissue cells unlabeled (242). The naïve brain tissue contained few 
CNS-infiltrating, CD45hi leukocytes, corresponding to immunofluorescence microscopy 
data (Figure 3.2.A-B). In contrast, total CNS-infiltrating leukocytes, i.e., non-microglia 
CNS tissue cells, increase by >5 fold inside the brain during infection (Figure 3.2.C), 
agreeing with immunofluorescence microscopy data. CNS-infiltrating CD45hi leukocytes 
consist of myeloid and lymphoid cells with a distinct composition. That is, compared to 
the naïve CNS, the EMCV-infected CNS contains significantly more dendritic cells 
(DCs) and Ly6Chi monocytes, while neutrophils and Ly6Clo monocytes did not increase. 
Among lymphocytes, bulk TCRβ+ T cells increased an average of 4.1 fold, whereas B 
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cells decreased an average of 1.95 fold. (Figure 3.2.B). These same populations are 
unaffected in the spleen during infection (Figure 3.2.B), with the exception of a small 
decrease in bulk TCRβ+ T cells in the spleen, indicating a distinct, EMCV-induced 
immune response within the CNS.  
Among CNS-infiltrating T cells, the total numbers of Tregs 
(CD45hiTCRβ+CD4+FoxP3+), Tcons (CD45hiTCRβ+ CD4+FoxP3-) and CD8+ T cells 
(CD45hiTCRβ+CD8+) all increased significantly inside the infected CNS while their 
splenic counterparts did not increase (Figure 3.3.A-D). Importantly, the fold-increase of 
Tregs within the infected CNS is greater than that of Tcons or CD8+ T cells: Tregs 
increase an average of 8.3 fold during infection, whereas Tcons and CD8+ T cells 
increased 3.6 fold and 4.3 fold, respectively (Figure 3.3.B). Moreover, the percentage of 
Tregs among CNS-infiltrating CD4+ T cells was higher than that of the circulation 
(Figure 3.4.A). In contrast, the percentage of Tregs among spleen CD4+ T cells was 
equal to that of the circulation (Figure 3.4.B), indicating a specific enrichment of Tregs 
inside the CNS. Together these data demonstrate that the EMCV-induced, CNS-specific 
immune response is comprised of dendritic cell, Ly6Chi monocyte and T cell increase, 
including a specific accumulation of FoxP3+ Tregs. 
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Bulk T cells exacerbate paralysis while Tregs temper CNS tissue pathology during 
EMCV infection 
EMCV-infected, Rag1-/- mice reconstituted with bulk T cells demonstrate increased 
incidence of pathology compared to EMCV-infected, Rag1-/- mice 
 To understand the consequence of Tcon and Treg increase during EMCV 
infection, we sought to determine the impact of Tcon and Treg depletion during EMCV-
infection. Previous studies have shown that treatment with anti-CD4 and/or anti-CD8 
antibodies is sufficient to limit paralysis in EMCV-infected mice (223), implicating T 
lymphocytes as the arbiters of paralysis. To confirm the role of bulk T cells in EMCV-
induced CNS tissue pathology and paralysis, we infected Rag1-/- mice, which lack B and 
T cells, and Rag1-/- mice that received adoptive transfer of MACS-purified, WT T cells.  
Both groups demonstrated CNS tissue pathology, including microglial nodules in the 
lumbosacral spinal cord, as observed previously in WT mice (Figure 3.5). However, T 
cell-reconstituted Rag1-/- mice demonstrate increased frequency and severity of paralysis 
compared to non-reconstituted controls (Table 3.1). Therefore, viral replication alone 
initiates CNS tissue pathology while bulk T lymphocytes contribute to disease. 
Treg ablation significantly exacerbates EMCV-induced pathology in the pons and spinal 
cord 
To determine the function of Tregs during EMCV infection, we made use of 
FoxP3DTR/GFP (FoxP3-DTR) mice where all Tregs express the diphtheria toxin receptor 
(31), allowing the systemic and conditional depletion of Tregs with diphtheria toxin (Dtx) 
treatment. To mitigate the rapid autoimmunity and illness caused by direct Dtx treatment 
of FoxP3-DTR mice, we transferred 20x106 FoxP3-DTR splenocytes into T cell-
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deficient, Rag1-/- mice, infected recipients with or without Dtx co-treatment, and 
monitored the effect on immune response and CNS Treg pathology. Tregs were readily 
detectable in the periphery and infected CNS of the untreated recipients, but were 
undetectable after Dtx treatment (Figure 3.6.A), indicating complete Treg ablation in 
Dtx-treated, recipient mice. EMCV-infected Treg-ablated mice did not succumb earlier to  
infection (not shown) or demonstrate exacerbated paralysis compared to EMCV-
infected, Treg-sufficient controls (Table 3.2). Despite equal incidence of paralysis, 
however, CNS pathology was exacerbated in Treg-depleted mice after EMCV infection. 
That is, using a score based on (236) (see Methods) to grade CNS pathology, we 
determined that compared to EMCV-infected, Treg-sufficient recipients, Treg-ablated 
mice exhibited increased inflammation in the cerebellar molecular layer, significantly 
increased pathology, including perivascular cuffing, in the pons and significantly increase 
pathology, including microglial nodules and vacuolation, in the lumbo-sacral spinal cord 
(Figure 3.6.B and 3.6.C). These data indicate that Tregs are protective against excessive 
CNS pathology during EMCV infection. 
 
Tregs are restricted to a unique niche—the cerebrospinal fluid—distinct from the 
circulation and the brain parenchyma 
The perivascular space can be defined as the “donut” between concentric rings of pan-
laminin staining 
We sought to determine the anatomic localization of tissue protective CNS Tregs 
during EMCV infection. We infected FoxP3-GFP mice, harvested intact brains and 
analyzed Treg localization by microscopy. In coronal sections, GFP+ Tregs were nowhere 
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to be found (data not shown), contradicting the significant increase of Tregs in the 
infected bulk brain revealed by flow cytometry as in Figure 3.3. This led us to speculate 
that GFP+ Tregs reside in the cerebrospinal fluid (CSF), which may be flushed from the 
ventricles during cryosectioning. To test our conjecture, we evaluated the presence of 
Tregs in the CSF using two separate approaches. First, we took advantage of the fact that 
CSF generated in the ventricles flows in free communication with the subarachnoid space 
(SAS) and the perivascular space (PVS), which surrounds the brain post-capillary venules 
and is confined enough to retain CSF-borne cells even after sectioning (243). We 
sectioned the brain axially to enrich for blood vessel cross-sections and to detect the PVS, 
we stained for anti-pan-laminin, which labels both the parenchymal basement membrane 
and endothelial basement membrane, and CD31, which stains endothelial cell junctions 
(as schematized in Figure 3.7) (243). The PVS is identifiable as the donut shape between 
an inner ring of anti-CD31/anti-pan-laminin co-staining and an outer ring of anti-pan-
laminin staining, or simply, between concentric rings of pan-laminin staining (Figure 
3.8.A) (243).  
FoxP3+ Tregs are retained within the PVS while CD3+ T cells pass through the PVS and 
penetrate the brain parenchyma 
Using this staining method, we observed that CD3+ T cells were detected in both 
the PVS and the brain parenchyma of EMCV-infected mice (Figure 3.8.B). In contrast, 
GFP+ Tregs were detected only in the PVS, and undetectable beyond the donut shape, i.e. 
undetectable in the brain parenchyma (Figure 3.8.B). Thus, our staining indicates that 
FoxP3+ Tregs are restricted to the CSF-containing PVS whereas CD3+FoxP3- Tcons pass 
through the CSF and infiltrate the brain parenchyma.  
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Flow cytometry analysis of CSF harvested directed from the cisterna magna reveals a 
specific accumulation of Tregs within the CSF after infection.  
To confirm the retention of Tregs within the CSF-containing PVS as observed by 
immunofluorescence microscopy, we harvested CSF directly from the cisterna magna of 
non-infected and EMCV-infected FoxP3-GFP mice and evaluated the presence of GFP+ 
Tregs using flow cytometry. In agreement with our microscopy data, both Tcons 
(TCRβ+CD4+GFP-) and Tregs (TCRβ+CD4+GFP+) were detected in the CSF during 
infection (Figure 3.8.C and 3.8.D).  Importantly, the percentage of Tregs among CD4+ T 
cells in the CSF of infected animals (32.5±3.08%) is much higher than that in the 
circulation (15.97±2.97%) and the bulk brain (25.6±3.38%) (Figure 3.8.E), indicating a 
preferential accumulation of Tregs in the CSF during infection. Furthermore, although 
blood cells were labeled by i.v.-injected CD45, the cells harvested from the CSF of 
EMCV-infected mice remained unlabeled, indicating that the CSF remains separate from 
circulating blood cells even during infection (Figure 3.8.F). We conclude that Tregs 
exert a tissue protective function during EMCV infection and are retained within a 
discrete niche. That is, CNS Tcons traffic through the CSF into the brain parenchyma 
during infection while CNS-infiltrating Tregs are restricted to the CSF, a unique niche 
distinct from both the brain parenchyma and the circulation. Importantly, the CSF 
remains intact—separate from the blood—even during infection. 
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CNS Tregs are not converted from Tcons and are recruited to and proliferate 
within the CNS, independently of lymph nodes 
CNS Tregs are nTregs that are recruited to the EMCV-infected CNS  
Because both Tregs and Tcons are found in the infected CNS, and because Tcons 
are capable of up-regulating FoxP3 in other tissues, thereby converting to peripherally 
induced pTregs, we asked whether CNS Tregs arise from Tcons. To test for conversion, 
we adoptively transferred either an excess of naïve Tcons (CD45.2+CD4+GFP-) or Tregs 
(CD45.2+CD4+GFP+) from FoxP3-GFP mice into CD45.1 mice intravenously. One day 
after transfer, we infected recipients with EMCV and measured the appearance of GFP+ 
Tregs within donor-derived (CD45.2+) cells five days post-infection. In this method, the 
derivation of GFP+ cells from GFP- Tcon donor cells indicates conversion or induction of 
FoxP3 and identifies pTreg populations (39, 143). Five days post-infection, as expected, 
few if any Tregs arise from Tcons in the spleen, but ~1% adoptively transferred GFP- 
Tcons converted to GFP+ Treg cells in the mesenteric lymph node (mLN), confirming 
that our adoptive transfer model can report pTreg conversion (Figure 3.9.A). In the CNS, 
GFP+ cells were only detected in mice that received GFP+ donor Tregs, not in mice 
receiving GFP- Tcons (Figure 3.9.A). This indicated that CNS Tregs do not arise from 
Tcons. In support, the majority of CNS Tregs are Helios+ (~86%), suggestive of nTreg 
origin (Figure 3.10) (68). Thus, Tregs in the infected CNS likely originate from thymic-
derived nTreg and are not converted from Tcons. Moreover, because intravenously 
adoptively transferred donor nTregs were detected in the infected CNS but not the naïve 
CNS (Fig. 3.9.A), we conclude that nTregs are recruited from the periphery to the CNS, 
and that infection is requisite for recruitment.  
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EMCV-infected, lymph node-deficient mice demonstrate robust CNS Treg expansion 
In the classic view, naïve T cells only circulate between blood and lymph nodes. 
Thus, recruitment of effector T cells to distinct tissue sites must be preceded by priming 
in the peripheral lymph nodes, where APCs activate T cells by presenting their cognate 
antigens (244, 245). To determine if such lymph node priming is required for the 
recruitment of Tregs to the infected CNS, we assessed the accumulation of CNS Tregs in 
EMCV-infected, lymphotoxin alpha-deficient (LTα-/-) mice, which lack peripheral lymph 
nodes (LNs) and Peyer’s patches (246). Surprisingly, CNS Tregs, CNS Tcons and CNS 
CD8+ T cells accumulated normally in infected LTα-/- mice (Figures 3.9.B and 3.9.C). 
Therefore, Treg recruitment to and expansion within the infected CNS occurs 
independent of lymph nodes.  
Division in situ contributes to enrichment of Tregs in the infected CNS  
As we have shown, nTregs in the circulation can be recruited to the infected CNS 
(Fig. 3.9.A). However, the percentage of Tregs among CD4+ T cells in the CSF is 
dramatically higher than that of the circulation (Figure 3.8.E), suggesting a mechanism 
for additional accumulation, such as division in situ. We thus measured expression of 
Ki67, a nuclear marker for proliferation, in CNS T cells. Indeed, CNS-infiltrating Tregs 
contain a higher percentage of Ki67+ cells than splenic Tregs (Figure 3.11.A-B), 
suggesting that CNS Treg are actively dividing in situ. Notably, CNS Tcons also contain 
a high frequency of Ki67+ cells (Figure 3.11.A-B). Most importantly, CNS-infiltrating 
Tregs, Tcons and CD8+ T cells contain a higher percentage of Ki67+ cells than their 
circulating counterparts, suggesting that proliferation of T cells occurs in situ after their 
entry into the CNS (Figure 3.11.C-D). We conclude that nTregs are recruited from the 
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circulation into the infected CNS independently of lymph nodes; upon entry into the 
infected CNS, they likely further divide in situ.  
 
CNS Tregs maintain FoxP3 expression but are more like CNS Tcons than their 
peripheral counterparts, unveiling a CNS T cell-specific gene signature  
CNS Tregs express core Treg signature genes but cluster with CNS Tcons rather than 
with their peripheral counterparts 
To understand the molecular mechanism underlying the proliferation, localization 
and function of CNS Tregs, we submitted tissue-infiltrating (i.e. non-blood labeled) Tregs 
(CD45hiTCRβ+CD4+GFP+) and Tcons (CD45hiTCRβ+CD4+GFP-), from the spleen (SP), 
lymph node (LN) and brain (CNS) of EMCV-infected FoxP3-GFP mice for 
transcriptome analysis by RNAseq. Inadequate numbers of T cells in the healthy CNS 
precluded comparison with analogous populations in non-infected mice. While typical 
microarray and RNAseq analysis requires a minimum of 50ng total RNA (a concentration 
difficult to achieve from purified CNS T cells), new technology allows indexed library 
generation from as little as 100pg by harvesting total RNA using magnetic beads, 
fragmenting, synthesizing cDNA and amplifying cDNA using barcoded primers. This 
technology allowed us to isolate RNA from CNS T cells and perform RNAseq analysis 
on rare, CNS-infiltrating T cells for the first time. First, to determine if CNS Tregs 
maintain the canonical Treg identity, we assessed the expression of the canonical Treg 
gene signature (44) within our samples. As expected, CNS Tregs express Treg signature 
genes including FoxP3, CD25 (IL2ra), Helios (Ikzf2), Itgae and IL-10 (Figure 3.12.A). 
The expression of these genes is comparable between CNS Tregs and peripheral Tregs 
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(Figure 3.12.A). Similarly, when we performed unsupervised hierarchical clustering of 
CNS Tregs, CNS Tcons and their peripheral counterparts based on the normalized 
mRNA expression values of signature genes that are up-regulated in Tregs, such as 
FoxP3, CD25, Helios, Itgae and IL-10, we found that Tregs from the CNS and the 
periphery cluster away from Tcons (Figure 3.12.B). However, when we compared the 
global transcriptomes of our samples using principle component analysis (PCA), we 
observed that PC1, which accounts for 51% of the sample variability, separates samples 
by tissue localization, while PC2, which accounts for only 19% of the sample variability, 
separates Tcons and Tregs (Figure 3.12.B). This suggests that transcription profile of 
CNS Tregs is globally more similar to that of CNS Tcons than to that of their peripheral 
counterparts (Figure 3.12.A). Because CNS Tregs do not derive from CNS Tcons 
(Figure 3.9.A), the similarity between CNS Tregs and CNS Tcons suggests that selective 
recruitment, entry or response to the CNS induces shared gene expression in both CNS 
Tregs and CNS Tcons.  
Unsupervised and supervised analysis reveals a core set of genes that distinguish CNS T 
cells from their peripheral counterparts 
We sought to determine which genes distinguish CNS Tregs and CNS Tcons from 
their peripheral counterparts using two independent analyses. First, we used an 
unsupervised method to determine the significantly variable genes across all samples in 
our data set (95% COI, winsorized) (Figure 3.13.A). This analysis yielded 280 
significantly variable genes across all samples in our data set (Table 3.3). Unsupervised 
hierarchical clustering using this gene list clusters CNS Tregs together with CNS Tcons 
(Figure 3.13.B), and heat map visualization demonstrates that the majority of these genes 
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were similarly expressed in CNS Tregs and CNS Tcons, but differentially expressed 
between CNS T cells and peripheral T cells (Figure 3.13.B). Therefore, the significantly 
variable genes primarily reflect the variability between CNS T cells and peripheral T 
cells. Second, we used a supervised method to determine differentially expressed genes 
between all CNS samples and all peripheral samples. We used EdgeR (247) to compare 
all CNS samples to all peripheral samples and determined that 159 genes distinguish 
CNS T cells from peripheral T cells (FC>1.0, FDR<0.05) (Figure 3.13.C and Table 
3.4). Strikingly, the lists generated from unsupervised and supervised analyses overlap 
dramatically, showing 105 genes in common (Figure 3.13.D). Therefore, both 
unsupervised and supervised analyses yielded overlapping gene lists that distinguish CNS 
T cells from peripheral T cells, confirming the global similarity of CNS Tcons and Tregs 
calculated by PCA (Figure 3.12.B). 
 
CNS Tregs and CNS Tcons share expression of IFN-induced genes, chemokine 
receptors and corticoid response genes with injured muscle and VAT T cells, 
revealing a shared response to tissue inflammation  
CNS T cells share a gene signature with T cells isolated from inflamed and injured sites 
The difference between the CNS T cells and peripheral T cells could be ascribed 
either to tissue or viral antigen(s) or to tissue injury and inflammation caused by 
infection. Our observation of lymph node-independent accumulation of CNS T cells 
(Figure 3.9.B-C), suggests an antigen-independent route of accumulation. Therefore we 
speculated that tissue injury and inflammation contribute to T cell recruitment to and 
specification within the infected CNS. If so, one would expect that Tregs harvested from 
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distinct inflamed tissue sites would exhibit a common molecular response. To test this 
hypothesis, we compared the CNS T cell-specific gene signature (Figure 3.13.C) to 
injured muscle T cell-specific genes and VAT T cell-specific genes. That is, using 
Genespring to analyze publically available microarray data (Series GSE50096 for injured 
muscle Tregs (160) and Series GSE37535 for VAT Tregs (36)), we determined 141 
injured muscle T cell-specific genes by finding genes differentially expressed by injured 
muscle Tregs compared to their peripheral counterparts that were also differentially 
expressed by injured muscle Tcons compared to their peripheral counterparts (FC>2, 
p<0.05) (Table 3.5). Similarly, we determined 191 VAT T cell-specific genes by finding 
genes differentially expressed by VAT Tregs compared to their peripheral counterparts 
that were also differentially expressed by VAT Tcons compared to their peripheral 
counterparts (FC>2, p<0.05) (Table 3.6). We then compared these gene lists to CNS T 
cell specific genes (Table 3.4). Surprisingly, we found a core set of 15 genes that overlap 
between all three lists, 15 genes that overlap exclusively CNS T cells and injured muscle 
T cells, and 7 genes that overlap exclusively between CNS T cells and VAT T cells 
(Figure 3.14). Therefore, although CNS T cells are substantially different from their 
peripheral counterparts in the same mice, they share a gene signature with T cells that 
enter dystrophic muscle of uninfected mice and T cells that accumulate in the visceral 
adipose tissue of aged mice. This suggests that these genes are induced commonly by 
tissue injury and inflammation. In support, when the list of 141 injured muscle T cell-
specific genes and the list of 191 VAT T cell-specific genes (Tables 3.5 and 3.6) were 
separately submitted to pathway analysis using EnrichR (Wikipathways 2016 module), 
one of the pathways significantly enriched in both gene sets was spinal cord injury 
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(p=0.0002410, injured muscle T cell gene list, and p=0.002180, VAT T cell gene list) 
including the genes CXCL10, NR4A1, ANXA1, VIM, MMP9, TNF, RHOB and CCR2 
(Figure 3.15). Therefore, T cells entering injured muscle and aged adipose tissue express 
genes typically induced by CNS injury, further supporting a common molecular response 
to injury and inflammation in disparate sites.  
Among genes commonly expressed by T cells entering injured and inflamed sites are 
Type I and II IFN response genes, genes controlling chemotaxis, and corticosteroid 
response genes  
We sought to better understand the inflammation-induced signals and pathways 
that specify Treg response in the EMCV-infected CNS. The list of overlapping genes 
between CNS, injured muscle, and VAT T cells reveals five main classes as calculated by 
EnrichR ontology analysis—genes broadly involved in immune response, leukocyte 
differentiation, corticosteroid/stress response, chemotaxis, and metabolism (Figure 3.14 
and Table 3.7). Interestingly, the genes that overlap exclusively between CNS and 
injured muscle T cells include known targets of the Type I and Type II IFN pathways: 
Mx1, Ifitm3 and CXCL10, indicating that these genes may be commonly induced by 
tissue injury. Therefore, to determine if activation of these pathways separated CNS T 
cells from peripheral cells, we began by evaluating expression of the other known 
members of the Type I and Type II IFN (IFN- γ) pathways within CNS T cells. The IFN-
γ pathway is initiated by IFN-γ binding Ifngr (comprised of Ifngr1 and Ifngr2 subunits), 
resulting in receptor oligomerization and activation of JAK1 and JAK2, finally leading to 
STAT1 phosphorylation, dimerization, translocation to the nucleus and activation of 
target genes such as Ifitm3 and CXCL10 (248). We confirmed CNS Tcon IFN-γ 
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production by FACs (Figure 3.16.E), and observed that CNS Tregs and CNS Tcons 
express Ifngr1, STAT1, and the STAT1 target genes including Ifitm3, CXCL10, Isg15 
and Psmb8 (Figure 3.16.A). In contrast, peripheral T cells do not express STAT1 target 
genes (Figure 3.16.A).   
The Type I IFN pathway is initiated by IFN-α/β binding to IFNAR, stimulating 
the JAK/STAT pathway, resulting in assembly of the ISGF3 complex—comprised of 
STAT1, STAT2 and IRF9—which translocates to the nucleus and activates target genes 
such as Mx1, Mx2 and Isg15 (249). We confirmed that CNS Tregs and CNS Tcons 
express IFNAR1, STAT1, STAT2, and IRF9, as well as downstream STAT1/2 target 
genes including Ifi44 and Ifit3 (Figure 3.16.B). In contrast, peripheral T cells do not 
express STAT1/2 target genes (Figure 3.16.B). Therefore, protein and mRNA expression 
in CNS Tregs and CNS Tcons support a role of Type II and Type I IFNs in initiating Treg 
and Tcon response to the infected CNS.  
A second set of genes enriched in CNS, VAT and injured muscle T cells includes 
genes involved in chemotaxis, specifically CCR2, CCR5, CCL5, CXCR5 and CXCR6 
(Figure 3.16.C). CCR5 is known to mediate CD4+ T cell entry into the MHV-infected 
CNS (250). Correspondingly, its ligand, CCL5 or RANTES, is known to be produced by 
glial cells during viral infection (228, 251). However, RANTES can also be secreted by 
the CNS during sterile injury such as spinal cord trauma or ischemia (252, 253), 
suggesting that tissue injury due to viral infection, not necessarily infection itself, induces 
RANTES production in the infected CNS. Using flow cytometry we confirmed that only 
CNS T cells, but not peripheral T cells, express CCR5  (Figure 3.16.E). Together this 
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suggests that injury-induced RANTES recruits CNS Tregs and CNS Tcons via CCR5 to 
the EMCV-infected CNS.  
A third class of genes shared by T cells in injured and inflamed tissue is 
corticosteroid/stress response genes. Corticosteroids, including cortisol, are chiefly 
produced by the adrenal cortex in response to stress, injury and infection (254). CNS T 
cells highly express genes involved in response to several classes of corticosteroids—
glucocorticoids, mineralocorticoids, corticosterone, and progesterone—including genes 
such as Fos, Fosb, Fosl2, Junb, Cdkn1a, IL-10, Sparc, Dusp and Irg1, (Figure 3.16.D, 
listed in Table 3.7). Supporting CNS T cell response to steroids, CNS T cells but not 
peripheral T cells, highly express transthyretin (Ttr), a thyroid hormone binding protein 
induced by corticosteroids and progesterone, whose function is to traffic neuro-protective 
T4 into the brain (255-259). Ttr has previously only been shown to be produced by the 
liver and choroid plexus (260), but not by leukocytes.  We confirmed dramatic up-
regulation of Ttr mRNA in CNS T cells compared to peripheral T cells (Figure 3.18.F). 
Interestingly, increased cortisol concentration in the CSF has also been reported in human 
patients with bacterial infections and traumatic brain injury (261, 262). Altogether, this 
suggests that injury-induced corticosteroids act on Tregs and Tcons in the CSF, resulting 
in a dramatic increase of transthyretin transcripts.    
CNS Tcons are Th1 cells that uniquely express genes regulating response to wounding    
 In a third approach to identify genes expressed uniquely by CNS Tregs or CNS 
Tcons, we first performed pairwise comparisons between CNS Tregs and LN Tregs or SP 
Tregs and between CNS Tcons and LN Tcons using DESeq2. In order to determine genes 
expressed exclusively by CNS Tregs or CNS Tcons, we determined genes that were 
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differentially expressed by CNS Tregs compared to LN or SP Tregs that were not also 
differentially expressed by CNS Tcons compared to LN Tcons (CNS Treg-specific 
genes) and conversely, determined genes that were differentially expressed by CNS 
Tcons compared to LN Tcons that were not also differentially expressed by CNS Tregs 
compared their peripheral counterparts (CNS Tcon-specific genes). This analysis 
revealed the following: first, reflecting the overall similarity between CNS Tregs and 
CNS Tcons, CNS Tregs only differentially express 14 genes that are not also 
differentially expressed by CNS Tcons (i.e. CNS Treg-specific genes). These are: Fos, 
Tiparp, Cep57l1, Stxbp3, Rgs2, Gng12, Fam107a, Dock9, Itgb3, Ppp1r15a, Itgav, Jun, 
Dusp1 and Fam46a. Among these, the increased expression of Fos and Jun, a pro-
proliferative transcription factor complex, correlates with increased Ki67 expression in 
CNS Tregs.  
Next, CNS Tcons up-regulate 432 genes compared to LN Tcons that are not also 
up-regulated in CNS Tregs compared to their peripheral counterparts (i.e. CNS Tcon-
specific genes). To understand the significance of these genes we submitted them to 
EnrichR ontology analysis (Table 3.8), which revealed that one ontology enriched in 
CNS Tcon-specific genes but not other gene lists is regulation of response to wounding 
(p=3.57761x10-7), which includes genes such as Sema7a, Cfh, Stk39, Rora, Metrnl, 
Pla2g7, C2, Il1rl1, Irg1, CCL5, Casp4, CCL3, Casp1, Apoe, Tgm2, Arfgef1, Anxa2, F2r, 
Tnfrsf1b, Hopx, Il2ra, Ilr7, and PIK3AP1. This suggests that infiltration into injured 
brain parenchyma induces a subset of genes in CNS Tcons alone that regulate response to 
damaged tissue. Moreover, when we submit these 432 CNS Tcon-specific genes to 
Ingenuity Pathway Analysis, we observe that one of the top predicted upstream regulators 
 80
is lipopolysaccharide (p value of overlap=1.70 X 10-58), which is odd considering the lack 
of bacterial infection. However, it is known that by-products of spinal cord damage, 
particular matrix proteins, can activate TLR4 and downstream, LPS-associated signaling 
(263). Therefore, infection and tissue damage converge on common inflammatory 
pathways.  Finally, when the list of CNS Tcon-specific genes is submitted to ChEA 
(within EnrichR) to predict transcription factor regulators, we find that STAT3, STAT4 
and IRF8 are top ranked. STAT4 is known to stabilize Tbet signaling downstream of IFN 
signaling in Th1-skewed CD4+ T cells (264),, while IRF8 activation is known to suppress 
Th17 phenotype (265). Indeed, Th1 signature genes are expressed in CNS Tcons, while 
Th17 signature genes are repressed (Figure 3.17). Therefore, these data suggest that CNS 
Tcons regulate response to wounding within the infected CNS and further, a delicate 
balance is occurring within CNS T cells themselves to promote a Th1 response sufficient 
to clear virus while inhibiting an excessive Th17 response that may cause demyelination 
and excessive tissue damage (266).  
 
Microarray data confirms that CNS Tregs maintain FoxP3 expression but are more 
like CNS Tcons than their peripheral counterparts, sharing expression of IFN-
induced genes, chemokine receptors and corticoid response genes with CNS Tcons 
 In support of our RNAseq data, we also present microarray analysis on lymphoid 
(splenic and lymph node) CD45hi TCRβ+ CD4+ GFP+ (Tregs) and CD45hi TCRβ+ CD4+ 
GFP- (Tcons) cells from naive FoxP3-GFP mice, as well as lymphoid Tregs and Tcons 
and CNS Tregs and Tcons harvested from EMCV-infected, FoxP3-GFP mice. In 
agreement with RNAseq data, microarray data shows that CNS Tregs maintain the 
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canonical Treg identity, including increased expression of canonical Treg genes such as 
FoxP3, CD25 (IL2rα), Helios (Ikzf2), Itgae and Nrp1 compared to CNS and peripheral 
Tcons (Figure 3.18.A). Despite their Treg identity, however, unsupervised hierarchical 
clustering on normalized microarray expression values reveals that CNS Tregs and CNS 
Tcons cluster together, away from their peripheral counterparts (Figure 3.18.B). Further, 
unsupervised hierarchical clustering shows that, generally, peripheral cells harvested 
from naïve mice cluster together and peripheral cells harvested from EMCV-infected 
mice cluster together, next to cells harvested from naïve mice (Figure 3.18.B). Together 
this supports our RNAseq data, and suggests that infection induces only modest changes 
in peripheral Tregs and Tcons while entry into or response to the infected CNS induces 
distinct, shared gene expression in both CNS Tregs and CNS Tcons. 
 Using the microarray data, we also determined genes that distinguish CNS Tregs 
and CNS Tcons from their peripheral counterparts, harvested from both naïve and 
EMCV-infected mice. That is, we used Genespring Venn diagram analysis to determine 
genes shared between the following pairwise comparisons: genes differentially expressed 
in CNS Tregs compared to lymph node Tregs harvested from EMCV-infected mice, 
genes differentially expressed in CNS Tregs compared to lymph node Tregs harvested 
from naive mice, genes differentially expressed in CNS Tregs compared to splenic Tregs 
harvested from naive mice, genes differentially expressed in CNS Tcons compared to 
lymph node Tcons harvested from EMCV-infected mice, genes differentially expressed 
in CNS Tcons compared to lymph node Tcons harvested from naïve mice and genes 
differentially expressed in CNS Tcons compared to splenic Tcons harvested from naïve 
mice (FC>2, p<0.05 for all comparisons). The overlaps between these comparisons 
 82
yielded 171 CNS T cell-specific genes (Table 3.9). When these genes were submitted to 
EnrichR ontology analysis, response to type I interferon (GO:0035455, p=0.00001886) 
and the type I interferon signaling pathway (GO:0060337, p=0.00001854) were two of 
the most significantly enriched ontologies.  Moreover, when these genes were submitted 
to EnrichR pathway analysis (WikiPathways 2016), one of the most significantly 
enriched pathways was Type II interferon signaling (WP1253, p=0.005859). Indeed, heat 
map visualization of the normalized microarray expression data of genes within the Type 
I (Figure 3.18.C) and Type II IFN (Figure 3.18.D) signaling pathways revealed that 
these genes distinguish CNS Tregs and CNS Tcons from their peripheral counterparts, 
independently supporting our RNAseq data. Additionally, heat map visualization of the 
normalized microarray expression data of corticosteroid response genes, including the 
glucocorticoid receptor, Nr3c1, and transthyretin, revealed that these genes distinguish 
CNS Tregs and CNS Tcons from their peripheral counterparts (Figure 3.18.E), 
independently supporting our RNAseq data.  
In sum, both RNAseq and microarray transcriptome analysis reveal the following: 
first, while CNS Tregs maintain the core Treg signature associated with FoxP3 
expression, they are globally more similar to CNS Tcons than to their peripheral 
counterparts. The genes separating CNS T cells from their peripheral counterparts 
overlap with genes up-regulated in injured muscle T cells, thereby revealing a shared set 
of mechanisms employed by injured tissue that shape T cell response. These mechanisms 
include IFN response, RANTES-CCR5 interaction and corticosteroid response, which 
were previously unappreciated. Additionally, while CNS Tregs and CNS Tcons are 
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markedly similar, CNS Tcons uniquely express genes that indicate a delicate balance 
between an antiviral and anti-inflammatory phenotype.    
 
3. Discussion 
In this chapter, we employed a series of methods to characterize Tregs that 
accumulate in the CNS of mice infected with EMCV, filling the gaps in knowledge about 
this specialized cell population. The main difficulty in studying CNS Tregs had been the 
scarcity of Tregs that can be recovered from the bulk CNS. Further, contamination of 
blood cells remaining after perfusion during bulk brain tissue preparation made it difficult 
to differentiate tissue-specific Treg response from systemic Treg response. Additionally, 
the exact anatomic localization of CNS Tregs inside the infected CNS was unclear.  To 
overcome these obstacles, we employed a simple, flow cytometry-based method to 
differentiate circulating cells from tissue-infiltrating cells, thereby interrogating CNS 
Treg origin, and mechanisms of accumulation. Next, we observed that despite flow 
cytometry data showing significant accumulation of Tregs within the infected bulk brain, 
Tregs were not detectable in the brain parenchyma of coronal brain sections. This 
discrepancy prompted us to search for Tregs within the CSF, which may have been 
flushed from coronal sections during cryosectioning. To do so, we collected CSF directly 
from the cisterna magna and assessed Treg localization to the perivascular space (PVS) 
by immunofluorescence microscopy of axial sections; the PVS is a smaller, confined 
space, containing CSF whose integrity can be preserved even after sectioning. Last, we 
employed a novel method to collect and amplify RNA from <30,000 cells, thereby 
facilitating the first transcriptome analysis of scarce, CNS-infiltrating Tregs.  
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Using these methods, we show that CNS Tregs prevent excessive infection-
induced pathology in the CNS during EMCV infection. This tissue protective function is 
not surprising given previous published data showing that Tregs protect against excessive 
CNS tissue pathology during MHV (197) and WNV infection (198), for example. What 
is unique about our study is that we show that thymus-derived Tregs accumulate within a 
distinct niche—the cerebrospinal fluid (CSF)—of the EMCV-infected CNS, 
independently of lymph node priming. Most interestingly, these new findings have 
implications for neuro-immune cross-talk between cells circulating in the CSF and neural 
progenitor cells that extend their apical domains into the CSF of the ventricles. These and 
other implications are discussed further in Chapter IV: Discussion. 
We also analyzed the gene expression of CNS Tregs and CNS Tcons by RNAseq 
and microarray. This analysis revealed that while CNS Tregs maintain expression of core 
Treg signature genes, including FoxP3, their global transcriptome is more similar to that 
of Tcons harvested from the infected CNS than to that of peripheral Tregs. 
Bioinformatics analysis of RNAseq and microarray data reveals that genes shared by 
CNS Tcons and CNS Tregs are also shared by Tregs and Tcons from injured muscle and 
the visceral adipose tissue of aged mice, indicating that tissue inflammation and injury, 
rather than viral infection per se, contribute to CNS Treg accumulation, function and 
phenotype. These data suggest that common, inflammation driven mechanisms may be 






Figure 3.1: EMCV induces CNS disease typified by lethal hind-limb paralysis, CNS 
tissue pathology and leukocyte infiltration into the brain and spinal cord. (A) 
Survival curve of B6 mice after i.p. inoculation with 107, 2x106, 2X105 and 2x104 pfu 
EMCV-R. Mice were euthanized when moribund and paralyzed. Two independent 
experiments pooled, n=20 mice. (B) Viral titer in whole spinal cords, brains, spleens and 
100uL blood from EMCV-infected B6 mice, 5DPI. Representative of two independent 
experiments, n=2-4 mice per experiment. (C) Schematic summary of regions of the brain 
and spinal cord where CNS tissue pathology was observed across six independent 
experiments in EMCV-infected WT mice, 5DPI. 1: Granule layer of the cerebellum; 2: 
molecular layer of the cerebellum; 3: pons; 4: the anterior horn of the lumbo-sacral spinal 
cord.  (D-F): Representative histopathological H&E staining of the cerebellum (D), pons 
(E), and lumbo-sacral spinal cord (F) of naïve and EMCV-infected WT mice. In (D), 
arrows mark the spacing of Purkinje neurons (“P”) and “G” indicates the granule layer. 
Bracket in (D) encompasses Purkinje cell loss and arrows mark rod-shaped nuclei, 
indicative of activated microglia. In (E), circles encompass microglial nodules and arrow 
points to perivascular leukocytes. In (F), motor neurons are indicated as “M” and circles 
encompass microglial nodules. Representative of six independent experiments, n=2-4 
mice per group. (G) IF confocal microscopy of coronal brain and lateral spinal cord 
sections from naïve or EMCV-infected WT mice. CD45 (red) and DAPI (green). 


















































































































































Figure 3.2: EMCV induces dendritic cell, monocyte and T cell accumulation in the 
CNS but not the spleen. (A) Flow cytometry plots showing gating strategy of tissue-
infiltrating leukocyte populations including dendritic cells (DCs)(CD45hiB220-
CD11c+MHCII+), Ly6Chi monocytes (CD45hiLy6G-CD11b+Ly6Chi), Ly6Clo monocytes 
(CD45hiLy6G-CD11b+Ly6Clo), neutrophils (CD45hiLy6G+), B cells (CD45hiB220+) and T 
cells (CD45hiTCRβ+) in the brain and spleen of naïve and EMCV-infected B6 mice 
(5DPI, 107 pfu). Parent gate is live, single cells. Numbers are frequencies of parent gates. 
Representative of three experiments, n=3-5 mice per group. (B) Absolute numbers of 
tissue-infiltrating leukocyte populations in the brain and spleen of naïve and EMCV-
infected mice as gated in (A). Data is mean ± SEM representative of three experiments, 
n=3-5 mice per group. (C) Absolute numbers of tissue-infiltrating leukocytes in the brain 
and spleen of naïve and EMCV-infected mice as gated in (A). Data is mean ± SEM 
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Figure 3.3: EMCV induces a specific accumulation of regulatory T cells within the 
CNS but not the spleen. (A-B) Flow cytometry plots of circulating and tissue-infiltrating 
T cells in the brain and spleen of naïve or EMCV-infected B6 mice showing gating 
strategy for Tregs (CD45hiTCRβ+CD4+FoxP3+), Tcons (CD45hiTCRβ+CD4+FoxP3-) and 
CD8+ T cells (CD45hiTCRβ+CD8+). Numbers are frequencies of parent gates. 
Representative of 3 independent experiments, n=2-5 mice per group.  (C-D) Absolute 
numbers of Tregs, Tcons and CD8+ T cells in the brain (C) and spleen (D) of naïve and 
EMCV-infected mice as gated in (A) and (B). Data are mean ± SEM representative of 
more than 10 independent experiments, n=2-5 mice per group. *p<0.05, **p<0.01, 
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Figure 3.4: A specific enrichment of Tregs occurs inside the EMCV-infected CNS. 
Percentage of FoxP3+ cells among circulating and tissue-infiltrating CD4+ T cells in the 
brain (A) and spleen (B). Gated as in Fig. 3.3. Data are mean ± SEM representative of 






















































































Figure 3.5: Adoptive transfer of bulk T cells into T cell-deficient, Rag1-/- mice has 
no effect on pathology during EMCV infection. Representative histopathological H&E 
staining of the lumbo-sacral spinal cord of naïve and EMCV-infected Rag1-/- mice with 
or without adoptive transfer MACS-purified T cells. Motor neurons are indicated as “M” 
and circles encompass microglial nodules. Representative of two independent 







Figure 3.6: Tregs protect against excessive CNS pathology during EMCV infection. 
(A) Flow cytometry plots of splenic, lymph node and CNS Tregs in control Rag1-/- mice 
and Rag1-/- mice that received Foxp3DTR/GFP T cells and +/- 107 pfu EMCV +/- Dtx 
treatment (see Methods). Live, Single, CD45hi cells are shown. Numbers are frequencies 
of parent gate. Representative of three independent experiments, n=2-3 mice per group. 
(B) Representative histopathological H&E staining of cerebellum, pons and lumbo-sacral 
spinal cord of paralyzed EMCV-infected Rag1-/- mice that received Foxp3DTR/GFP T cells 
+/- Dtx treatment (as in (A)). Arrow marks perivascular cuffing (pons) and arrowheads 
mark neuronal vacuolation (spinal cord). Representative of three independent 
experiments, n=4-5 mice per group. (C) Pathology score (see Methods) of cerebellar, 
pons, and spinal cord H&E in Treg-sufficient and Treg-deficient mice treated as in (A-B). 
Representative of three independent experiments, n=4-5 mice per group. *p<0.05, 












































































































































































































































Figure 3.7: Schematic of pan-laminin and CD31 expression patterns in a post-
capillary venule cross section. Laminin isoforms are expressed at the endothelial 
basement membrane and the parenchymal basement membrane and are recognized by 
anti-pan-laminin antibody. CD31 (PECAM-1), is an endothelial cell adhesion marker that 
contributes to the endothelial junction complex. The PVS is identifiable as the donut 
shape between an inner ring of anti-CD31/anti-pan-laminin co-staining and an outer ring 
of anti-pan-laminin staining, or simply, between concentric rings of pan-laminin staining. 































 Figure 3.8: CNS Tregs preferentially accumulate within a unique niche—the CSF—
separate from both the blood and brain parenchyma. (A) IF confocal microscopy of 
axial brain sections from naïve WT mice showing the perivascular space (PVS) as the 
donut shape contoured by Pan-laminin (red) and CD31 (green) staining. Representative 
of two experiments. (B) IF confocal microscopy of axial brain sections from EMCV-
infected, FoxP3-GFP mice, stained with anti-Pan-laminin (white) and anti-CD3 (red) or 
anti-GFP (green). Representative of four independent experiments, n=2-4 mice per 
experiment. (C) Flow cytometry of 1μL CSF from naïve or EMCV-infected, FoxP3-GFP 
mice. Numbers are frequencies of parent gate. Representative of three independent 
experiments, n=2-5 mice per group. (D) Absolute numbers of FoxP3+ Tregs in 1μL CSF. 
Data are mean ± SEM representative of three independent experiments, n=2-5 mice per 
group. (E) Percentage of FoxP3+ Tregs among CD4+ T cells in the CSF. Data are mean ± 
SEM representative of three independent experiments, n=2-5 mice per group. (F) Flow 
cytometry plots of 1μL CSF and blood of naïve and EMCV-infected B6 mice that 
received blood labeling via i.v. injection of anti-CD45 prior to euthanasia as in methods. 
Numbers are frequencies of parent gate. Representative of two independent experiments, 
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Figure 3.9: CNS Tregs are nTregs that are recruited to the CNS independently of 
lymph nodes. (A) Flow cytometry of T cells in the brain, spleen and mesenteric lymph 
node (mLN) of naïve or infected recipient CD45.1 mice that received either 1x106 GFP- 
Tcons or 3x105 GFP+ Tregs from FoxP3-GFP donors. Shown are live, single, CD45hi 
TCRβ+CD4+ cells. Numbers are frequencies of parent gate. Representative of two 
independent experiments, n=2-3 mice per group. (B) Flow cytometry of brain Tregs, 
Tcons, and CD8+ T cells from naïve or infected WT or LTα-/- mice. Shown are live, 
single, CD45hi TCRβ+ cells. Numbers are frequencies of parent gate. Representative of 
three independent experiments, n=2-5 mice per group. (C) Absolute numbers of Tregs, 
Tcons and CD8+ T cells in the brains of naïve or infected WT or LTα-/- mice as gated in 
(B). Data are mean ± SEM representative of three independent experiments, n=2-5 mice 
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Figure 3.10: CNS Tregs are predominantly Helios+, suggestive of nTreg origin. 
Representative flow cytometry plots of Helios expression in CNS Tregs isolated from 
naïve and EMCV-infected WT mice. Shown are live, size, single CD45hiTCRβ+CD4+ 
cells. Numbers are frequencies of parent gate. Representative of three independent 



















































Figure 3.11: CNS T cells likely proliferate in situ after infiltrating the infected CNS.  
(A) Flow cytometry showing Ki67 expression in tissue-infiltrating (i.e. Blood-labeled-) 
Tregs (red, CD45hiCD11b- TCRβ+CD4+FoxP3+), Tcons (blue, CD45hiCD11b- 
TCRβ+CD4+FoxP3-) or CD8+ T cells (black, CD45hiCD11b- TCRβ+CD8+) from the brain, 
spleen, and blood of naïve or EMCV-infected mice. Frequencies shown are percents of 
parent gates. Representative of one of three experiments. (B) Percentage of Ki67+ cells 
within Treg, Tcons or CD8+ T cells from the brain, spleen, and blood of naïve and 
EMCV-infected WT mice as gated in (A). Data is mean ± SEM representative of three 
experiments, n=3-5 mice per group. (C) Flow cytometry showing Ki67 expression of 
circulating (i.e. Blood-labeled+) and CNS-infiltrating (i.e. Blood-labeled-) Tregs 
(CD45hiCD11b-TCRβ+CD4+ FoxP3+), Tcons (CD45hiCD11b-TCRβ+CD4+ FoxP3-) or 
CD8+ T cells (CD45hiCD11b-TCRβ+CD8+) from naïve and infected mice. Numbers are 
frequencies of parent gate. Representative of three independent experiments, n=2-5 mice 
per group. (D) Percentage of Ki67+ cells among circulating and CNS-infiltrating Tregs, 
Tcons and CD8+ T cells as in (C). Data are mean ± SEM representative of three 
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Figure 3.12: CNS Tregs express core Treg signature genes but their global 
transcriptome is more similar to that of CNS Tcons than to that of peripheral Tregs. 
A) Heat map showing normalized mRNA expression values of published Treg signature 
genes (as in (44)) within CNS Tregs, CNS Tcons and their peripheral counterparts. 
Highlighted on the right are key Treg genes. (B) Unsupervised hierarchical clustering of 
CNS Tregs, CNS Tcons and their peripheral counterparts based on normalized mRNA 
expression values of signature genes that are published to be up-regulated in Tregs (as in 
(44)). Highlighted on the right are key genes. (C) PCA analysis comparing global 








Figure 3.13: Unsupervised and supervised transcriptome analysis reveals a CNS T 
cell-specific gene signature. (A) Graph showing log(means) versus log(variance) of 
normalized mRNA expression values determined by RNAseq from all genes across all 
samples. Slope used to determine significantly variable genes as in (Methods). Red 
circles represent top 100 significantly variable genes. (B) Heat map showing normalized 
mRNA expression of 280 significantly variable genes (95% COI) across Tregs and Tcons 
in the CNS, spleen and lymph nodes of EMCV-infected mice as calculated in (A) 
(individual genes listed in Table 3.3); dendrogram showing unsupervised hierarchical 
clustering of samples. (C) Heat map showing normalized mRNA expression of the 159 
genes differentially expressed (FC>1.0, FDR<0.05) between CNS samples and peripheral 
samples as calculated by EdgeR (see methods) (individual genes listed in Table 3.4); 
dendrogram showing unsupervised hierarchical clustering of samples. (D) Venn diagram 
of the overlap between gene lists generated from the unsupervised analysis (C) and 
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Figure 3.14: T cells infiltrating inflamed tissue share a core set of genes. Venn 
diagram of the overlap between CNS T cell-specific genes (Table 3.4), injured muscle T 
cell-specific genes (Table 3.5, (160)), and VAT T cell-specific genes (Table 3.6, (36)). 
Listed are overlapping genes and their corresponding functional classes (ontologies) as 






















Figure 3.15: Muscle and VAT T cell-specific gene signatures are enriched for genes 
induced by spinal cord injury. (A-B) Top 10 pathways enriched in the injured muscle T 
cell gene signature (A) (Table 3.5) and the VAT T cell gene signature (B) (Table 3.6) as 







































Figure 3.16: The shared response to inflamed tissue includes expression of IFN-
induced genes, chemokine receptors and corticoid response genes. (A-D) 
Transcriptome profiling of biological pathways in Tregs and Tcons from the CNS and 
periphery of infected mice. Heat map showing normalized mRNA expression of all genes 
within the Type II IFN response pathway (A), all genes within the Type I IFN response 
pathway (B), genes within chemokine, chemokine receptor and cytokine receptor 
ontologies (C), and genes within corticosteroid response ontologies. For (C) and (D), 
shown are genes within these classes that are differentially expressed by CNS T cells 
compared to peripheral T cells as calculated in (Fig. 3.11.C). Graphical schematics 
showing the average normalized mRNA expression of genes within in the Type II IFN 
response pathway (A), Type I IFN response pathway (B) in CNS and peripheral T cells. 
(E) Flow cytometry of IFN-γ and CCR5 expression in Tregs (CD45hi TCRβ+ CD4+ 
FoxP3+) and Tcons (CD45hi TCRβ+ CD4+ FoxP3-) from the brain and spleen of EMCV-

















Figure 3.17: CNS Tcons express stereotypical Th1 genes. Heat map showing 
normalized mRNA expression of stereotypical Th1 genes and graphical schematic 
































Figure 3.18: Microarray transcriptome analysis shows that CNS Tregs maintain 
FoxP3 expression but are more like CNS Tcons than their peripheral counterparts, 
sharing expression of IFN-induced genes, chemokine receptors and corticoid 
response genes with CNS Tcons. (A) Heat map showing normalized mRNA expression 
values of Treg signature genes (44) expressed by Tregs and Tcons in the CNS or lymph 
node (LN) of EMCV-infected FoxP3-GFP mice detected by Illumina microarray. 
Bracketed in red are genes stereotypically up-regulated in Tregs, bracketed in blue are 
genes stereotypically down-regulated in Tregs. Plotted using Genespring. (B) Heat map 
showing unsupervised hierarchical clustering of normalized mRNA expression values of 
Tregs and Tcons from CNS, lymph nodes (LN), or spleen (SP) of naïve or EMCV-
infected FoxP3-GFP mice, detected by Illumina microarray. Plotted using Genespring. 
(C-E) Heat map showing normalized expression mRNA values of Type II IFN response 
genes (C), Type I IFN response genes (D) and corticosteroid response genes (E) in Tregs 
and Tcons from the CNS or LN of EMCV-infected FoxP3-GFP mice detected by 
Illumina microarray. Plotted using Genespring. (F) Normalized mRNA expression values 
of Mx1, IFN-γ, CCR5 and transthyretin (Ttr) by Tregs and Tcons in the CNS or LN of 













CNS Tcons EMCV 
CNS Tregs EMCV 
LN Tcons EMCV 
LN Tcons Naïve  
LN Tregs Naïve  
LN Tregs EMCV 
SP Tregs Naïve  







































































































































































Incidence of Paralysis 
Rag1-/- 107 2/7 (28.5%) 






















Table 3.1: Bulk T cells exacerbate paralysis during 
EMCV infection. Incidence of paralysis among EMCV-
infected, Rag1-/- mice with or without adoptive transfer of 





















(107 pfu)? Dtx? 
Number 
paralyzed 
Rag1-/- - + - 1/2 (50%) 
Rag1-/- - + + 1/2 (50%) 
Rag1-/- FoxP3-DTR splenocytes + - 5/8 (62.5%) 
Rag1-/- FoxP3-DTR splenocytes + + 6/9 (67%) 
Figure 3.2: Treg deficiency has no effect on the incidence of paralysis 
during EMCV infection. Incidence of paralysis among EMCV-infected, Rag1-/- 
mice that received transfer of FoxP3-DTR splenocytes with or without Dtx 






symbol Gene symbol Gene symbol Gene symbol
1 Gm4956 71 Nampt 141 Ms4a1 211 Plac8
2 Khdc1a 72 F730043M19Rik 142 Ms4a6d 212 Sparcl1
3 Dst 73 Hdac9 143 Mpeg1 213 Gbp6
4 Il18rap 74 Hif1a 144 Cd274 214 Tgfbr3
5 Als2 75 Fos 145 Pdcd1lg2 215 Brdt
6 Ikzf2 76 Ston2 146 Ifit2 216 Oasl2
7 Igfbp5 77 Ifi27l2a 147 Ifit3 217 Oasl1
8 Fam124b 78 Serpina3g 148 Gm14446 218 Oas2
9 Il10 79 Itgb8 149 I830012O16Rik 219 Oas3
10 5430435G22R 80 Klf6 150 Ifit1 220 Oas1b
11 Atp2b4 81 Gpr141 151 Pik3ap1 221 Oas1a
12 Rgs1 82 Serpinb6b 152 Got1 222 Trafd1
13 Lamc1 83 Serpinb9 153 Itih5 223 Parp12
14 Tor3a 84 Cd83 154 Il2ra 224 Clec5a
15 BC094916 85 Tgfbi 155 Il1rn 225 Mgam
16 Pydc4 86 Ctla2b 156 Bmyc 226 Gimap7
17 Pyhin1 87 Ctla2a 157 Lypd6b 227 Osbpl3
18 Pydc3 88 Vcan 158 Ermn 228 Herc6
19 AI607873 89 Naip6 159 Ifih1 229 Il12rb2
20 Ifi204 90 Naip7 160 Myo3b 230 Hk2
21 Mnda 91 Ankrd55 161 Ttn 231 Mxd1
22 Ephx1 92 Gzma 162 Ube2l6 232 Bhlhe40
23 Themis 93 Fam107a 163 Slc1a2 233 Srgap3
24 Cep57l1 94 Kcnk5 164 Thbs1 234 Usp18
25 Gp49a 95 4930431P03Rik 165 Ehd4 235 Ptpro
26 Lilrb4 96 Peli2 166 Pla2g4f 236 Bicd1
27 Chst3 97 Gzmb 167 Capn3 237 Fosb
28 Tet1 98 Phf11 168 AA467197 238 Cd79a
29 Egr2 99 Gm4902 169 Mir147 239 Cd22
30 Ggt5 100 Gm6907 170 Atp8b4 240 Nkg7
31 Ifng 101 Cysltr2 171 Mertk 241 Ptpn5
32 Msrb3 102 Epsti1 172 Siglec1 242 Igf1r
33 Kif5a 103 Irg1 173 Zfp937 243 Arrdc4
34 Lrp1 104 Myo10 174 9830001H06Rik 244 Ntrk3
35 Stat2 105 Enpp2 175 Mafb 245 Isg20
36 Ikzf4 106 Ly6a 176 Znfx1 246 Lrrc32
37 Hba-a1 107 Ly6c2 177 B4galt5 247 Trim30a
38 Hba-a2 108 Eppk1 178 Zbp1 248 Trim30d
39 Havcr2 109 Parp10 179 BC006779 249 Swap70
40 Irgm1 110 Dgat1 180 Il21 250 Pde3b
41 Gm5431 111 Apol9b 181 Ift80 251 Cd19
42 Gm12185 112 Tmem184b 182 Fnip2 252 Mki67
43 Slc22a5 113 Rtp4 183 She 253 Ifitm3
44 Sparc 114 Parp14 184 Il6ra 254 B4galnt4
45 Gm12250 115 Dtx3l 185 Fcgr1 255 Irf7
46 Igtp 116 Parp9 186 Gpsm2 256 Igf2
47 Snord49b 117 Tiam1 187 Gbp1 257 D8Ertd82e
48 Hs3st3b1 118 Mx1 188 Gbp2 258 Unc13a
49 Gas7 119 Mx2 189 Ifi44 259 Sall1
50 Xaf1 120 Ccr6 190 Penk 260 Gpr83
51 Itgae 121 Airn 191 Gem 261 Folr4
52 Aldoc 122 Cdkn1a 192 Atp6v0d2 262 Amica1
53 Slfn5 123 Daxx 193 Ddx58 263 Arhgap20
54 Slfn1 124 H2-Ob 194 Rmrp 264 Pml
55 Slfn4 125 H2-Aa 195 D630039A03Rik 265 Bcl2a1b
56 Slfn3 126 C4b 196 Jun 266 Acpp
57 Ccl5 127 Cfb 197 Plk3 267 Ccrl2
58 Brip1 128 Pla2g7 198 Sdc3 268 Vipr1
59 Tbx21 129 Runx2 199 Trnp1 269 Cxcr6
60 Thra 130 Crem 200 Clic4 270 Ccr5
61 Igfbp4 131 Ttr 201 Luzp1 271 Foxp3
62 Dhx58 132 Rnf125 202 C1qb 272 Syp
63 Grn 133 Gm4951 203 C1qa 273 Gpr34
64 Itgb3 134 Gm4841 204 Isg15 274 Cd40lg
65 Ccdc46 135 F830016B08Rik 205 Abcb1b 275 5430427O19Rik
66 Slc16a5 136 Iigp1 206 Sema3d 276 Xist
67 Lgals3bp 137 Csf1r 207 Fosl2 277 Kdm5d
68 Id2 138 Nedd4l 208 Sult1d1 278 Eif2s3y
69 Rsad2 139 Spire1 209 Igj 279 Uty
70 Cmpk2 140 Ctsw 210 Cxcl10 280 Ddx3y





logFC        
(CNS vs 
Periphery) logCPM LR P  Value FDR Gene symbol
logFC         
(CNS vs 
Periphery) logCPM LR P Value FDR Gene symbol
logFC         
(CNS vs 
Periphery) logCPM LR P Value FDR
1 Gprasp2 8.4 2.7 14.4 0.00014735 0.02983369 47 Gbp6 -1.9 8.9 13.1 0.00028847 0.04538304 104 Ccrl2 -3.2 5.5 15.2 9.72E-05 0.02135885
2 4931406C07R 8.3 2.5 12.9 0.00032698 0.0488038 48 Pml -2.0 8.5 13.6 0.0002308 0.03951476 105 Ifi44 -3.2 6.6 25.0 5.65E-07 0.00037608
3 Gucy1a3 6.8 3.4 14.0 0.00018222 0.03475354 49 Cd69 -2.0 8.1 13.3 0.00027197 0.04378963 106 Ppp1r15a -3.3 7.7 32.8 1.05E-08 1.28E-05
4 Il11ra1 6.6 3.4 14.0 0.00018707 0.03478148 50 Eif2ak2 -2.0 8.7 13.4 0.00024705 0.0413831 107 Rgs2 -3.3 6.4 26.5 2.68E-07 0.00021513
5 Cd19 6.3 4.0 20.4 6.43E-06 0.00258253 51 BC006779 -2.0 9.8 14.6 0.00013311 0.02767235 108 Gp49a -3.3 5.5 15.2 9.71E-05 0.02135885
6 Chst3 6.2 3.7 17.8 2.47E-05 0.00767751 52 Parp14 -2.0 10.2 14.6 0.00013602 0.02778238 109 Trafd1 -3.3 6.5 27.2 1.80E-07 0.0001499
7 Egr3 5.9 4.1 17.4 3.10E-05 0.00913159 53 Odc1 -2.0 7.7 13.7 0.00021416 0.03749243 110 Oas3 -3.3 7.7 32.9 9.47E-09 1.23E-05
8 D8Ertd82e 5.0 4.8 21.6 3.36E-06 0.00150436 54 Lgals3bp -2.0 8.3 14.4 0.00015131 0.03037184 111 Fgl2 -3.4 6.8 26.2 3.00E-07 0.00022563
9 Snord49b 4.8 6.5 64.5 9.52E-16 1.11E-11 55 Tnfaip3 -2.0 9.0 14.6 0.00013258 0.02767235 112 Cep57l1 -3.4 5.3 17.1 3.59E-05 0.01044009
10 H2-Aa 4.5 4.4 15.3 9.12E-05 0.02103064 56 Zbp1 -2.1 9.2 15.3 9.36E-05 0.02117031 113 Oasl2 -3.4 7.9 35.0 3.28E-09 5.28E-06
11 Ramp1 4.4 4.4 16.2 5.85E-05 0.01485031 57 Gramd3 -2.1 6.9 13.0 0.00031682 0.04813073 114 Oas2 -3.5 7.8 37.0 1.18E-09 2.50E-06
12 Cd83 4.2 5.5 26.3 2.94E-07 0.00022563 58 Ddx58 -2.1 7.8 15.4 8.52E-05 0.01983099 115 Havcr2 -3.5 5.4 16.4 5.08E-05 0.01392539
13 Igj 4.1 5.3 35.3 2.87E-09 5.13E-06 59 Znfx1 -2.2 8.6 16.2 5.61E-05 0.01467567 116 Rsad2 -3.6 7.8 37.4 9.87E-10 2.50E-06
14 Adcy6 4.1 5.4 21.0 4.66E-06 0.00204552 60 Dusp1 -2.2 7.5 16.0 6.32E-05 0.01565999 117 Fosl2 -3.6 4.9 13.9 0.00019746 0.0356403
15 Ovgp1 4.0 4.5 13.7 0.000218 0.03759854 61 Slfn3 -2.2 6.5 13.0 0.00031834 0.04813073 118 Ifitm3 -3.8 5.1 15.5 8.34E-05 0.01960476
16 Cd22 4.0 5.5 27.5 1.54E-07 0.00013846 62 Ehd4 -2.2 6.4 13.0 0.00031291 0.04793219 119 Fosb -3.9 5.1 18.1 2.09E-05 0.00689788
17 Hs3st3b1 3.9 5.0 16.2 5.79E-05 0.01485031 63 Lamc1 -2.3 6.7 13.9 0.00018822 0.03478148 120 Parp12 -3.9 6.1 28.4 9.98E-08 9.68E-05
18 Ephx1 3.8 6.0 33.3 7.81E-09 1.07E-05 64 Cd274 -2.3 7.5 17.1 3.63E-05 0.01044009 121 Dgat1 -4.0 5.2 19.9 8.02E-06 0.00300696
19 Dzip1 3.8 5.0 19.0 1.30E-05 0.00464193 65 Tmem184b -2.4 6.5 15.0 0.00010552 0.02296093 122 Gm4951 -4.0 6.7 36.5 1.54E-09 2.99E-06
20 Egr2 3.7 5.0 16.0 6.27E-05 0.01565999 66 Trim30d -2.4 7.5 18.0 2.22E-05 0.00707503 123 Ccr5 -4.0 7.4 40.2 2.29E-10 6.67E-07
21 Itm2a 3.7 4.9 18.1 2.11E-05 0.00689788 67 Atp2b4 -2.4 8.7 17.4 2.98E-05 0.00888461 124 Ctsw -4.1 5.0 16.3 5.33E-05 0.01425503
22 Amigo2 3.6 5.3 21.7 3.25E-06 0.00148474 68 Gm6907 -2.4 6.8 16.4 5.19E-05 0.01405555 125 Gpsm2 -4.1 4.8 15.3 9.32E-05 0.02117031
23 Fam101b 3.5 6.6 37.1 1.14E-09 2.50E-06 69 Fos -2.4 6.5 15.6 7.89E-05 0.01875641 126 Apol9b -4.1 5.1 17.5 2.86E-05 0.00863703
24 Pou2af1 3.3 4.9 14.6 0.00013473 0.0277616 70 Stat2 -2.4 8.8 20.3 6.68E-06 0.0026353 127 Il10 -4.1 5.3 20.1 7.53E-06 0.00287578
25 H2-Ob 3.1 5.5 18.6 1.60E-05 0.00555243 71 Dhx58 -2.5 7.2 18.0 2.27E-05 0.00713049 128 Il18rap -4.1 5.7 25.6 4.29E-07 0.00029657
26 Dtx1 2.9 6.3 24.4 7.96E-07 0.00048748 72 Sdc3 -2.5 6.7 17.0 3.74E-05 0.01062837 129 Mnda -4.2 4.8 13.8 0.00020303 0.03636449
27 Nsg2 2.7 7.7 24.9 5.96E-07 0.00038033 73 Rgs1 -2.5 10.0 17.7 2.54E-05 0.00776847 130 Gzmb -4.3 9.8 46.1 1.14E-11 4.43E-08
28 Gm14085 2.7 6.1 20.4 6.29E-06 0.00258253 74 Herc6 -2.5 8.3 20.7 5.25E-06 0.00222382 131 Mx2 -4.4 6.1 34.9 3.40E-09 5.28E-06
29 Gm4956 2.4 6.1 16.3 5.48E-05 0.01451087 75 Pnpt1 -2.5 5.9 13.2 0.0002727 0.04378963 132 Cdkn1a -4.5 4.4 13.3 0.00026313 0.04317766
30 Rps21 2.4 7.4 19.9 8.14E-06 0.00300696 76 Daxx -2.5 8.9 22.0 2.70E-06 0.00128284 133 Mx1 -4.6 9.5 58.0 2.68E-14 2.08E-10
31 Rnu11 2.4 5.8 13.3 0.00026468 0.04317766 77 Oas1a -2.5 5.9 12.9 0.00033464 0.04931485 134 Cxcl10 -4.7 6.4 41.7 1.04E-10 3.47E-07
32 Hivep3 2.3 6.9 18.9 1.37E-05 0.00482296 78 Nampt -2.6 6.5 16.7 4.30E-05 0.01192613 135 AI607873 -4.7 5.1 23.2 1.42E-06 0.00078889
33 Rpl36a 2.3 6.1 14.6 0.00013223 0.02767235 79 Pydc4 -2.6 8.3 22.7 1.88E-06 0.00093278 136 Ifi204 -4.8 7.1 50.2 1.36E-12 6.35E-09
34 Pacsin1 2.3 5.8 13.4 0.00025365 0.04218524 80 Iigp1 -2.6 9.3 22.9 1.68E-06 0.00084877 137 F830016B08R -4.8 7.4 55.8 8.22E-14 4.79E-10
35 Hvcn1 2.3 6.0 13.9 0.00019723 0.0356403 81 Luzp1 -2.6 6.5 18.2 1.98E-05 0.00668456 138 Ctla2a -5.1 5.6 34.1 5.30E-09 7.71E-06
36 St8sia1 2.2 7.0 13.7 0.00021336 0.03749243 82 2010111I01R -2.6 5.8 14.0 0.00018481 0.03475354 139 Slfn4 -5.6 7.2 67.2 2.44E-16 5.69E-12
37 Rps26 2.1 7.2 15.6 7.66E-05 0.01857785 83 I830012O16R -2.7 8.0 23.5 1.25E-06 0.0007121 140 Irg1 -5.7 3.9 12.9 0.00032214 0.04839153
38 Folr4 2.0 7.4 15.6 7.76E-05 0.01863031 84 Ifit2 -2.7 9.5 24.9 6.04E-07 0.00038033 141 Cfb -6.8 3.7 13.9 0.00019178 0.03516019
39 Ccr7 2.0 6.6 13.2 0.0002855 0.04537505 85 Jun -2.7 7.1 22.0 2.66E-06 0.00128284 142 Olfr56 -6.9 3.8 16.1 5.87E-05 0.01485031
40 Cxcr5 2.0 6.3 13.2 0.00028647 0.04537505 86 Ifit1 -2.8 9.0 25.8 3.86E-07 0.00028105 143 Eppk1 -7.1 4.3 23.1 1.54E-06 0.00081384
41 Pitpnm2 2.0 6.8 14.1 0.0001705 0.03364301 87 Phf11 -2.8 5.8 12.9 0.00033202 0.04924086 144 Mertk -9.6 3.3 14.9 0.00011224 0.02418535
42 Card6 1.9 7.9 14.9 0.00011322 0.02418535 88 Sco1 -2.8 5.5 13.0 0.00030699 0.04765299 145 Sgip1 -9.8 2.9 12.8 0.00033977 0.04975542
43 Rplp2 1.9 7.4 13.7 0.00021635 0.03759255 89 Als2 -2.8 6.1 16.9 3.86E-05 0.01082542 146 Cxcr6 -9.9 4.5 27.5 1.58E-07 0.00013846
44 Rps15a 1.9 9.2 14.0 0.00018192 0.03475354 90 Isg20 -2.8 7.3 23.0 1.60E-06 0.00082531 147 Dlg5 -9.9 3.1 14.1 0.00017362 0.0339717
45 Gm9846 1.8 9.9 13.5 0.00023851 0.04027797 91 Lilrb4 -2.9 6.0 14.0 0.00018361 0.03475354 148 Hspa1b -10.2 3.7 20.4 6.35E-06 0.00258253
46 Rps27 1.8 9.9 13.5 0.00023872 0.04027797 92 Gm4841 -2.9 6.6 20.9 4.91E-06 0.00211545 149 Hspa1a -10.2 3.0 14.0 0.00018508 0.03475354
93 Mpeg1 -2.9 6.0 15.8 6.93E-05 0.0169863 150 Slc7a8 -10.3 3.0 13.8 0.00020853 0.03706327
94 Clic4 -2.9 7.0 23.2 1.49E-06 0.00080741 151 Slco2b1 -10.3 3.0 14.2 0.00016084 0.0320075
95 Cmpk2 -3.0 6.3 20.2 7.05E-06 0.00273617 152 Ermn -10.9 3.0 15.2 9.55E-05 0.02135885
96 Isg15 -3.0 6.1 19.7 8.94E-06 0.00325188 153 4933434I20R -11.0 2.8 13.3 0.00026518 0.04317766
97 Ube2l6 -3.0 5.3 13.0 0.00031177 0.04793219 154 Mir147 -11.1 4.1 29.1 6.98E-08 7.07E-05
98 Hip1 -3.0 6.5 21.9 2.82E-06 0.00131301 155 AA467197 -11.3 4.1 30.2 3.82E-08 4.05E-05
99 Oasl1 -3.1 6.4 23.5 1.25E-06 0.0007121 156 Fam107a -11.4 3.3 18.2 1.94E-05 0.00663849
100 Ccr2 -3.1 7.1 25.5 4.33E-07 0.00029657 157 Sparc -11.8 3.3 18.1 2.13E-05 0.00689788
101 Hk2 -3.1 5.3 13.1 0.00029503 0.04610361 158 Ttr -11.9 3.7 24.0 9.55E-07 0.00056992
102 Mxd1 -3.1 8.9 30.8 2.83E-08 3.14E-05 159 Sall1 -12.5 3.8 27.5 1.61E-07 0.00013846
103 Ifit3 -3.1 9.9 32.5 1.16E-08 1.35E-05
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1 Nsg2 -6.1 1.23E-09 -2.1 2.90E-07 14 Il1rl1 11.8 1.33E-08 3.2 3.01E-09 68 Lamc1 3.3 0.001942 2.8 0.000011
2 Dtx1 -6.1 9.38E-08 -2.3 7.11E-06 15 Ccr2 9.5 2.71E-09 7.7 9.90E-10 83 Atxn1 3.3 1.77E-05 2.5 1.51E-06
3 Treml2 -5.6 2.54E-09 -2.3 5.83E-07 16 Gzmb 8.8 1.52E-07 5.6 5.45E-10 84 Osbpl3 3.3 5.62E-09 3.4 9.35E-10
4 Igfbp4 -5.4 3.09E-08 -2.1 4.36E-06 17 Fgl2 8.5 1.12E-08 7.5 6.38E-11 86 Rgs16 3.2 5.16E-08 2.0 2.68E-05
5 Actn1 -4.5 1.09E-09 -2.0 3.73E-06 18 Cxcl10 8.5 1.94E-07 7.2 3.55E-10 87 Lamc1 3.2 2.11E-07 2.5 1.44E-07
6 Cxcr5 -4.2 3.82E-07 -2.5 1.47E-06 19 Lmna 8.4 2.05E-08 4.1 4.86E-09 88 Rbpj 3.1 4.58E-08 2.6 5.66E-07
7 Art2b -3.9 2.97E-09 -2.7 5.50E-08 20 Klrg1 7.6 1.55E-09 4.1 1.21E-07 89 Sept11 3.1 2.43E-08 2.2 1.78E-07
8 Ift80 -3.6 7.69E-09 -2.2 1.90E-07 21 Anxa1 7.2 3.47E-07 8.2 7.33E-09 90 Cobll1 3.1 6.67E-09 4.2 1.85E-09
9 Sgk3 -2.9 1.28E-06 -2.0 1.64E-06 22 Fosl2 7.0 6.00E-08 3.1 7.08E-09 91 Tnfaip3 3.1 3.46E-07 2.8 3.95E-08
10 Nd5 -2.8 2.76E-05 -2.3 1.83E-04 23 Nr4a3 6.9 3.19E-08 3.3 1.13E-08 92 Lgals3 3.0 5.91E-08 2.7 2.43E-08
11 Itma2 -2.7 1.31E-05 -2.2 1.03E-05 24 Dennd4a 6.6 1.92E-06 4.4 1.23E-07 93 Atp2b4 3.0 5.23E-07 5.0 3.34E-09
12 Gm16489 -2.3 1.48E-05 -2.6 8.37E-08 25 Dennd4a 6.5 2.03E-06 4.6 7.72E-08 94 Cass4 2.9 1.69E-07 2.2 1.69E-04
13 Amigo2 -2.1 2.71E-05 -2.1 5.06E-06 26 Gadd45b 6.1 1.83E-09 4.0 1.12E-09 95 Cysltr2 2.9 8.75E-08 2.9 3.06E-08
27 Myadm 6.1 1.23E-07 4.5 5.58E-07 96 Crmp1 2.9 8.93E-08 3.1 5.19E-07
28 Id2 6.0 4.68E-10 3.7 2.77E-09 97 Ahnak 2.9 1.35E-07 4.1 2.60E-10
29 Adam8 6.0 7.19E-10 2.5 7.19E-07 98 Crip1 2.9 3.83E-08 2.2 6.88E-08
30 Odc1 6.0 2.26E-08 3.2 9.08E-09 99 Car5b 2.9 5.01E-05 4.7 3.18E-09
31 Ccr5 5.9 2.01E-07 3.8 1.17E-08 100 Itga2 2.9 1.53E-06 2.1 1.75E-06
32 Ccr5 5.9 2.01E-07 3.8 1.17E-08 101 Stx11 2.8 3.04E-07 2.0 2.36E-07
33 Ccl3 5.8 5.79E-09 4.2 9.10E-10 102 Atxn1 2.8 4.31E-06 2.4 6.63E-08
34 Fam110a 5.8 7.04E-10 2.1 9.39E-06 103 Samsn1 2.8 1.47E-07 2.7 1.97E-07
35 Dennd4a 5.7 3.93E-07 3.7 1.94E-06 104 Icos 2.8 6.87E-07 2.7 3.40E-07
36 Fosb 5.6 1.48E-08 3.7 5.48E-08 105 Irf4 2.8 6.87E-08 2.0 3.17E-07
37 Ctla2a 5.5 4.75E-06 4.8 1.18E-08 106 Tigit 2.7 7.71E-07 2.2 4.45E-06
38 Cdkn1a 5.4 2.74E-08 2.8 5.06E-09 107 Tbx21 2.7 1.67E-07 6.0 3.69E-09
39 Gm15470 5.4 6.66E-09 2.6 2.00E-07 108 Plek 2.7 9.81E-06 2.4 6.82E-08
40 Lilr4b 5.4 1.72E-06 15.5 1.92E-10 109 Atf3 2.7 1.42E-05 2.2 2.55E-07
41 Dennd4a 5.4 1.84E-07 4.3 1.35E-07 110 Dkkl1 2.7 3.75E-07 3.7 2.25E-07
42 Dennd4a 5.3 6.56E-07 4.5 1.50E-08 111 Crip2 2.6 2.14E-07 2.7 1.00E-07
43 Dennd4a 5.1 2.43E-07 4.3 1.66E-08 112 Vim 2.6 4.11E-08 2.5 1.77E-08
44 Il18rap 5.1 2.26E-08 6.4 6.92E-10 113 Pdcd1 2.5 1.29E-06 3.1 3.12E-06
45 Dgat1 5.0 3.81E-08 2.0 6.33E-07 114 Tnfrsf1b 2.5 2.81E-06 2.7 1.44E-07
46 Ttc39c 5.0 2.32E-08 4.6 4.83E-08 115 Fam129a 2.5 8.79E-07 3.5 1.57E-08
47 S100a4 4.9 9.36E-09 4.4 8.09E-10 116 Bcl2a1a 2.5 1.04E-06 2.5 5.97E-08
48 Ell2 4.9 1.61E-08 2.0 3.49E-05 117 Bcl2a1c 2.5 2.78E-06 2.4 6.59E-06
49 Odc1 4.9 5.68E-09 2.6 9.44E-08 118 Il18r1 2.4 5.18E-05 3.3 5.61E-08
50 Gem 4.8 1.73E-09 3.5 3.39E-07 119 Ifngr1 2.4 8.19E-07 3.7 1.13E-07
51 Dennd4a 4.8 2.37E-06 3.7 1.49E-09 120 Ccl5 2.4 1.71E-05 4.7 3.09E-06
52 Nr4a2 4.8 7.61E-08 3.2 1.63E-08 121 Bcl2a1a 2.4 1.28E-06 2.4 7.76E-08
53 Bhlhe40 4.7 8.11E-08 7.9 1.23E-10 122 Dusp1 2.4 4.32E-06 2.0 5.31E-06
54 Rora 4.6 3.50E-08 3.5 7.65E-09 123 Cdk6 2.4 2.12E-06 2.1 1.41E-06
55 Cxcr6 4.6 1.40E-07 6.2 3.63E-09 124 Bcl2a1a 2.4 4.21E-06 2.4 1.23E-07
56 Cpd 4.5 5.00E-09 3.0 5.92E-08 125 Slc25a24 2.3 6.58E-07 3.5 2.81E-08
57 S100a6 4.4 1.00E-07 6.9 2.06E-09 126 S100a11 2.3 8.43E-07 2.4 2.38E-06
58 Dennd4a 4.4 1.71E-07 3.3 3.60E-09 127 IL10ra 2.3 9.96E-07 2.6 6.28E-07
59 Mir27a 4.3 3.53E-06 2.7 1.73E-07 128 S100a11 2.3 1.06E-06 2.4 2.91E-06
60 Mir23a 4.3 1.47E-06 2.2 1.89E-06 129 Rsad2 2.3 1.31E-06 3.2 5.35E-09
61 Csrnp1 4.3 4.27E-09 2.3 2.44E-06 130 Entpd1 2.3 1.00E-05 2.9 2.52E-08
62 Odc1 4.3 7.12E-08 2.3 5.97E-07 119 Ifitm3 2.3 1.54E-03 9.3 2.44E-03
63 Mmp9 4.2 4.04E-08 2.5 1.41E-05 131 Lgals1 2.3 5.09E-07 2.8 2.56E-07
64 Ccr8 4.2 8.69E-09 4.8 3.78E-07 132 Tnfrsf4 2.2 2.70E-06 2.4 2.02E-07
65 Prdm1 4.2 4.96E-09 2.5 9.38E-09 124 AA467197 2.2 4.40E-02 2.0 2.09E-02
66 Ccrl2 4.1 3.61E-08 2.6 3.62E-08 133 Tnf 2.2 5.05E-07 2.6 8.12E-08
67 Dennd4a 4.0 1.73E-08 3.4 2.90E-09 134 Klf6 2.2 2.37E-06 2.1 1.30E-07
68 Gna15 4.0 8.46E-09 4.4 4.44E-08 135 Runx2 2.2 1.35E-06 2.4 1.21E-07
69 Lilrb4a 4.0 1.55E-05 11.6 2.93E-08 134 Mx1 2.2 0.000309 5.0 0.011202
70 Nfkbid 4.0 1.26E-08 2.3 1.34E-07 136 Acsbg1 2.1 4.55E-07 2.8 9.49E-09
71 Nr4a1 3.9 1.54E-09 3.4 6.02E-08 137 Cish 2.1 2.92E-07 4.0 1.93E-09
72 Cd44 3.9 6.70E-08 2.9 2.51E-08 138 Il12rb1 2.1 5.63E-07 2.2 2.03E-07
73 Dusp5 3.8 7.47E-08 3.7 6.44E-08 139 Furin 2.1 3.56E-07 2.1 7.26E-08
74 Dusp4 3.7 7.43E-09 2.4 1.71E-07 140 Nkg7 2.1 2.49E-05 6.7 6.11E-09
75 Raph1 3.6 2.87E-06 2.2 7.55E-06 141 Ctla4 2.1 2.52E-06 2.6 1.21E-07
76 Glrx 3.6 7.42E-09 2.6 1.97E-07 142 Atf6 2.1 3.86E-06 2.0 4.46E-07
77 Plk3 3.6 3.23E-07 3.1 1.78E-08 143 Antxr2 2.1 8.00E-06 2.2 2.84E-07
78 Chsy1 3.5 3.11E-08 3.1 1.53E-08 144 Hopx 2.1 4.45E-06 2.3 2.39E-08
79 Sytl2 3.5 2.54E-07 2.1 1.72E-06 145 Cmpk2 2.0 5.08E-06 2.9 1.15E-06
80 Ctla2b 3.4 4.92E-08 3.2 1.33E-07 144 Ifit3 2.0 1.24E-02 4.4 6.49E-03
81 Hip1 3.4 6.58E-09 3.4 2.04E-09 146 Asb2 2.0 2.18E-06 2.7 4.37E-08
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1 Igfbp4 12.1 7.28E-10 2.8 1.89E-04 31 Il10 66.7 9.11E-10 2.4 5.79E-04 112 Chsy1 4.2 6.89E-09 3.5 1.48E-04
2 Rtp4 8.5 1.95E-07 2.7 0.00133882 32 Lilr4b 45.9 6.65E-08 11.1 1.70E-04 113 Dennd4a 4.2 2.11E-07 2.5 5.53E-04
3 St8sia1 7.3 6.37E-09 2.2 1.08E-04 33 Anxa1 45.1 1.36E-09 7.4 2.01E-05 114 Rnf125 4.1 2.23E-05 2.1 1.09E-04
4 Treml2 7.1 5.05E-10 3.1 1.11E-05 34 Fosb 30.0 8.18E-08 8.8 7.11E-06 115 Atxn1 4.1 3.69E-07 3.7 3.64E-05
5 Usp18 6.3 6.05E-09 2.6 1.93E-05 35 Lilrb4a 27.3 1.62E-08 6.2 3.31E-04 116 Samsn1 4.0 1.22E-07 2.3 4.14E-04
6 BC094916 5.8 2.79E-07 2.4 7.23E-05 36 Klrg1 26.4 1.61E-09 4.7 9.35E-04 117 Osbpl3 4.0 1.02E-08 4.8 9.64E-05
7 Apol7b 5.7 3.37E-08 2.1 3.64E-05 37 Il1rl1 24.0 2.23E-11 3.3 2.09E-05 118 Cysltr2 4.0 1.24E-06 3.7 8.94E-04
8 Ifit1 5.6 1.77E-07 3.2 2.65E-04 38 Ccr2 22.4 3.42E-09 7.2 5.74E-06 119 Naip6 3.9 6.08E-08 2.0 5.46E-04
9 Apol7b 5.5 2.38E-08 2.1 3.40E-05 39 Fos 21.3 3.74E-07 7.4 2.27E-06 120 Anxa2 3.9 1.02E-06 6.7 1.01E-04
10 H2-T24 4.5 9.59E-08 3.0 5.77E-07 40 Mir27a 19.4 1.49E-10 3.1 4.29E-04 121 Dkkl1 3.9 8.61E-07 2.9 5.05E-04
11 P2rx7 4.1 2.12E-09 2.8 8.46E-04 41 Cxcr6 19.1 2.06E-09 6.5 2.11E-05 122 Acot7 3.8 4.02E-08 3.9 2.41E-05
12 Gm16489 4.1 3.70E-06 3.1 0.00106531 42 Myadm 18.3 4.24E-11 2.8 0.00104178 123 Tigit 3.8 2.10E-07 5.1 1.54E-05
13 Pydc4 3.9 1.50E-05 2.5 5.63E-05 43 Ctla2a 18.2 3.08E-08 3.5 3.98E-05 124 Myo1e 3.7 1.28E-07 2.6 4.50E-05
14 Tcrg 3.7 1.26E-06 4.5 5.60E-04 44 S100a6 18.0 1.15E-07 9.2 8.64E-05 125 Gpr68 3.7 1.09E-07 3.1 1.05E-05
15 Nt5e 3.7 3.32E-07 3.1 3.31E-05 45 Mmp9 17.0 7.45E-09 3.6 0.00165648 126 Atf6 3.6 6.70E-08 2.2 7.57E-04
16 Cxcr5 3.6 6.24E-06 3.6 1.85E-04 46 Gadd45b 17.0 1.94E-09 4.6 4.25E-04 127 Nabp1 3.6 3.05E-08 2.3 2.02E-05
17 Trgv2 3.2 5.95E-06 5.0 3.04E-04 47 Rgs2 14.9 7.49E-07 5.4 1.25E-06 128 Lgals1 3.5 1.88E-07 3.2 4.89E-05
18 Rnf213 2.9 1.08E-06 2.0 6.74E-05 48 Fgl2 14.4 1.86E-09 8.2 2.27E-04 129 Cxcr4 3.5 3.43E-05 3.2 1.16E-04
19 Rnf213 2.9 1.80E-07 2.1 2.66E-05 49 Gem 13.9 1.01E-08 3.4 1.72E-04 130 Zdhhc2 3.5 3.70E-07 5.9 1.74E-05
20 Rnf213 2.9 6.61E-07 2.0 7.54E-05 50 Fosl2 13.0 2.66E-07 3.3 4.44E-04 131 Gm7665 3.4 6.70E-05 2.0 1.20E-04
21 Rnf213 2.9 2.85E-06 2.0 5.67E-04 51 S100a4 12.9 3.00E-08 4.0 1.37E-04 132 Naip2 3.4 1.19E-08 2.8 9.75E-05
22 Amigo2 2.9 2.16E-07 2.6 7.30E-06 52 Lmna 11.9 1.51E-09 2.0 3.04E-05 133 Ccr4 3.3 6.08E-07 3.1 0.00102275
23 Rnf213 2.8 2.79E-07 2.1 1.47E-05 53 Id2 11.8 5.24E-08 3.5 5.16E-05 134 Ptpn13 3.3 3.94E-08 2.8 1.32E-04
24 Rnf213 2.8 6.88E-05 2.1 0.00135971 54 Car5b 10.6 4.22E-07 5.3 2.75E-04 135 Myo1f 3.3 2.01E-08 6.7 1.34E-05
25 Oas1b 2.7 1.49E-06 2.1 1.80E-05 55 Hspa1b 10.3 3.87E-05 7.1 1.27E-04 136 Spock2 3.2 7.69E-07 2.8 7.43E-05
26 Rnf213 2.7 3.20E-06 2.0 2.80E-04 56 Cobll1 10.3 3.91E-11 3.2 7.71E-05 137 BC005685 3.2 3.05E-07 2.8 0.00136421
27 Rnf213 2.7 5.70E-06 2.2 3.63E-05 57 Tnfaip3 10.0 7.96E-08 5.4 1.91E-05 138 Rgs16 3.1 8.99E-07 2.4 2.90E-04
28 Parp11 2.6 4.95E-06 2.0 1.41E-06 58 Nr4a2 9.8 1.37E-06 4.7 3.66E-04 139 Rbpj 3.1 1.76E-07 2.2 8.21E-04
29 Ifi44 2.4 1.11E-04 2.4 5.21E-04 59 Dusp1 9.4 1.72E-07 6.2 1.84E-05 140 BC005685 3.1 1.19E-07 3.0 4.62E-04
30 Slamf7 2.3 1.24E-04 3.3 7.31E-04 60 Ttc39c 9.3 8.00E-09 4.6 3.33E-04 141 Rap1gap2 3.0 1.03E-06 2.4 1.35E-04
61 Tmem176b 9.2 2.37E-07 4.2 8.01E-04 142 LOC641050 3.0 1.12E-06 2.7 9.61E-04
62 Ctla2b 9.0 5.26E-09 2.0 9.25E-04 143 LOC641050 3.0 1.12E-06 2.7 9.61E-04
63 Il18rap 8.6 4.14E-08 6.7 2.00E-05 144 Atxn1 3.0 5.68E-07 2.7 1.07E-04
64 Cass4 8.1 1.01E-09 2.2 0.00119725 145 Plp2 2.9 1.33E-07 2.5 2.33E-06
65 Nr4a1 8.1 4.90E-09 3.2 1.30E-04 146 Notch4 2.9 8.28E-08 2.6 3.88E-04
66 Rora 8.1 1.94E-09 3.9 3.50E-05 147 Syne3 2.9 8.21E-08 2.1 5.37E-04
67 Ppp1r15a 7.9 5.79E-07 3.6 4.36E-05 148 Plp2 2.9 2.41E-07 2.3 6.95E-06
68 Dennd4a 7.3 1.94E-07 3.1 2.76E-04 149 Phactr2 2.9 1.07E-06 2.0 2.21E-04
69 Alcam 7.2 4.94E-10 2.2 1.01E-04 150 Wee1 2.9 5.66E-08 2.3 7.70E-04
70 Nebl 7.0 1.21E-08 2.3 0.00122072 151 Tjp2 2.8 1.63E-07 2.2 4.61E-05
71 Gna15 7.0 6.44E-09 3.7 1.95E-04 152 2lp2 2.8 1.67E-07 2.2 5.07E-06
72 Nr4a3 6.8 1.72E-06 3.8 3.26E-04 153 Rhob 2.8 9.72E-05 3.7 2.18E-05
73 Ccr5 6.8 2.14E-07 6.0 1.80E-04 154 Notch4 2.8 6.24E-07 2.9 4.44E-04
74 Ccr4 6.8 2.14E-07 6.0 1.80E-04 155 Stx11 2.8 4.76E-05 2.0 7.60E-04
75 Dennd4a 6.8 8.72E-06 2.9 0.00144198 156 Plek 2.8 1.21E-05 2.9 2.29E-04
76 Dennd4a 6.6 1.90E-05 3.5 1.81E-04 157 Notch4 2.7 4.01E-07 2.6 6.32E-04
77 Itga1 6.5 1.84E-07 4.3 0.00147279 158 Notch4 2.7 3.90E-07 2.8 4.19E-04
78 Junb 6.5 1.98E-08 3.3 2.44E-05 159 Fam129a 2.7 1.44E-06 4.0 1.12E-04
79 Sik1 6.1 6.56E-07 3.1 5.35E-05 160 Slc25a24 2.7 6.90E-07 3.9 7.09E-05
80 Hspa1a 5.9 5.73E-04 5.6 5.02E-05 161 Maf 2.7 1.31E-07 4.1 3.49E-05
81 Dusp5 5.8 5.95E-09 3.3 4.26E-04 162 Erbb2 2.6 1.09E-07 4.1 2.15E-05
82 Glrx 5.8 2.95E-08 2.7 0.00124136 163 Cdc42ep3 2.6 1.04E-06 2.4 4.03E-05
83 Hip1 5.8 5.08E-10 2.5 4.41E-04 164 Tgif1 2.6 5.06E-05 2.6 2.96E-04
84 Il10ra 5.8 1.11E-07 4.2 1.84E-05 165 Crmp1 2.6 1.59E-06 3.0 2.80E-04
85 Dennd4a 5.5 6.79E-06 3.0 6.52E-04 166 Errfi1 2.5 5.46E-05 2.4 1.42E-04
86 Sytl3 5.5 8.59E-06 3.5 6.85E-04 167 Mir19b-1 2.5 9.54E-04 3.0 2.30E-04
87 Klf6 5.5 2.34E-07 4.6 4.29E-08 168 Unc119 2.5 6.69E-07 2.3 3.19E-04
88 Ar 5.4 5.70E-08 2.1 0.00138658 169 Pros1 2.5 1.03E-06 2.0 3.74E-05
89 Raph1 5.3 2.44E-07 2.2 0.00128433 170 CD38 2.4 9.03E-07 3.5 4.53E-04
90 Bcl2a1a 5.2 3.49E-07 2.9 3.96E-04 171 Atp2b1 2.4 2.76E-07 2.3 9.10E-06
91 Plk3 5.2 4.21E-07 2.7 1.52E-04 172 Mapre2 2.4 2.78E-05 2.6 8.45E-04
92 Prdm1 5.2 9.88E-08 2.7 2.67E-04 173 Capn2 2.4 1.88E-07 2.2 3.49E-04
93 Atp2b4 5.1 1.35E-07 5.5 3.65E-05 174 Pim1 2.4 1.60E-06 2.9 2.37E-05
94 S100a11 5.1 6.04E-09 3.1 5.91E-05 175 Stk32c 2.3 1.74E-04 3.7 0.00113917
95 Crip1 5.1 7.62E-08 2.4 5.37E-06 176 Cyfip1 2.3 1.21E-06 3.5 8.44E-05
96 S100a11 5.1 3.06E-08 3.0 5.69E-05 177 Dstn 2.3 1.03E-04 2.1 9.89E-05
97 Bcl2a1a 5.0 6.97E-07 2.7 5.53E-04 178 Ifngr1 2.3 3.03E-04 3.0 3.27E-04
98 Plk2 5.0 3.21E-05 2.4 8.35E-06 179 Syt11 2.2 1.05E-05 2.5 5.49E-05
99 Dennd4a 4.9 4.84E-06 2.7 1.18E-04 180 Asb2 2.2 6.47E-04 3.8 3.80E-04
100 Nfil3 4.9 1.23E-08 2.2 4.70E-05 181 Cish 2.2 2.56E-06 3.0 7.39E-04
101 Dennd4a 4.9 1.03E-06 2.4 0.00116072 182 Plxnc1 2.2 2.09E-05 2.4 0.00100603
102 Emp1 4.8 7.94E-07 2.7 2.81E-05 183 Hexim1 2.2 1.71E-04 2.1 1.21E-05
103 Naip5 4.7 1.76E-09 2.6 1.80E-05 184 Cdc25b 2.1 1.97E-05 2.5 3.59E-05
104 Bcl2a1c 4.7 3.40E-07 2.5 0.00161324 185 Hopx 2.1 1.84E-04 2.5 1.54E-04
105 Itpripl2 4.7 7.41E-07 2.0 3.76E-05 186 Nqo2 2.1 8.48E-07 2.1 6.07E-04
106 Ryk 4.7 2.31E-09 2.6 1.42E-04 187 Mir92-1 2.0 0.00134676 2.7 1.27E-04
107 Coq1b 4.6 8.10E-06 2.4 6.85E-06 188 Atxn7l1 2.0 1.05E-05 2.3 7.55E-04
108 Pdcd1 4.4 6.36E-09 3.6 4.46E-04 189 Racgap1 2.0 1.57E-04 3.3 0.0014044
109 Ahnak 4.4 3.01E-09 5.2 1.89E-06 190 Farp1 2.0 1.21E-05 2.2 3.25E-04
110 Odc1 4.3 9.61E-07 2.3 2.08E-04 191 Ctla4 2.0 1.80E-05 6.9 2.60E-05
111 Cd44 4.3 1.19E-08 3.2 8.27E-05













response to virus (GO:0009615) 20/250 8.72773E-18 1.29083E-14 -2.37839327 76.06316825
IFITM3;RSAD2;DDX58;MX2;STAT2;MX1;ODC1;EIF2AK2;IFI44;ISG15;IFIT1;I
FIT3;PML;IFIT2;ISG20;CXCL10;OAS2;OAS3;DHX58;HSPA1A
defense response to virus (GO:0051607) 16/147 2.76336E-16 2.0435E-13 -2.25263247 65.81953371
IFITM3;RSAD2;MX2;STAT2;MX1;EIF2AK2;ISG15;IFIT1;IFIT3;PML;IFIT2;ISG2
0;CXCL10;OAS2;OAS3;DHX58
response to other organism (GO:0051707) 22/462 4.75377E-15 2.34361E-12 -2.40804668 64.48587242
IFITM3;GBP6;IL10;RSAD2;DDX58;MX2;STAT2;MX1;ODC1;EIF2AK2;IFI44;IS
G15;IFIT1;IFIT3;PML;IFIT2;ISG20;CXCL10;OAS2;OAS3;DHX58;HSPA1A
cellular response to cytokine stimulus (GO:0071345) 21/471 7.7169E-14 2.28266E-11 -2.45586242 60.17623
IFITM3;GBP6;PNPT1;MX2;STAT2;MX1;ISG15;UBE2L6;CXCR6;IFIT1;IFIT3;P
ML;IFIT2;ISG20;CXCL10;IRG1;OAS2;OAS3;CCRL2;CCR5;CCR2
defense response to other organism (GO:0098542) 18/328 2.21673E-13 4.09818E-11 -2.350541 56.21998924
GBP6;IL10;IFITM3;RSAD2;MX2;STAT2;MX1;EIF2AK2;ISG15;IFIT1;IFIT3;PM
L;IFIT2;ISG20;CXCL10;OAS2;OAS3;DHX58
cytokine-mediated signaling pathway (GO:0019221) 18/342 4.3581E-13 6.44562E-11 -2.37334134 55.69053621
IFITM3;MX2;STAT2;MX1;ISG15;UBE2L6;CXCR6;IFIT1;IFIT3;PML;IFIT2;ISG2
0;CXCL10;OAS2;OAS3;CCRL2;CCR5;CCR2
negative regulation of multi-organism process (GO:0043901) 14/133 3.64416E-14 1.34743E-11 -2.17526497 54.44739883
IFITM3;IL10;JUN;RSAD2;MX1;TNFAIP3;EIF2AK2;ISG15;IFIT1;PML;ISG20;IR
G1;OAS3;DHX58
type I interferon signaling pathway (GO:0060337) 11/65 2.20652E-13 4.09818E-11 -2.1597932 51.65770366 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
cellular response to type I interferon (GO:0071357) 11/65 2.20652E-13 4.09818E-11 -2.15603979 51.56792986 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
response to type I interferon (GO:0034340) 11/66 2.56339E-13 4.2125E-11 -2.15598129 51.5072136 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
regulation of multi-organism process (GO:0043900) 15/306 1.29117E-10 1.59137E-08 -2.37108151 42.57534326
IL10;IFITM3;JUN;RSAD2;DDX58;MX1;EIF2AK2;TNFAIP3;ISG15;IFIT1;PML;IS
G20;IRG1;OAS3;DHX58
negative regulation of viral process (GO:0048525) 10/75 2.46655E-11 3.31639E-09 -2.12550141 41.49911933 IFITM3;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PML
negative regulation of viral genome replication (GO:0045071) 8/40 1.51028E-10 1.71823E-08 -2.31308207 41.35648849 IFITM3;ISG20;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1
negative regulation of type I interferon production (GO:0032480) 7/39 4.40681E-09 4.07355E-07 -2.37157589 34.89437401 IL10;IRG1;DDX58;DHX58;TNFAIP3;UBE2L6;ISG15
regulation of symbiosis, encompassing mutualism through parasitism (GO:0043903) 11/174 3.89756E-09 3.843E-07 -2.30311674 34.02127865 IFITM3;IL10;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PML
regulation of viral genome replication (GO:0045069) 8/57 1.87805E-09 1.98402E-07 -2.20289602 33.99722768 IFITM3;ISG20;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1
response to interferon-alpha (GO:0035455) 5/17 9.59165E-08 7.88114E-06 -2.67108852 31.38806425 IFITM3;MX2;EIF2AK2;IFIT3;IFIT2
regulation of viral process (GO:0050792) 10/152 1.46595E-08 1.27537E-06 -2.29027049 31.08417495 IFITM3;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PML
negative regulation of immune system process (GO:0002683) 12/311 1.37657E-07 1.07155E-05 -2.41467121 27.63305374
IL10;CD274;IRG1;DHX58;TRAFD1;EIF2AK2;TNFAIP3;MNDA;MERTK;IFIT1;LI
LRB4;CCR2
negative regulation of response to biotic stimulus (GO:0002832) 5/26 5.95972E-07 4.19735E-05 -2.6028985 26.23324184 IRG1;DHX58;EIF2AK2;TNFAIP3;IFIT1
regulation of type I interferon production (GO:0032479) 8/108 1.89925E-07 1.40449E-05 -2.23175476 24.93595139 IL10;ZBP1;IRG1;DDX58;DHX58;TNFAIP3;ISG15;UBE2L6
chemokine-mediated signaling pathway (GO:0070098) 5/36 2.52079E-06 0.000156057 -2.50747675 21.978766 CXCL10;CCRL2;CXCR6;CCR5;CCR2
regulation of immune effector process (GO:0002697) 10/264 1.95482E-06 0.000131417 -2.41596637 21.59181051 IL10;RSAD2;DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;CFB;PML;CCR2
response to lipopolysaccharide (GO:0032496) 9/228 4.79697E-06 0.000283789 -2.34593359 19.1598989 IL10;CXCL10;IRG1;JUN;SPARC;TNFAIP3;CMPK2;FOS;CCR5
regulation of response to biotic stimulus (GO:0002831) 7/107 2.53236E-06 0.000156057 -2.18425093 19.14559727 IRG1;DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;PML
response to molecule of bacterial origin (GO:0002237) 9/243 7.88637E-06 0.000416569 -2.37309697 18.47090121 IL10;CXCL10;IRG1;JUN;SPARC;TNFAIP3;CMPK2;FOS;CCR5
regulation of cytokine production (GO:0001817) 12/482 0.000011703 0.000556832 -2.4321879 18.22498339
ZBP1;IL10;IRG1;CD274;RSAD2;DDX58;DHX58;EIF2AK2;TNFAIP3;ISG15;UB
E2L6;CCR2
negative regulation of defense response (GO:0031348) 7/120 5.20193E-06 0.000292809 -2.19334194 17.84500725 IL10;IRG1;DHX58;TRAFD1;EIF2AK2;TNFAIP3;IFIT1
response to corticosterone (GO:0051412) 4/23 1.22749E-05 0.000556832 -2.33708319 17.5123404 CDKN1A;FOSB;FOS;FOSL2
regulation of innate immune response (GO:0045088) 9/254 1.11175E-05 0.000548091 -2.31562005 17.38815049 ZBP1;IRG1;JUN;DDX58;STAT2;DHX58;TRAFD1;TNFAIP3;FOS
regulation of defense response to virus (GO:0050688) 6/77 5.3454E-06 0.000292809 -2.12142221 17.2598691 DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;PML
response to glucocorticoid (GO:0051384) 7/130 8.57887E-06 0.000437522 -2.17199132 16.79901245 IL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;FOSL2
response to alcohol (GO:0097305) 9/274 1.99276E-05 0.000818693 -2.3583737 16.76285125 IL10;CXCL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;CCR5;FOSL2
response to cAMP (GO:0051591) 6/90 1.24242E-05 0.000556832 -2.23235243 16.72756695 JUN;SPARC;DUSP1;FOSB;FOS;FOSL2
regulation of defense response to virus by host (GO:0050691) 4/26 1.89351E-05 0.000800143 -2.31097828 16.47893795 DDX58;TNFAIP3;IFIT1;PML
negative regulation of innate immune response (GO:0045824) 4/28 2.46447E-05 0.000934602 -2.35250498 16.4096394 IRG1;DHX58;TRAFD1;TNFAIP3
response to mineralocorticoid (GO:0051385) 4/28 2.46447E-05 0.000934602 -2.33483872 16.28641032 CDKN1A;FOSB;FOS;FOSL2
response to corticosteroid (GO:0031960) 7/140 1.36053E-05 0.000591831 -2.17799115 16.1874591 IL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;FOSL2
response to calcium ion (GO:0051592) 6/100 0.000021913 0.000875929 -2.1498972 15.13576121 CLIC4;JUN;SPARC;DUSP1;FOSB;FOS
inflammatory response (GO:0006954) 10/376 3.90701E-05 0.00131329 -2.27406464 15.08891938 IL10;CXCL10;IRG1;IL18RAP;CCRL2;TNFAIP3;FOS;CXCR6;CCR5;CCR2
response to ketone (GO:1901654) 6/105 0.000028475 0.001027182 -2.1888169 15.06110857 IRG1;CDKN1A;DUSP1;FOSB;FOS;FOSL2
negative regulation of immune response (GO:0050777) 6/103 2.56834E-05 0.000949645 -2.14143352 14.90314076 IL10;IRG1;DHX58;TNFAIP3;TRAFD1;CCR2
cellular response to lipopolysaccharide (GO:0071222) 6/110 3.65327E-05 0.001256556 -2.18661637 14.60524336 IL10;CXCL10;IRG1;CMPK2;TNFAIP3;CCR5
cellular response to molecule of bacterial origin (GO:0071219) 6/116 4.85175E-05 0.001559944 -2.20541514 14.25383033 IL10;CXCL10;IRG1;TNFAIP3;CMPK2;CCR5
response to interferon-gamma (GO:0034341) 6/108 3.31152E-05 0.001166128 -2.09595154 14.15619512 IFITM3;GBP6;IRG1;OAS2;OAS3;PML
response to progesterone (GO:0032570) 4/33 4.43518E-05 0.001457694 -2.16158964 14.11712452 IRG1;FOSB;FOS;FOSL2
response to organophosphorus (GO:0046683) 6/118 5.31467E-05 0.001637584 -2.17246262 13.93533369 JUN;SPARC;DUSP1;FOSB;FOS;FOSL2
negative regulation of leukocyte activation (GO:0002695) 6/120 0.000058123 0.001754367 -2.18546762 13.86820631 IL10;CD274;TNFAIP3;MNDA;MERTK;CCR2
negative regulation of cytokine production (GO:0001818) 7/185 7.53353E-05 0.002184723 -2.25151343 13.79337057 IL10;IRG1;DDX58;DHX58;TNFAIP3;ISG15;UBE2L6
cellular response to calcium ion (GO:0071277) 4/38 7.36529E-05 0.002178653 -2.19720058 13.46674839 JUN;CLIC4;FOSB;FOS
response to purine-containing compound (GO:0014074) 6/132 9.63711E-05 0.002658567 -2.2003161 13.04780404 JUN;SPARC;DUSP1;FOSB;FOS;FOSL2
cellular response to biotic stimulus (GO:0071216) 6/132 9.63711E-05 0.002658567 -2.18381476 12.94995157 IL10;CXCL10;IRG1;TNFAIP3;CMPK2;CCR5
negative regulation of cell activation (GO:0050866) 6/135 0.000108518 0.002918142 -2.20223026 12.8539956 IL10;CD274;TNFAIP3;MNDA;MERTK;CCR2
mitotic cell cycle arrest (GO:0071850) 3/11 5.19171E-05 0.001633733 -1.99332982 12.79097392 CDKN1A;PNPT1;DUSP1
negative regulation of immune effector process (GO:0002698) 5/81 9.70674E-05 0.002658567 -2.13883054 12.68319659 IL10;DHX58;EIF2AK2;IFIT1;CCR2
negative regulation of defense response to virus (GO:0050687) 3/16 0.000135561 0.003580255 -2.19450758 12.36017141 DHX58;EIF2AK2;IFIT1
response to oxidative stress (GO:0006979) 8/290 0.00019207 0.004814768 -2.24165973 11.96164724 JUN;PNPT1;ALS2;DUSP1;TNFAIP3;FOS;PML;HSPA1A
response to interferon-beta (GO:0035456) 3/18 0.000184631 0.004708089 -2.19051295 11.73780488 IFITM3;IRG1;PNPT1
cellular response to interferon-gamma (GO:0071346) 5/88 0.000140686 0.003650423 -2.04569764 11.48232116 GBP6;IRG1;OAS2;OAS3;PML
negative regulation of protein modification process (GO:0031400) 9/407 0.000375742 0.008820993 -2.31416542 10.94743905 CDKN1A;JUN;RGS2;DUSP1;ATP2B4;TNFAIP3;ISG15;PML;HSPA1A
negative regulation of lymphocyte activation (GO:0051250) 5/102 0.000271466 0.006691637 -2.1350798 10.69012423 IL10;CD274;TNFAIP3;MNDA;MERTK
positive regulation of cytokine production (GO:0001819) 8/327 0.000422416 0.009611588 -2.28861267 10.63011577 ZBP1;IL10;CD274;RSAD2;DDX58;DHX58;EIF2AK2;CCR2
negative regulation of leukocyte proliferation (GO:0070664) 4/56 0.000298266 0.007231737 -2.13792592 10.53842711 IL10;CD274;TNFAIP3;MNDA
regulation of leukocyte proliferation (GO:0070663) 6/176 0.000432445 0.0096907 -2.24172481 10.39395578 IL10;CD274;CDKN1A;TNFAIP3;MNDA;CCR2
morphogenesis of a branching structure (GO:0001763) 6/170 0.000361701 0.008628312 -2.12336502 10.09173044 IL10;CLIC4;SALL1;DLG5;ERMN;PML
negative regulation of B cell activation (GO:0050869) 3/29 0.000659926 0.014050137 -2.25182139 9.604295529 IL10;TNFAIP3;MNDA
positive regulation of defense response (GO:0031349) 7/272 0.000736126 0.015334227 -2.25758497 9.431440188 ZBP1;JUN;DDX58;DHX58;TNFAIP3;FOS;CCR2
response to inorganic substance (GO:0010035) 8/370 0.000932034 0.018628083 -2.30348733 9.174985857 JUN;CLIC4;SPARC;DUSP1;ATP2B4;TNFAIP3;FOSB;FOS
response to steroid hormone (GO:0048545) 8/369 0.000916228 0.018563021 -2.26987998 9.04906677 IL10;IRG1;CDKN1A;SPARC;DUSP1;FOSB;FOS;FOSL2
cellular defense response (GO:0006968) 4/60 0.000382382 0.008836615 -1.91282071 9.04544489 LGALS3BP;MNDA;CCR5;CCR2
negative regulation of angiogenesis (GO:0016525) 4/64 0.000482234 0.010645134 -1.98201854 9.00362131 CXCL10;SPARC;PML;CCR2
negative regulation of blood vessel morphogenesis (GO:2000181) 4/66 0.000538554 0.011713555 -1.9901997 8.850435164 CXCL10;SPARC;PML;CCR2
negative regulation of vasculature development (GO:1901343) 4/70 0.000664983 0.014050137 -1.9858142 8.469742129 CXCL10;SPARC;PML;CCR2
positive regulation of myeloid cell differentiation (GO:0045639) 4/74 0.000811139 0.016662142 -2.02491487 8.291249014 JUN;ISG15;FOS;HSPA1A
negative regulation of response to external stimulus (GO:0032102) 6/215 0.001193326 0.023222751 -2.18814144 8.233150965 IL10;IRG1;DHX58;EIF2AK2;TNFAIP3;IFIT1
regulation of toll-like receptor signaling pathway (GO:0034121) 3/37 0.001274638 0.023564862 -2.18281862 8.181201111 IRG1;RSAD2;TNFAIP3
cell cycle arrest (GO:0007050) 5/140 0.00108617 0.021419278 -2.085691 8.016278115 PPP1R15A;CDKN1A;PNPT1;DUSP1;PML
regulation of homeostatic process (GO:0032844) 7/314 0.001659103 0.028204758 -2.23917394 7.989965055 CXCL10;SGIP1;TNFAIP3;ISG15;CCR5;PML;HSPA1A
cellular response to oxidative stress (GO:0034599) 5/148 0.001379396 0.025186741 -2.09210177 7.701942081 PNPT1;TNFAIP3;FOS;PML;HSPA1A
leukocyte migration (GO:0050900) 6/226 0.001529689 0.026307093 -2.05705779 7.483404828 IL10;CXCL10;SLC7A8;CCR5;MERTK;CCR2
regulation of myeloid cell differentiation (GO:0045637) 5/156 0.001727364 0.029031496 -2.10082112 7.435591587 JUN;ISG15;FOS;LILRB4;HSPA1A
regulation of lymphocyte activation (GO:0051249) 7/344 0.002744679 0.040085212 -2.2432417 7.215942772 IL10;CD274;CDKN1A;TNFAIP3;MNDA;MERTK;CCR2
response to radiation (GO:0009314) 8/442 0.002795348 0.040139029 -2.19654607 7.062787669 CXCL10;CDKN1A;JUN;TTR;DUSP1;SDC3;FOS;PML
regulation of lymphocyte proliferation (GO:0050670) 5/170 0.002485644 0.038010295 -2.15775727 7.05564669 IL10;CD274;CDKN1A;MNDA;CCR2
response to metal ion (GO:0010038) 6/255 0.002764497 0.040085212 -2.18899379 7.041440935 JUN;CLIC4;SPARC;DUSP1;FOSB;FOS
regulation of mononuclear cell proliferation (GO:0032944) 5/171 0.002547748 0.03845019 -2.15416358 7.019108623 IL10;CD274;CDKN1A;MNDA;CCR2
regulation of B cell activation (GO:0050864) 4/92 0.001756509 0.029189632 -1.97732133 6.987738279 IL10;CDKN1A;TNFAIP3;MNDA
regulation of sequence-specific DNA binding transcription factor activity (GO:0051090) 7/338 0.0024929 0.038010295 -2.13549071 6.982837327 IL10;IRG1;JUN;DDX58;EIF2AK2;TNFAIP3;FOS
morphogenesis of a branching epithelium (GO:0061138) 5/162 0.002027772 0.032956865 -2.02896904 6.923969867 IL10;CLIC4;SALL1;DLG5;PML
response to drug (GO:0042493) 7/354 0.003207358 0.04372193 -2.18931674 6.852354433 IL10;JUN;CDKN1A;FOSB;FOS;CD69;FOSL2
taxis (GO:0042330) 6/263 0.00320933 0.04372193 -2.13224984 6.67374042 IL10;CXCL10;CCRL2;CXCR6;CCR5;CCR2
chemotaxis (GO:0006935) 6/263 0.00320933 0.04372193 -2.1296123 6.665485188 IL10;CXCL10;CCRL2;CXCR6;CCR5;CCR2
regulation of adaptive immune response based on somatic recombination of immune 
receptors built from immunoglobulin superfamily domains (GO:0002822) 4/103 0.002610291 0.038996161 -2.03832941 6.612935958 IL10;RSAD2;TNFAIP3;CCR2
cellular response to metal ion (GO:0071248) 4/99 0.002272682 0.036535837 -1.98653956 6.574376529 JUN;CLIC4;FOSB;FOS
response to mechanical stimulus (GO:0009612) 5/176 0.00287532 0.040890366 -2.03251636 6.497671877 CXCL10;JUN;FOSB;FOS;FOSL2
regulation of angiogenesis (GO:0045765) 5/179 0.003085931 0.043467538 -2.03425975 6.378911432 CXCL10;SPARC;TNFAIP3;PML;CCR2
leukocyte chemotaxis (GO:0030595) 4/100 0.002354078 0.037437435 -1.93951893 6.37148287 IL10;CXCL10;CCR5;CCR2
regulation of adaptive immune response (GO:0002819) 4/112 0.003492786 0.045314308 -2.01250376 6.226953185 IL10;RSAD2;TNFAIP3;CCR2
cellular response to inorganic substance (GO:0071241) 4/110 0.003281362 0.04372193 -1.97988316 6.196847116 JUN;CLIC4;FOSB;FOS
positive regulation of innate immune response (GO:0045089) 5/190 0.003954187 0.049114732 -2.0455279 6.164395196 ZBP1;JUN;DDX58;TNFAIP3;FOS









response to virus (GO:0009615) 20/250 8.72773E-18 1.29083E-14 -2.37839327 76.06316825
IFITM3;RSAD2;DDX58;MX2;STAT2;MX1;ODC1;EIF2AK2;IFI44;ISG15;
IFIT1;IFIT3;PML;IFIT2;ISG20;CXCL10;OAS2;OAS3;DHX58;HSPA1A
defense response to virus (GO:0051607) 16/147 2.76336E-16 2.0435E-13 -2.25263247 65.81953371
IFITM3;RSAD2;MX2;STAT2;MX1;EIF2AK2;ISG15;IFIT1;IFIT3;PML;IFI
T2;ISG20;CXCL10;OAS2;OAS3;DHX58




cellular response to cytokine stimulus (GO:0071345) 21/471 7.7169E-14 2.28266E-11 -2.45586242 60.17623
IFITM3;GBP6;PNPT1;MX2;STAT2;MX1;ISG15;UBE2L6;CXCR6;IFIT1;I
FIT3;PML;IFIT2;ISG20;CXCL10;IRG1;OAS2;OAS3;CCRL2;CCR5;CCR2
defense response to other organism (GO:0098542) 18/328 2.21673E-13 4.09818E-11 -2.350541 56.21998924
GBP6;IL10;IFITM3;RSAD2;MX2;STAT2;MX1;EIF2AK2;ISG15;IFIT1;IFI
T3;PML;IFIT2;ISG20;CXCL10;OAS2;OAS3;DHX58
cytokine-mediated signaling pathway (GO:0019221) 18/342 4.3581E-13 6.44562E-11 -2.37334134 55.69053621
IFITM3;MX2;STAT2;MX1;ISG15;UBE2L6;CXCR6;IFIT1;IFIT3;PML;IFIT
2;ISG20;CXCL10;OAS2;OAS3;CCRL2;CCR5;CCR2
negative regulation of multi-organism process 
(GO:0043901) 14/133 3.64416E-14 1.34743E-11 -2.17526497 54.44739883
IFITM3;IL10;JUN;RSAD2;MX1;TNFAIP3;EIF2AK2;ISG15;IFIT1;PML;IS
G20;IRG1;OAS3;DHX58
type I interferon signaling pathway (GO:0060337) 11/65 2.20652E-13 4.09818E-11 -2.1597932 51.65770366 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
cellular response to type I interferon (GO:0071357) 11/65 2.20652E-13 4.09818E-11 -2.15603979 51.56792986 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
response to type I interferon (GO:0034340) 11/66 2.56339E-13 4.2125E-11 -2.15598129 51.5072136 IFITM3;ISG20;OAS2;STAT2;OAS3;MX2;MX1;ISG15;IFIT1;IFIT3;IFIT2
regulation of multi-organism process (GO:0043900) 15/306 1.29117E-10 1.59137E-08 -2.37108151 42.57534326
IL10;IFITM3;JUN;RSAD2;DDX58;MX1;EIF2AK2;TNFAIP3;ISG15;IFIT1;
PML;ISG20;IRG1;OAS3;DHX58
negative regulation of viral process (GO:0048525) 10/75 2.46655E-11 3.31639E-09 -2.12550141 41.49911933 IFITM3;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PML
negative regulation of viral genome replication 
(GO:0045071) 8/40 1.51028E-10 1.71823E-08 -2.31308207 41.35648849 IFITM3;ISG20;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1
negative regulation of type I interferon production 
(GO:0032480) 7/39 4.40681E-09 4.07355E-07 -2.37157589 34.89437401 IL10;IRG1;DDX58;DHX58;TNFAIP3;UBE2L6;ISG15
regulation of symbiosis, encompassing mutualism 
through parasitism (GO:0043903) 11/174 3.89756E-09 3.843E-07 -2.30311674 34.02127865
IFITM3;IL10;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PM
L
regulation of viral genome replication (GO:0045069) 8/57 1.87805E-09 1.98402E-07 -2.20289602 33.99722768 IFITM3;ISG20;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1
response to interferon-alpha (GO:0035455) 5/17 9.59165E-08 7.88114E-06 -2.67108852 31.38806425 IFITM3;MX2;EIF2AK2;IFIT3;IFIT2
regulation of viral process (GO:0050792) 10/152 1.46595E-08 1.27537E-06 -2.29027049 31.08417495 IFITM3;ISG20;JUN;RSAD2;OAS3;MX1;EIF2AK2;ISG15;IFIT1;PML
negative regulation of immune system process 
(GO:0002683) 12/311 1.37657E-07 1.07155E-05 -2.41467121 27.63305374
IL10;CD274;IRG1;DHX58;TRAFD1;EIF2AK2;TNFAIP3;MNDA;MERTK;I
FIT1;LILRB4;CCR2
negative regulation of response to biotic stimulus 
(GO:0002832) 5/26 5.95972E-07 4.19735E-05 -2.6028985 26.23324184 IRG1;DHX58;EIF2AK2;TNFAIP3;IFIT1
regulation of type I interferon production 
(GO:0032479) 8/108 1.89925E-07 1.40449E-05 -2.23175476 24.93595139 IL10;ZBP1;IRG1;DDX58;DHX58;TNFAIP3;ISG15;UBE2L6
chemokine-mediated signaling pathway (GO:0070098) 5/36 2.52079E-06 0.000156057 -2.50747675 21.978766 CXCL10;CCRL2;CXCR6;CCR5;CCR2
regulation of immune effector process (GO:0002697) 10/264 1.95482E-06 0.000131417 -2.41596637 21.59181051 IL10;RSAD2;DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;CFB;PML;CCR2
response to lipopolysaccharide (GO:0032496) 9/228 4.79697E-06 0.000283789 -2.34593359 19.1598989 IL10;CXCL10;IRG1;JUN;SPARC;TNFAIP3;CMPK2;FOS;CCR5
regulation of response to biotic stimulus (GO:0002831) 7/107 2.53236E-06 0.000156057 -2.18425093 19.14559727 IRG1;DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;PML
response to molecule of bacterial origin (GO:0002237) 9/243 7.88637E-06 0.000416569 -2.37309697 18.47090121 IL10;CXCL10;IRG1;JUN;SPARC;TNFAIP3;CMPK2;FOS;CCR5
regulation of cytokine production (GO:0001817) 12/482 0.000011703 0.000556832 -2.4321879 18.22498339
ZBP1;IL10;IRG1;CD274;RSAD2;DDX58;DHX58;EIF2AK2;TNFAIP3;ISG
15;UBE2L6;CCR2
negative regulation of defense response (GO:0031348) 7/120 5.20193E-06 0.000292809 -2.19334194 17.84500725 IL10;IRG1;DHX58;TRAFD1;EIF2AK2;TNFAIP3;IFIT1
response to corticosterone (GO:0051412) 4/23 1.22749E-05 0.000556832 -2.33708319 17.5123404 CDKN1A;FOSB;FOS;FOSL2
regulation of innate immune response (GO:0045088) 9/254 1.11175E-05 0.000548091 -2.31562005 17.38815049 ZBP1;IRG1;JUN;DDX58;STAT2;DHX58;TRAFD1;TNFAIP3;FOS
regulation of defense response to virus (GO:0050688) 6/77 5.3454E-06 0.000292809 -2.12142221 17.2598691 DDX58;DHX58;EIF2AK2;TNFAIP3;IFIT1;PML
response to glucocorticoid (GO:0051384) 7/130 8.57887E-06 0.000437522 -2.17199132 16.79901245 IL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;FOSL2
response to alcohol (GO:0097305) 9/274 1.99276E-05 0.000818693 -2.3583737 16.76285125 IL10;CXCL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;CCR5;FOSL2
response to cAMP (GO:0051591) 6/90 1.24242E-05 0.000556832 -2.23235243 16.72756695 JUN;SPARC;DUSP1;FOSB;FOS;FOSL2
regulation of defense response to virus by host 
(GO:0050691) 4/26 1.89351E-05 0.000800143 -2.31097828 16.47893795 DDX58;TNFAIP3;IFIT1;PML
negative regulation of innate immune response 
(GO:0045824) 4/28 2.46447E-05 0.000934602 -2.35250498 16.4096394 IRG1;DHX58;TRAFD1;TNFAIP3
response to mineralocorticoid (GO:0051385) 4/28 2.46447E-05 0.000934602 -2.33483872 16.28641032 CDKN1A;FOSB;FOS;FOSL2
response to corticosteroid (GO:0031960) 7/140 1.36053E-05 0.000591831 -2.17799115 16.1874591 IL10;CDKN1A;SPARC;DUSP1;FOSB;FOS;FOSL2
response to calcium ion (GO:0051592) 6/100 0.000021913 0.000875929 -2.1498972 15.13576121 CLIC4;JUN;SPARC;DUSP1;FOSB;FOS
inflammatory response (GO:0006954) 10/376 3.90701E-05 0.00131329 -2.27406464 15.08891938 IL10;CXCL10;IRG1;IL18RAP;CCRL2;TNFAIP3;FOS;CXCR6;CCR5;CCR2
response to ketone (GO:1901654) 6/105 0.000028475 0.001027182 -2.1888169 15.06110857 IRG1;CDKN1A;DUSP1;FOSB;FOS;FOSL2
negative regulation of immune response (GO:0050777) 6/103 2.56834E-05 0.000949645 -2.14143352 14.90314076 IL10;IRG1;DHX58;TNFAIP3;TRAFD1;CCR2
cellular response to lipopolysaccharide (GO:0071222) 6/110 3.65327E-05 0.001256556 -2.18661637 14.60524336 IL10;CXCL10;IRG1;CMPK2;TNFAIP3;CCR5
cellular response to molecule of bacterial origin 
(GO:0071219) 6/116 4.85175E-05 0.001559944 -2.20541514 14.25383033 IL10;CXCL10;IRG1;TNFAIP3;CMPK2;CCR5
response to interferon-gamma (GO:0034341) 6/108 3.31152E-05 0.001166128 -2.09595154 14.15619512 IFITM3;GBP6;IRG1;OAS2;OAS3;PML
response to progesterone (GO:0032570) 4/33 4.43518E-05 0.001457694 -2.16158964 14.11712452 IRG1;FOSB;FOS;FOSL2
response to organophosphorus (GO:0046683) 6/118 5.31467E-05 0.001637584 -2.17246262 13.93533369 JUN;SPARC;DUSP1;FOSB;FOS;FOSL2
negative regulation of leukocyte activation 
(GO:0002695) 6/120 0.000058123 0.001754367 -2.18546762 13.86820631 IL10;CD274;TNFAIP3;MNDA;MERTK;CCR2
negative regulation of cytokine production 
(GO:0001818) 7/185 7.53353E-05 0.002184723 -2.25151343 13.79337057 IL10;IRG1;DDX58;DHX58;TNFAIP3;ISG15;UBE2L6
cellular response to calcium ion (GO:0071277) 4/38 7.36529E-05 0.002178653 -2.19720058 13.46674839 JUN;CLIC4;FOSB;FOS
Table 3.8: Top 50 enriched biological processes (EnrichR GO analysis, GO Biological Processes 2015) for genes differentially expressed by CNS Tcons compared to LN Tcons that are not also 
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Rps3 0.01842587 5.2717514 down 7.31E-05 4.332505 down Fes 7.06E-04 3.4608388 up 6.86E-05 5.6882277 up Oas1b 2.48E-04 5.216868 up 1.61E-04 6.648277 up
Snrpd3 0.00256425 2.8508067 down 3.28E-04 2.5724661 down Acap3 0.00136976 3.8036666 up 6.90E-04 2.3661246 up Chac1 5.05E-05 6.787184 up 3.42E-04 8.366181 up
Actn1 6.04E-04 2.399842 down 4.41E-04 2.6189456 down Tmem49 3.22E-04 6.1248717 up 6.09E-04 5.963284 up Agpat4 0.00951303 2.1167436 up 1.05E-04 3.7773411 up
Tgfbr2 0.00308219 2.173973 down 7.40E-04 2.7259583 down Vldlr 0.00258142 2.422722 up 8.09E-04 2.1863441 up C4b 0.00130167 3.6472325 up 7.38E-04 2.7123153 up
Cnr2 6.06E-04 2.2376428 down 5.52E-04 2.5302548 down Mlxipl 0.00154645 3.328907 up 8.23E-04 3.4770005 up Slc1a3 0.0190683 3.6754663 up 1.56E-04 2.6547706 up
Prkd3 0.01725611 2.1564963 down 3.60E-04 2.6645622 down Gp49a 3.68E-04 4.4014 up 3.14E-04 10.375321 up Arsg 0.01188504 2.1339476 up 2.94E-04 3.960272 up
Nrn1 0.00680009 5.7305746 down 3.84E-04 2.5098953 down Iigp1 7.27E-04 5.5948043 up 5.44E-04 4.0843806 up Ctnnal1 0.00211385 4.3701415 up 5.88E-04 3.9878066 up
Fgf13 6.65E-04 2.4895806 down 7.58E-04 2.095639 down Pycr1 0.00103608 2.4562254 up 2.25E-04 2.6940296 up Sdc3 7.10E-04 3.4790454 up 6.11E-04 2.3390362 up
Gnpnat1 0.00189927 2.7378416 down 2.54E-04 2.345739 down Lmx1a 0.00374653 2.3961506 up 5.67E-04 2.2726436 up Nat5 0.00307375 2.1409264 up 4.57E-04 2.5357533 up
Nol5a 0.00205939 2.6674426 down 2.35E-04 3.1220007 down Tgfbi 0.00195324 4.492107 up 5.26E-04 2.5272915 up Abcb1a 0.00119113 2.6547084 up 2.79E-04 3.0554788 up
Rsu1 0.00635814 2.967668 down 1.73E-04 2.8133588 down
LOC100046
044
0.00551687 2.259464 up 3.02E-04 2.4161105 up Oas1g 1.90E-04 2.9665442 up 1.57E-04 4.0057607 up
Cct3 0.00691377 3.0775185 down 1.31E-04 2.6367273 down Apob48r 0.01626719 4.958684 up 1.31E-04 5.565611 up Oas1g 0.01876554 2.1954703 up 2.18E-04 2.3961787 up
Acss2 0.00117027 2.3997838 down 1.97E-04 3.2385485 down Snx2 0.00444753 2.5223305 up 2.27E-04 2.392328 up Hk3 0.00329686 7.490652 up 5.37E-05 3.8636587 up
Snrpd1 0.01706071 5.524827 down 7.98E-05 3.5212362 down
LOC100047
934
0.00110696 2.6554127 up 2.60E-04 6.6833115 up Sema7a 0.00534428 5.097547 up 2.77E-05 6.536206 up
Rabac1 2.06E-04 4.6571016 down 5.41E-04 4.526913 down Phf11 0.00320973 2.6377301 up 4.14E-05 3.9329054 up LOC225594 1.20E-04 3.9950597 up 5.87E-04 5.848784 up
Serbp1 0.02115954 3.22602 down 2.10E-04 2.3535476 down Asb13 0.00311387 3.599282 up 5.59E-04 2.864375 up Cyp27a1 0.0106727 3.2024052 up 4.35E-04 2.699882 up
Serbp1 0.03079429 2.6332102 down 5.23E-04 2.0450957 down Lilrb4 3.40E-05 6.113127 up 1.42E-04 9.567557 up Fhl1 0.0011673 2.10544 up 4.14E-04 2.2217517 up
Ifngr2 4.49E-04 4.36479 down 3.16E-04 11.670161 down Efs 0.00327197 4.0052304 up 8.83E-05 6.1231227 up Oas1b 1.17E-04 5.0445266 up 4.33E-04 6.324501 up
Ifngr2 6.50E-04 5.0589395 down 2.13E-04 12.306132 down Inppl1 0.00137062 2.8974195 up 3.56E-04 3.213449 up Oas1a 0.02466584 2.9835072 up 4.38E-04 3.6260202 up
Smarce1 0.01143495 2.144061 down 7.60E-04 2.1010916 down Inppl1 4.32E-04 3.0505278 up 3.08E-04 3.185575 up Trafd1 0.00191764 2.859083 up 5.90E-04 2.4566183 up
LOC100048
480
0.00115261 9.041677 down 1.23E-04 2.8634455 down Soat2 1.75E-04 4.6536 up 4.98E-05 5.1933117 up Enpp2 6.07E-05 14.979469 up 7.02E-05 16.29162 up
Tcf7 0.00479234 3.8769116 down 4.39E-04 4.886764 down Tbx21 0.02443471 2.9178898 up 2.01E-05 5.901536 up Csprs 3.75E-05 4.933625 up 8.78E-04 5.956532 up
Klf16 3.67E-04 3.4047892 down 6.00E-04 2.8669736 down BC003281 0.01739753 4.3957796 up 7.09E-04 3.0127075 up Tmem86b 0.003381 3.259821 up 1.74E-04 3.1724737 up
Pigp 5.04E-04 3.71126 down 8.31E-05 3.2503614 down Jak3 3.85E-04 4.0300694 up 6.31E-04 4.50765 up Rrbp1 0.0010534 3.238847 up 3.21E-04 2.1452262 up
Pigp 2.48E-04 2.9878213 down 1.47E-04 2.9028368 down Tmem140 7.14E-04 2.2970839 up 2.83E-04 2.4703977 up Zic1 0.0029617 9.45485 up 1.73E-05 8.679583 up
EG434858 0.00160825 3.3418005 down 1.48E-04 4.350609 down Tmem49 9.66E-04 5.7620997 up 5.09E-04 5.4326134 up Slc6a9 0.00241596 5.601568 up 3.45E-04 5.934071 up
Prps2 0.0010821 5.399625 down 3.02E-04 2.5554893 down Tmem49 4.64E-04 5.5300264 up 8.08E-05 3.91537 up Mtus1 4.82E-05 5.320096 up 5.49E-04 2.4279616 up
Ctdsp2 0.00152582 2.3199139 down 4.60E-04 2.2984507 down Ier3 0.01081613 2.6098914 up 5.76E-04 3.412758 up Unc13b 0.00422987 3.2069585 up 1.18E-04 2.6288774 up
Cct6a 3.16E-04 2.6901968 down 1.31E-04 3.2951968 down Rsad2 4.03E-04 3.8253422 up 2.99E-04 3.1745374 up Sh3bp2 3.62E-04 3.1299894 up 7.05E-04 3.4001317 up
Hspa9 0.00281903 2.8020253 down 1.10E-04 3.1289074 down Kif5c 0.00226615 4.2462697 up 3.23E-04 2.3589995 up Ifit3 3.09E-04 2.9494848 up 3.55E-04 2.552879 up
LOC100043
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0.008822 7.2864423 down 3.49E-04 5.7978773 down Rab7l1 5.06E-04 2.3216536 up 2.30E-04 2.836323 up
LOC100047
963
0.00143436 2.739252 up 4.30E-04 3.7881746 up
Klhl21 0.00326293 2.2266512 down 2.67E-04 3.0899255 down Parp14 0.00180494 2.60999 up 1.37E-04 2.5894365 up
LOC100047
963
0.00752087 4.598486 up 2.31E-04 6.509479 up
Rasgrp1 0.01503402 2.8958728 down 3.25E-04 3.7713244 down Sytl3 8.66E-04 2.8349988 up 4.18E-04 5.244941 up Camp 0.0153044 3.3866622 up 8.31E-04 2.2953212 up
Bccip 0.00393518 2.4193845 down 2.37E-04 2.466595 down Cxcl10 0.02777018 2.6249287 up 3.19E-04 7.0126243 up AW111922 3.26E-04 5.9379773 up 8.34E-04 5.9349575 up
Tcf7 0.00540721 4.699182 down 1.03E-04 4.8061886 down Cpne2 6.08E-04 3.1607096 up 5.24E-04 3.6272728 up Fgd2 0.00284835 2.8278687 up 1.52E-04 3.4577425 up
Btf3 0.00110601 3.0698774 down 3.77E-04 3.0759168 down Tmem184b 0.00768419 2.5595832 up 5.34E-04 2.0782201 up C2 6.59E-04 4.908031 up 7.78E-05 4.274759 up
Ppp1ca 0.00578122 3.0556514 down 7.01E-05 3.1066697 down Timp3 0.02725675 2.482257 up 6.84E-04 2.1555302 up Hif1a 2.33E-04 3.9575522 up 3.79E-04 4.613982 up
Ola1 0.00611871 2.6775513 down 1.95E-04 2.8606815 down Tmem106a 0.0019595 3.2696393 up 6.04E-04 2.713932 up Slc4a10 6.01E-04 2.7828763 up 5.81E-04 2.170424 up
Surf2 0.00259637 2.4122338 down 2.76E-04 2.1837645 down Abca4 0.00479074 3.3978765 up 4.31E-04 2.8642638 up Hip1r 0.02288557 2.3537476 up 7.46E-05 4.0485063 up
Naca 0.00285744 3.4955513 down 6.69E-04 3.7864327 down Abca4 9.22E-04 3.469062 up 1.78E-04 2.5123978 up Trib3 0.00837727 2.2483938 up 7.98E-04 2.5154908 up
Naca 0.00333388 3.694942 down 3.80E-04 3.570333 down Rilpl1 0.0022254 3.3029723 up 2.64E-04 4.2929153 up
5430435G2
2Rik
0.00568458 2.5104537 up 7.25E-04 2.115393 up
Mettl1 0.00159084 2.0457509 down 4.51E-04 2.656916 down Grina 0.00295382 5.697693 up 1.12E-04 5.694434 up Sdccag8 6.87E-04 2.4077847 up 4.51E-04 2.1816304 up
Snrpd1 0.01570565 6.3056436 down 2.36E-04 3.473617 down Slco2b1 1.20E-04 3.9053547 up 3.20E-04 3.5612068 up Oasl1 6.69E-04 3.7622104 up 4.70E-04 2.8311489 up
Trat1 0.00355927 3.0490909 down 9.86E-05 3.3446934 down Oasl1 7.81E-04 3.8750556 up 2.66E-04 2.845188 up Dapk2 4.99E-04 2.771868 up 1.39E-04 6.1440635 up
Irf6 1.48E-04 3.3528109 down 7.83E-04 2.48764 down Oas3 0.00458165 2.3316991 up 1.77E-04 2.4298003 up LOC626152 0.00115832 7.6767807 up 4.02E-04 4.470725 up
Rsl1d1 2.77E-04 3.5203629 down 5.89E-04 3.466128 down Rilp 0.01276411 2.22319 up 4.98E-04 2.1044374 up Mx2 0.00114569 7.243382 up 4.96E-05 5.9694896 up
D230037D0
9Rik
2.77E-04 2.8890421 down 7.78E-04 2.6007595 down Sytl3 0.01664805 3.9615145 up 8.92E-05 5.6209164 up Als2 4.21E-04 5.3078165 up 4.59E-04 3.5189145 up
D230037D0
9Rik
1.78E-04 3.0397847 down 9.75E-05 2.9445376 down Grb10 3.46E-04 5.4297743 up 2.82E-05 6.220456 up Ifitm1 0.00535448 3.2997322 up 9.41E-05 4.3948927 up
Gadd45a 2.91E-04 3.8556104 down 6.28E-05 4.660697 down Rai2 0.01773801 3.2123063 up 7.24E-04 4.0850506 up Rbm47 5.98E-05 11.977747 up 3.79E-05 7.427475 up
Gadd45a 3.44E-04 3.6624503 down 5.38E-05 4.1633816 down Siglech 0.0129637 2.4479344 up 5.29E-04 2.1545684 up Oas2 3.36E-04 7.3459244 up 3.79E-04 3.846931 up
Rps27a 4.27E-04 4.8982177 down 1.92E-04 3.819965 down Ctrl 0.01209495 2.0175884 up 1.49E-04 4.1561584 up Ttr 1.17E-05 248.24515 up 3.12E-04 155.9128 up
Tpt1 0.00162288 3.5110035 down 4.89E-04 3.727465 down Slc13a4 0.00308583 8.260977 up 5.00E-04 5.725059 up Gzmb 0.00497645 2.9891262 up 5.17E-04 5.9782624 up
Sp6 0.02041128 2.2507055 down 3.33E-04 2.5192974 down Igtp 0.02381074 2.7621574 up 3.80E-04 2.5023568 up Eif2ak2 9.40E-05 4.3313313 up 6.32E-04 5.0375266 up
Klf7 0.02521298 2.2936502 down 2.96E-04 2.6919286 down Hap1 0.00520919 5.6166024 up 3.29E-05 8.272728 up Luzp1 1.81E-04 4.951965 up 5.14E-05 4.148919 up
St8sia6 0.00721769 2.8419251 down 6.61E-04 5.940638 down Tmprss13 0.00609826 2.1928575 up 5.16E-04 4.269098 up Luzp1 0.00303358 5.909782 up 7.09E-05 4.779411 up
Cox7a2l 0.02127965 4.4864664 down 1.22E-04 3.8217518 down Tbxas1 0.00360889 3.2731614 up 2.75E-04 2.3331249 up D2Ertd391e 0.00775354 3.2969158 up 8.95E-04 2.0663452 up
Ifih1 0.00574878 2.4523642 up 8.23E-04 2.592511 up
Als2 7.29E-04 4.217062 up 1.54E-04 3.3460906 up
Grn 5.53E-04 4.025088 up 4.03E-04 4.333853 up

















Chapter IV.  Difficulty in ablating meningeal/choroid plexus dendritic cells while 
studying their role in EMCV-induced CNS Treg expansion reveals unappreciated 














 Classical dendritic cells (DCs) are a small population of specialized antigen-
presenting cells of the mammalian immune system, which constantly sample their 
environments for extracellular antigens to present to T lymphocytes (129-131). The 
moniker “classical” is used to distinguish cDCs from plasmacytoid dendritic cells 
(pDCs), a morphologically and functionally distinct subset that resembles antibody-
producing plasma cells, produces massive amounts of IFNα during viral infection, and, 
upon stimulation, can differentiate into immunogenic DCs that can prime T cells against 
viral antigens (267, 268). Classical DCs are capable of precisely modulating immune 
response due to the division of labor between, and discrete localization of distinct DC 
subsets (269-271). For example, lymphoid DCs are comprised of two mutually exclusive 
CD8α+ and CD8α- subsets, among which the CD8α+ DCs preferentially induce a Th1 
response in CD4+ T cells (272, 273), whereas the CD8α- DCs characteristically induce a 
Th2 response in CD4+ T cells (273), even when both DC types are pulsed with the same 
KLH antigen. Therefore, DCs with functionally distinct capacities exist in discrete tissue 
niches 
DCs are short-lived and must be constantly replenished from bone marrow 
precursors. Like the development of all other blood cells, DC development is thought to 
proceed through a series of increasingly restricted progenitors during hematopoiesis, 
though the contribution of each of these progenitors to the DC lineage has been hotly 
debated (274). That is, the relative contribution of lymphoid and myeloid precursors to 
the DC lineage is still unclear. What is known is that the penultimate stage of most DC 
development is the pre-cDC, which arises from committed DC progenitors (CDPs) in the 
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bone marrow, migrates through the blood, and seeds lymphoid and non-lymphoid tissues, 
where it undergoes a limited number of divisions and differentiates into specialized DC 
subsets (134). DC development is critically dependent on the hematopoietin, FMS-like 
receptor tyrosine kinase 3 ligand (Flt3L), which acts primarily on DCs and their 
precursors that express Flt3 receptor (CD135), both in the bone marrow and periphery 
(275-277). This is demonstrated, in part, by the fact that Flt3L-deficient mice are 
deficient in both populations—CD8α+ and CD8α-—of lymphoid-resident cDCs (278). As 
such, Flt3L dependence is a hallmark of the DC lineage has been used to trace dendritic 
cell development (134). 
A rare subset of DCs has recently been identified in the meninges and the choroid 
plexus of the steady-state mouse brain (m/chDCs)(193). These DCs display 
characteristics of classical DCs: they are MHCII+CD11c+, are YFP+ in naïve CD11c-Cre 
R26-STOPflox-YFP (CD11c-Cre iYFP) mice, and are radiosensitive, unlike microglia. 
This population is Flt3+ and has an intrinsic requirement for Flt3-signaling, as Flt3-/- bone 
marrow cells are unable to repopulate the m/chDC niche when transferred into lethally 
irradiated congenic recipients. In further support of their Flt3L-dependence, m/chDCs 
expand as much as 10 fold after injection with Flt3L, whereas microglia are unresponsive 
(193). M/chDCs are definitively derived from the pre-DC in the steady-state, as separate 
adoptive transfers of CD45.1+ monocyte and dendritic cell progenitors (MDPs), CDPs 
and pre-DCs into CD45.2+ mice give rise to m/chDCs, whereas singular transfers of 
monocytes do not. Transcriptomic characterization has demonstrated that m/chDCs are 
molecularly more akin to splenic cDCs than to microglia, expressing high levels of Batf3, 
Id2 and Flt3 as well as common cDC pattern recognition receptors, co-stimulatory 
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molecules, and antigen-presentation molecules (193). Finally, m/chDCs are as efficient as 
splenic DCs, and more efficient than microglia, in promoting allogeneic T cell 
proliferation and in antigen presentation to MOG-specific T cells. Therefore, m/chDCs 
exist at the gates of the CNS and display characteristic features of DCs, the initiators of 
immune responses. While their steady-state origin is known, much is uncharacterized 
about m/chDCs, including how they respond during immune perturbation in the CNS and 
their relationship to T cells that enter the CNS infection, inflammation or injury. 
DCs and regulatory T cells in the periphery are inextricably linked. That is, DCs 
are required for the persistence of natural, thymically-derived Tregs (nTregs). This is 
evidenced by DC-ablative mouse models, such as Dtx-treated CD11c-DTR (279) mice or 
CD11c-Cre iDTA mice (280), wherein conditional or constitutive loss of DCs leads to a 
compensatory reduction in regulatory T cells (133, 134). In corollary, conditional 
depletion of Tregs by Dtx treatment of FoxP3-DTR mice induces an expansion in DC 
populations (31, 132, 134). Moreover, the expansion of DCs with Flt3L injection is 
commensurate with an increase in peripheral Tregs (136). Finally, DCs have the capacity 
to promote Treg proliferation in vitro (137-140). Therefore, it is known that peripheral 
cDC and peripheral Treg homeostasis are intertwined. Although it is known that Flt3L 
injection can expand Tregs systemically, and it is known that DCs can promote Treg 
proliferation in vitro and in vivo, it is unknown if Flt3L treatment can drive Treg 
accumulation in the CNS, with or without infection, and whether m/chDCs are required 
for Treg increase in the CNS during pathological conditions. The answers to these 
questions may allow the indirect therapeutic manipulation of Tregs during CNS disease 
by exploiting the relationship between DCs and Tregs.  
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Here we show that Flt3L injection during EMCV infection dramatically enhances 
both m/chDC and CNS Treg increase. This interaction is independent of Flt3 receptor 
expression on CNS Tregs, indicating that a Flt3L-dependent population is responsible for 
promoting CNS Treg increase after Fl3L injection and EMCV infection. Total DC 
ablation using CD11c-Cre iDTA mice has no effect on CNS Treg increase during 
infection and Flt3L treatment, indicating that a Flt3L-dependent, CD11c-Cre- population 
may be linked to CNS Treg increase during infection. In an effort to identify this 
population, we found that m/chDCs are, surprisingly, not a homogeneous population as 
previously believed (193), but instead comprise three distinct subsets with unknown 
potential, paving the way for future study.  
 
2. Results 
Flt3L treatment in conjunction with EMCV infection dramatically enhances 
increase of m/chDCs and CNS Tregs independently of Flt3 receptor expression on 
Tregs 
Flt3L injection prior to infection dramatically enhances infection-induced m/chDC and 
CNS Treg accumulation 
In order to assess whether m/chDC increase was associated with CNS Treg 
increase during EMCV infection, we took advantage of the fact that m/chDCs are 
critically dependent upon Flt3L in the steady state and increase significantly after 
intraperitonal injection of recombinant Flt3L (193). Consequently, we injected mice with 
Flt3L intraperitoneally prior to infection and determined if Flt3L-dependent DC increase 
affected CNS Treg accumulation. We observed that Flt3L injection alone resulted in 
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significant m/chDC increase (Figure 4.1A-B). EMCV-infection, as we had noted 
previously, also resulted in significant m/chDC increase (Figure 4.1.A-B). Flt3L 
treatment in conjunction with EMCV infection significantly enhanced m/chDC increase 
compared to EMCV infection alone (Figure 4.1.A-B). This enhanced m/chDC expansion 
during infection and Flt3L treatment was accompanied by significant expansion of CNS 
Tregs (Figure 4.1.A-B). Notably, the Treg increase in the brain is critically dependent on 
infection; Flt3L injection in uninfected mice induced expansion of m/chDCs but failed to 
induce increase of CNS Tregs (Figure 4.1.A-B). Further, while Flt3L injection results in 
a modest increase in splenic Tregs (Figure 4.2.A-B), the increase of CNS Tregs in mice 
treated with EMCV+Flt3L surpassed the fold-change increase of Treg within the spleen 
of the same mice (Figure 4.2.A-B). These data reveal that infection is requisite for 
Flt3L+EMCV-induced CNS Treg increase and suggests a positive correlation between 
m/chDC and CNS Treg increase during the CNS infection.  
Enhanced CNS Treg increase resultant from EMCV+Flt3L treatment is independent of 
Flt3 expression on Tregs 
To determine if enhanced Treg expansion in the CNS of Flt3L+EMCV-treated 
mice was a result of cell-intrinsic Flt3 signaling, we adoptively transferred equal numbers 
of Flt3-/- and CD45.1 bulk splenocytes (including equal numbers of Tregs) into Rag1-/- 
mice and infected them with EMCV with or without Flt3L co-treatment. We used this 
adoptive transfer system because lack of competition from endogenous Tregs allowed us 
to better observe transferred cells in the infected CNS. Five days post-infection, we 
harvested bulk brain and spleen leukocytes and assessed the ratio of CD45.2+ (Flt3-/-) to 
CD45.1+ (WT) cells within TCRβ+CD4+FoxP3+ Tregs. We observed that splenic Tregs 
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included nearly equal percentages of CD45.2+ (Flt3-/-) and CD45.1+ (WT) cells in all 
treatments (Figure 4.3.A and 4.3.B), indicating, as expected, that Flt3L-mediated splenic 
Treg homeostasis is independent of Flt3 expression on Tregs. Similarly, CNS Tregs were 
nearly equally comprised of CD45.2+ and CD45.1 cells, in either EMCV or 
EMCV+Flt3L-treated mice (Figure 4.3.A-B). These data demonstrate that Treg 
expansion during EMCV+Flt3L treatment is cell extrinsic, meaning that enhanced CNS 
Treg expansion is due to involvement with a separate, Flt3L-dependent cell type or 
signaling pathway.  
DC ablation during EMCV+Flt3L treatment in CD11c-Cre+/- iDTA+/- mice has no effect 
on CNS Treg increase 
 In order to understand if m/chDCs are required for CNS Treg expansion during 
EMCV infection, we sought to ablate m/chDCs and determine if CNS Treg expansion 
was affected. Unfortunately, there are currently no DC-ablative models that are specific 
to m/chDCs because there are no known molecules that distinguish m/chDCs or their 
precursors from peripheral cDCs. Therefore, we decided to use general DC-ablative 
models that delete DCs systemically. Two models are widely used to deplete DCs. In 
CD11c-DTR mice, conditional depletion of CD11c-expressing cells, including DCs, can 
be induced by Dtx treatment (281). In CD11c-Cre R26-STOPflox-DTA (CD11c-Cre 
iDTA) mice, CD11c-expressing cells irreversibly express the catalytic subunit of 
diphtheria toxin, resulting in cessation of protein synthesis and subsequent cell death 
(280, 282). Because our experiments including Flt3L treatment and EMCV infection take 
up to 15 days, repeated Dtx injection is needed to maintain the DC ablation in the 
inducible model. However, repeated Dtx treatment of CD11c-DTR mice results in death, 
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presumably due to aberrant expression of the DTR transgene in non-hematopoietic cells 
(281). Consequently, use of CD11c-DTR mice requires bone marrow chimeras. For our 
purposes, the use of bone marrow chimeras was not feasible because reconstitution takes 
six to eight weeks and our model critically depends on infection before ten weeks of age. 
Therefore, we decided to use the constitutive DC-ablative model: CD11c-Cre iDTA mice 
(280, 282). Published data indicates that these mice have normal T cell and Treg 
development before five weeks of age, only exhibiting a slight increase in CD4:CD8 T 
cell ratios (282). To determine if DC-less mice demonstrate impaired CNS Treg 
accumulation during infection, we treated CD11c-Cre-/- iDTA+/- (DC-sufficient) and 
CD11c-Cre+/- iDTA+/- (DC-deficient) mice with and without EMCV. We observed that 
splenic cDCs (CD45hiB220-CD11c+MHCII+) were 95% depleted in naïve CD11c-Cre+/- 
iDTA+/- mice (Figure 4.4.A). In contrast, m/chDCs were unaffected in naïve CD11c-
Cre+/- iDTA+/- mice (Figure 4.5.A-B). This suggested either late or low expression of 
CD11c in m/chDCs, insufficient to induce adequate Cre expression and recombination. In 
other words, a threshold level of Cre recombinase expression is required to excise the 
floxed STOP codon, and cells that are newly differentiated or lowly express CD11c may 
not reach this threshold. After infection, modest m/chDC expansion was observed in 
EMCV-infected, DC-sufficient mice (Figure 4.5.A-B). Unexpectedly, a comparable 
m/chDC expansion was also observed in EMCV-infected, CD11c-Cre+/- iDTA+/- (DC-
deficient) mice. CNS Treg numbers in EMCV-infected, CD11c-Cre+/- iDTA+/- (DC-
deficient) mice were also comparable to those harvested from EMCV-infected, DC-
sufficient mice (Figure 4.5.A-B). However, this was not significantly different from 
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naïve controls, possibly due to increased inflammation in DC-deficient mice, which has 
been observed in CD11c-Cre+/- iDTA+/- mice past five weeks of age (282).  
 Given the inconclusive data resulting from EMCV-infection of CD11c-Cre+/- 
iDTA+/- (DC-sufficient) and CD11c-Cre+/- iDTA+/- (DC-deficient) mice, we decided to 
enhance the m/chDC increase in DC-sufficient and DC-deficient mice with recombinant 
Flt3L, infect them with EMCV and measure DC and Treg response in the spleen and 
brain. We found that Flt3L injection in conjunction with EMCV infection dramatically 
increases splenic cDCs in CD11c-Cre-/- iDTA+/- mice but had no effect on CD11c-Cre+/- 
iDTA+/- splenic cDCs (Figure 4.6), coinciding with the efficient depletion of cDCs in 
CD11c-Cre+/- iDTA+/- mice (Figure 4.4). Impaired splenic cDC expansion in 
EMCV+Flt3L-treated CD11c-Cre+/- iDTA+/- mice was correlated with a lack of splenic 
Treg increase (Figure 4.6). In contrast to splenic cDCs, m/chDCs expanded as 
dramatically in Flt3L-treated, EMCV-infected, CD11c-Cre+/- iDTA+/- mice as in Flt3L-
treated, EMCV-infected, CD11c-Cre-/- iDTA+/- mice (Figure 4.6). Moreover, CNS Tregs 
accumulated equally in Flt3L-treated, EMCV-infected, CD11c-Cre+/- iDTA+/- as in Flt3L-
treated, EMCV-infected, CD11c-Cre-/- iDTA+/- mice, despite lack of splenic Treg 
increase (Figure 4.7). These data indicate that the m/chDCs remaining in CD11c-Cre+/- 
iDTA+/- mice are Flt3L responsive or originate from a Flt3L-responsive progenitor. 
Additionally, the correlation between m/chDC increase and CNS Treg accumulation in 
Flt3L-treated, EMCV-infected CD11c-Cre+/- iDTA+/- mice suggests that Flt3L-




m/chDCs are heterogeneous—comprised of three distinct populations distinguishable by 
IRF8 and FcRγ 
 Because m/chDCs were unaffected in EMCV-infected CD11c-Cre+/- iDTA+/- 
mice, we wanted to confirm that m/chDCs were expressing Cre. To detect which cells 
were depleted in CD11c-Cre+/- iDTA+/- mice, we made use of CD11c-Cre x R26-
STOPflox-YFP mice, in which YFP can report the efficacy of Cre expression in CD11c-
expressing cells. In naïve mice and EMCV-infected mice, splenic cDCs are ~82% YFP+, 
reflecting their efficient depletion in CD11c-Cre+ iDTA+ mice (Figure 4.8). In naïve 
mice, m/chDCs are also predominantly YFP+ (~77%) (Figure 4.8), contradictory to their 
persistence in CD11c-Cre+/- iDTA+/- mice. These data suggest a compensatory expansion 
of CD11c-Cre- m/chDCs in CD11c-Cre+/- iDTA+/- mice. Moreover, in EMCV-infected, 
CD11c-Cre+/- iDTA+/- mice, only ~47% of m/chDCs are YFP+. These data indicate that 
m/chDCs in EMCV-infected mice are comprised of cells that heterogeneously express 
CD11c-Cre (Figure 4.8), which may explain the persistence of m/chDCs in EMCV-
infected, CD11c-Cre+/- iDTA+/- mice. Additionally, these data demonstrate that the 
increase in m/chDCs during EMCV infection is not resultant from division of pre-
existing CD11c-Cre iYFP+ cells. Such YFP+ cells and their progeny are irreversibly 
marked with YFP, therefore, YFP- m/chDCs observed in the EMCV-infected CNS must 
originate from a cell that is CD11c-Cre-.  
 To clarify the heterogeneity in m/chDCs, we sought to find markers that may 
segregate m/chDCs into discrete populations. Splenic DCs can be separated into two 
mutually exclusive populations based on the expression of CD8α and CD11b (283). 
Interestingly, published gene expression data suggests m/chDCs express transcription 
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factors and cell surface markers associated with both CD8α and CD11b populations 
(193). For instance, m/chDCs express both IRF8, which is stereotypically expressed by 
only CD8α+ cDCS (284, 285), and IRF4, which is stereotypically expressed by only 
CD11b+ lymphoid cDCs(284). Therefore, we hypothesized that m/chDCs could also be 
separated into CD8α+ and CD11b+ subsets. However, m/chDCs do not express CD8α 
and are predominantly CD11b+. Therefore, to assess the composition of m/chDCs, we 
stained with IRF4, IRF8, and FcRγ, which is known to be expressed on monocytes and 
macrophages but not on cDCs (286). We found that m/chDCs can be separated into three 
distinct populations, best separated using IRF8 and FcRγ: FcRγ- IRF8+, FcRγ-IRF8- and 
FcRγ+IRF8lo m/chDCs (Figure 4.9). IRF8loFcRγ+ m/chDCs were positive for IRF4. 
Therefore, m/chDCs are comprised of three, heretofore unappreciated, subsets with 
unknown potential. Because IRF8+ cDCs are known to express high levels of Flt3 
receptor and to be highly Flt3L responsive (287), we hypothesize that the IRF8+ 
m/chDCs may facilitate CNS Treg accumulation during EMCV infection. This provides 
an exciting avenue of further study.  
 
3. Discussion 
 It is well appreciated that lymphoid DCs mediate peripheral Treg homeostasis. 
Because we observed a simultaneous increase in meningeal/choroid plexus DCs and CNS 
Tregs during EMCV infection (Figure 3.2), we hypothesized that DCs in the brain may 
facilitate CNS Treg accumulation during infection. In this chapter, we show that the 
increase of both m/chDCs and CNS Tregs during EMCV infection can be artificially 
enhanced with injection of the DC-poietin, Flt3L. The increase of CNS Tregs during 
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EMCV and Flt3L co-treatment is independent of Flt3 expression on Tregs, strongly 
supporting the role of DCs in augmenting CNS Treg increase during EMCV+Flt3L 
treatment. In an effort to conclusively show that DCs were responsible for mediating 
CNS Treg increase, we attempted to ablate DCs using CD11c-Cre+/- iDTA+/- mice. These 
mice were replete in m/chDCs, associated with a normal accumulation of CNS Tregs. 
The persistence of m/chDCs in these mice suggested that they might be comprised of 
heterogeneous cells, negative for DTA expression. Indeed, we found m/chDCs consist of 
three distinct subsets, identifiable by IRF8 and FcRγ.  
 These results pave the way for many future studies. The main open questions are: 
which m/cDC subset, if any, mediates CNS Treg expansion during EMCV infection? Are 
there further divisions of labor among the three m/chDC subsets? i.e. does one subset 
preferentially prime Tcons or skew Tcon phenotype? What is the origin of these three 
m/chDC subsets? Is there an intra-progenitor relationship between any of the m/chDC 
subsets? i.e. are FcRγ-IRF8- m/chDCs precursors to either of the other two subsets? 
Where do these m/chDC subsets localize? Is MHCII expression on these cells required 
for EMCV-induced CNS Treg expansion?  
The answers to these questions are especially interesting because relatively little 
is known about m/chDC function, in the steady state or during CNS pathology. M/chDC 
localization at the gates of the CNS suggests they are poised to encounter T cells 
infiltrating the CNS at the choroid plexus or in the meninges, however, this has yet to be 
demonstrated. Prior to our observation that m/chDCs consist of three different subsets, 
analysis of their function would have been confounded by their heterogeneity. Now, more 
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precise experiments can be performed to determine the division of labor among these 
three subsets. We elaborate upon possible future experiments in Chapter V: Discussion.  
 





















Figure 4.1: Flt3L treatment in conjunction with EMCV infection enhances 
infection-induced m/chDC and CNS Treg increase. (A) Representative flow cytometry 
plots of m/chDCs (CD45hiB220-CD11c+MHCII+) and Tregs (CD45hiTCRβ+CD4+FoxP3-
GFP+) in the brain of naïve, Flt3L-treated, EMCV-infected or Flt3L-treated, EMCV-
infected FoxP3-GFP mice. Parent gate is live, size, single, CD45hiB220- cells for 
m/chDCs and live, size, single, CD45hiTCRβ+CD4+ cells for Tregs. Numbers are 
frequencies of parent gates. Representative of more than 5 independent experiments, n=2-
5 mice per group.  (B) Absolute numbers of m/chDCs and Tregs in the brain of naïve 
Flt3L-treated, EMCV-infected or Flt3L-treated, EMCV-infected FoxP3-GFP mice as 
gated in (A). Data are mean ± SEM pooled from 3 independent experiments, n=2-3 mice 

























































































































Figure 4.2: Flt3L treatment expands splenic cDCs. (A) Representative flow cytometry 
plots of splenic cDCs (CD45hiB220-CD11c+MHCII+) and Tregs 
(CD45hiTCRβ+CD4+FoxP3-GFP+) in the spleen of naïve, Flt3L-treated, EMCV-infected 
or Flt3L-treated, EMCV-infected FoxP3-GFP mice. Parent gate is live, size, single, 
CD45hiB220- cells for splenic cDCs and live, size, single, CD45hiTCRβ+CD4+ cells for 
Tregs. Numbers are frequencies of parent gates. Representative of more than 5 
independent experiments, n=2-5 mice per group.  (B) Absolute numbers of cDCs and 
Tregs in the spleen of naïve Flt3L-treated, EMCV-infected or Flt3L-treated, EMCV-
infected FoxP3-GFP mice as gated in (A). Data are mean ± SEM pooled from 3 



































































































































Figure 4.3: Flt3L-mediated CNS Treg increase during EMCV+Flt3L treatment is 
independent of Flt3 receptor expression on Tregs. (A) Representative flow cytometry 
plots of WT (CD45.1+) and Flt3-/- (CD45.2+) cells among Tregs 
(CD45hiTCRβ+CD4+FoxP3+) in the spleen and brain of Rag1-/- that received adoptive 
transfer of equal numbers of WT and Flt3L-/- Tregs followed by treatment with/without 
EMCV, and with/without Flt3L (Celldex). Parent gate is live, size, single, 
CD45hiTCRβ+CD4+FoxP3+ cells. Numbers are frequencies of parent gates. (B) 
Percentages of WT (CD45.1+) and Flt3-/- (CD45.2+) cells among Tregs in the spleen and 
brain of Rag1-/- that received adoptive transfer of equal numbers of WT and Flt3L-/- Tregs 
followed by treatment with/without EMCV, and with/without Flt3L (Celldex) as gated in 
(A). Data are mean ± SEM representative of 1 of 2 independent experiments, n=2-3 mice 






























































Figure 4.4: CD11c-cre+/- iDTA+/- mice are deficient in splenic cDCs. (A) 
Representative flow cytometry plots of cDCs (CD45hiB220-CD11c+MHCII+) and Tregs 
(CD45hiTCRβ+CD4+FoxP3-GFP+) in the spleen of naïve and EMCV-infected CD11c-cre-
/- iDTA+/- and CD11c-cre+/- iDTA+/- mice. Parent gate is live, size, single, CD45hi cells for 
splenic cDCs and live, size, single, CD45hi TCRβ+ cells for Tregs. Numbers are 
frequencies of parent gates. (B) Absolute numbers of cDCs and Tregs in the spleen of 
naïve and EMCV-infected CD11c-cre-/- iDTA+/- and CD11c-cre+/- iDTA+/- mice as gated 
in (A). Data are mean ± SEM pooled from 2 independent experiments, n=2-3 mice per 
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Figure 4.5: CD11c-cre+/- iDTA+/- mice are not deficient in m/chDCs. (A) 
Representative flow cytometry plots of m/chDCs (CD45hiB220-CD11c+MHCII+) and 
CNS Tregs (CD45hiTCRβ+CD4+FoxP3+) in the brain of naïve and EMCV-infected 
CD11c-cre-/- iDTA+/- and CD11c-cre+/- iDTA+/- mice. Parent gate is live, size, single, 
CD45hi cells for m/chDCs and live, size, single, CD45hi TCRβ+ cells for Tregs. Numbers 
are frequencies of parent gates. (B) Absolute numbers of m/chDCs and CNS Tregs in the 
brain of naïve and EMCV-infected CD11c-cre-/- iDTA+/- and CD11c-cre+/- iDTA+/- mice 
as gated in (A). Data are mean ± SEM pooled from 2 independent experiments, n=2-3 
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Figure 4.6: CD11c-cre+/- iDTA+/- mice treated with Flt3L and infected with EMCV 
demonstrate m/chDC, but not splenic cDC, expansion. (A-B) Representative flow 
cytometry plots of (A) m/chDCs and (B) splenic cDCs (CD45hiB220-CD11c+MHCII+) in 
the brain and spleen of EMCV-infected and Flt3L-treated, EMCV-infected CD11c-cre-/- 
iDTA+/- and CD11c-cre+/- iDTA+/- mice. Parent gate is live, size, single, CD45hi cells. 
Numbers are frequencies of parent gates. (C-D) Absolute numbers of (C) m/chDCs and 
(D) cDCs in the brain and spleen of EMCV-infected and Flt3L-treated, EMCV-infected 
as gated in (A and B). Data are mean ± SEM pooled from 2 independent experiments, 



































































































































Figure 4.7: CD11c-cre+/- iDTA+/- mice treated with Flt3L and infected with EMCV 
demonstrate comparable CNS Treg expansion to EMCV+Flt3L-treated CD11c-cre-/- 
iDTA+/- mice. (A-B) Representative flow cytometry plots of (A) CNS Tregs and (B) 
splenic Tregs (CD45hiTCRβ+CD4+FoxP3+) in the brain and spleen of EMCV-infected 
and Flt3L-treated, EMCV-infected CD11c-cre-/- iDTA+/- and CD11c-cre+/- iDTA+/- mice. 
Parent gate is live, size, single, CD45hi TCRβ+ cells. Numbers are frequencies of parent 
gates. (C-D) Absolute numbers of (C) CNS Tregs and (D) splenic Tregs in the brain and 
spleen of EMCV-infected and Flt3L-treated, EMCV-infected as gated in (A and B). Data 
are mean ± SEM pooled from 2 independent experiments, n=2-3 mice per group. 


























































































































Figure 4.8: m/chDCs, but not splenic cDCs, from CD11c-Cre iYFP mice 
demonstrate heterogeneous expression of YFP during EMCV infection. 
Representative flow cytometry plots of m/chDCs and cDCs (CD45hiB220-
CD11c+MHCII+) in the brain and spleen of naïve and EMCV-infected CD11c-cre+/- 
iYFP+/- mice. Parent gate is live, size, single, CD45hiB220- cells. Numbers are 
frequencies of parent gates. YFP expression is gated on CD11c-Cre-/- iYFP+/- mice (gray 





























































Figure 4.9: m/chDCs are comprised of three subsets, separable by IRF8 and FcRγ 
expression. Representative flow cytometry plots of m/chDCs (CD45hiB220-
CD11c+MHCII+) in the brain of naïve and EMCV-infected WT mice. Parent gate is live, 
size, single, CD45hi B220- cells. Numbers are frequencies of parent gates. Representative 





















































Chapter V. Discussion 
1. Results Summary 
Tregs are known to accumulate in the CNS during infection, inflammation and 
injury however they had been superficially studied, likely due to difficulty in isolating 
this rare population, as well as difficulty in differentiating contaminating, circulating 
Tregs from bona fide, CNS-infiltrating cells. Moreover, transcriptomic analysis of CNS 
Tregs had not been performed previously, possibly because older gene expression 
analysis formats, such as microarray analysis, required RNA concentrations that were 
unfeasible to obtain from CNS Tregs. However, recent improvements in RNA isolation 
and amplification protocols allow the purification of RNA from rare cell populations. 
Therefore, we overcame these difficulties by blood-labeling circulating cells with 
fluorescently conjugated antibodies, which allowed us to distinguish contaminating, 
circulating Tregs from bona fide, CNS-infiltrating cells. Moreover, we optimized 
techniques to isolate RNA from CNS Tregs and CNS Tcons by magnetic bead separation, 
which allowed us to evaluate the gene expression of CNS Tregs for the first time.  
Using these methods, in conjunction with a safe viral model of CNS infection—
EMCV—we characterize the localization, origin, mechanism of accumulation and 
molecular mechanisms underlying the function of Tregs that enter the CNS during viral 
infection.  We observe that EMCV results in lethal hind limb paralysis, CNS tissue 
pathology and a corresponding accumulation of leukocytes in the infected mouse brain, 
including a specific accumulation of Tregs in the CNS. This specific increase of Tregs 
within the infected CNS is reminiscent of tissue-specific enrichment of Tregs within the 
VAT (35) and injured muscle (160). We show that CNS Tregs are nTregs that 
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accumulate due to recruitment to and division within the infected CNS in a lymph-node 
independent manner. Tregs are CNS tissue protective during EMCV infection and confer 
this function within a unique niche—the CSF. Surprisingly, CNS Tregs display marked 
similarity to CNS Tcons, and transcriptomic analysis reveals an unexpected gene cluster, 
suggesting a molecular phenotype shared in T cells entering inflamed tissues.  
Additionally, we find that CNS Tregs can be artificially enhanced during EMCV 
infection by co-treatment with Flt3L, a DC hematopoietin and commonly used adjuvant. 
This effect is independent of Flt3 receptor expression on Tregs, implicating an indirect 
role for a Flt3L-dependent population, like DCs, in mediating enhanced CNS Treg 
expansion during Flt3L+EMCV co-treatment. In an effort to ablate meningeal/choroid 
plexus DCs to determine if they are required for enhanced CNS Treg accumulation 
during Flt3L+EMCV treatment infection, we determined a previously unappreciated 
heterogeneity in m/chDCs. Whereas m/chDCs were previously considered to be a 
homogeneous, CD45hiB220-CD11c+MHCII+ population, we have found them to contain 
three subsets, distinguishable by IRF8 and FcRγ expression. 
 
2. The potential for CNS Treg and neuronal cross-talk at the CSF barrier 
EMCV infection induces CNS disease, demonstrated by hind limb paralysis and 
CNS tissue pathology in regions that control voluntary muscle contraction and correlated 
with leukocyte accumulation near regions of CNS tissue pathology in the infected brain 
and spinal cord. T cells, including Tregs and Tcons, are among leukocytes that 
accumulate significantly in the infected CNS. Among T cells, a specific increase of Tregs 
inside the EMCV-infected CNS occurs. While both Tregs and Tcons accumulate in the 
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infected CNS, they are distinct functionally and spatially. That is, Tregs are CNS tissue 
protective during EMCV infection (Figure 3.6.B-C), while bulk T cells, including Tcons 
and CD8+ T cells, exacerbate paralysis (Table 3.1). The tissue protective function of 
Tregs during EMCV infection is not surprising, given other published studies, such as the 
study by Cervantes-Barragan et. al. (197) that showed that Treg depletion during MHV 
infection exacerbates leukocyte infiltration into the CNS and aggravates CNS 
inflammation. What is surprising is the distinct compartmentalization of CNS Tregs. That 
is, we show that CNS Tregs are retained within a unique niche—the cerebrospinal fluid—
while CNS Tcons pass through the cerebrospinal fluid and penetrate the brain 
parenchyma.  
  To our knowledge, ours is the first published study to show conclusively that 
Tregs are restricted to a unique niche during CNS viral infection—the CSF. Other studies 
have hinted at the perivascular retention of bulk CD4+ T cells and FoxP3+ CD4+ Tregs, 
though none have examined the perivascular accumulation of Tregs by microscopy or the 
presence of Tregs in the CSF harvested directed from animals. For instance, elegant 
intravital microscopy experiments have shown that during EAE, CD8+ T cells traffic 
beyond the cerebral vasculature into the brain parenchyma while CD4+ T cells are 
maintained in a restricted area around the vasculature (288). However, FoxP3+ cells 
within CD4+ T cells were not evaluated in this study. Another study demonstrated that 
FoxP3+ Tregs appear around the lateral ventricle (a reservoir of CSF) during ischemia 
(200), and a third study demonstrated apparent perivascular accumulation of Tregs during 
infarct or stroke (202). Moreover, analysis of patients with relapsing-remitting multiple 
sclerosis (RR-MS) revealed a dramatic enrichment of FoxP3+ cells within the CSF but 
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not within the peripheral blood (289). Despite the increase of Tregs within the CSF of 
RR-MS patients, FoxP3+ cells are rare within intracerebral MS lesions, indicating that 
few, if any, Tregs are capable of penetrating the inflamed parenchyma (201)). Together 
these data indicate that an unknown mechanism must prevent Treg entry, while 
promoting Tcon entry, into the injured and infected brain parenchyma of mice and 
humans.  
One explanation for the distinct compartmentalization of Tregs within the CSF is 
that only “activated” cells are capable of crossing the glia limitans into the brain 
parenchyma (290, 291). One major distinction between CNS Tcons and CNS Tregs is 
CNS Tcon production of IFN-γ and expression of CD40L, suggesting a higher activation 
state in CNS Tcons compared to CNS Tregs. It is possible, then, that CNS Tcon IFN-γ 
specifically alters the glia limitans or cells proximal to the glia limitans, such as 
perivascular macrophages, to enhance the exclusive migration of CNS Tcons into the 
brain parenchyma. These data suggest that targeting T cell activation could 
therapeutically prohibit or promote T cell entry into the infected CNS.  
The cerebrospinal fluid (CSF), which houses CNS Tregs, is a confined niche 
between the blood and the brain parenchyma, which is separate from both. The CSF is an 
interesting compartment for several reasons. In addition to keeping the brain at neutral 
buoyancy and buffering the CNS from physical shock, the CSF regulates the 
concentration of neuroendocrine factors within, and flushes metabolic waste, from the 
CNS (292). As such, the CSF is enriched for CNS-specific molecules including CNS 
antigens (293) and neurotrophic factors such as IGF, BDNF, NGF and GDNF (192, 294, 
295). Additionally, because Nestin+ cerebral neural progenitor cells expose their apical 
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domains to the CSF of the lateral ventricle (191, 192), they are subject to regulation by 
molecules carried in the CSF. Thus, cells infiltrating the CSF are subject to regulation by 
CSF-specific molecules and can conversely influence the homeostasis of the CNS by 
secreting molecules into the CSF. In support, IGF is known to prompt the proliferation of 
Tregs (296, 297). Furthermore, migrating neural progenitors proximal to the lateral 
ventricle express IL-10r1, and IL-10 treatment arrests these progenitors in an 
undifferentiated state (298, 299). Because we show that CSF-restricted CNS Tregs highly 
express IL-10 (Figure 3.11.A and 3.17.A), their potential effect on neurogenesis during 
viral infection is worth further investigation. 
 
3. Does lymph node-independent CNS Treg accumulation during viral infection 
represent a non-canonical mechanism of accumulation? 
CNS Tregs originate from thymus-derived nTregs and are recruited to the CSF in 
the absence of lymph nodes, after which they proliferate further in situ. These data have 
several important implications. First, while pTreg conversion occurs at mucosal sites that 
maintain constant contact with foreign antigen, pTreg conversion does not occur in the 
CNS even during viral infection (Figure 3.9A). These data strongly suggest that CNS 
Tregs arise from thymic nTregs because 1) pTreg conversion does not occur or is rare in 
the virally infected CNS, 2) Tregs are predominantly Helios+ (Figure 3.10), indicative of 
an nTreg origin and 3) there are few Tregs in naïve CNS tissue, suggesting that Tregs that 
accumulate in the infected CNS must arise in the periphery and enter the CNS. Thymic 
nTregs predominantly recognize self antigen (50, 300), meaning that if CNS Tregs are 
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antigen-dependent, they are likely responding to self-antigens. However, where they 
encounter these antigens is unclear.  
Traditionally, T cells are thought to encounter their cognate antigen within 
peripheral lymph nodes, which initiates T cell priming and proliferation. This has been 
demonstrated by elegant intravital microscopy experiments, which show that T cells enter 
the lymph node through high endothelial venules, where they are greeted by antigen-
loaded, mature DCs, and undergo priming through three successive stages (245). The first 
phase is characterized by multiple short encounters with DCs, followed by a second 
phase of long-lasting, stable interactions with DCs, correlating with T cell cytokine 
production, and culminating in a third phase of high motility and rapid proliferation (245, 
301). The lymph node-independent accumulation of CNS T cells during EMCV infection 
is contradictory to the traditional view of T cell priming in the draining lymph node, 
which has been observed in numerous models, including during spontaneous EAE 
induced in myelin basic protein (MBP) TCR-transgenic mice, in which MBP-specific T 
cells are found in the draining cervical lymph nodes (dcLNs) in significant numbers in 
pre-clinical EAE and their rapid decline in the dcLN is associated with a significant 
increase of MBP-specific cells in the CNS during symptomatic EAE (302).  
Intriguingly, the requirement for peripheral lymph nodes in the trafficking of 
nTregs to any tissue site is limited and rather appears to be presumed based on paradigms 
of T cell biology. That is, only two studies could be found that demonstrate a requirement 
for lymph nodes in priming of tissue Tregs. One study demonstrated that Helios+ Tregs 
(i.e. nTregs) are capable of accumulating in the gut in lymphotoxin alpha-deficient mice 
(303). A second study showed that Treg accumulation in the wounded skin is 
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significantly impaired in mice treated with FTY720, which blocks lymphocyte egress 
from the lymph node. These data suggested that these Tregs are primed in the lymph 
node prior to entry into the wounded skin. However, it is unknown if Tregs that 
accumulate in the wounded skin are thymus-derived or converted from CD4+FoxP3- T 
cells. Therefore, it is unclear if nTreg priming regularly occurs in the lymph node, as the 
T cell paradigm suggests, or if “non-traditional” routes of priming are commonplace for 
Tregs. Indeed, the constitutive, activated status of Tregs, demonstrated by their uniform 
high expression of CD44 (a receptor for hyaluronic acid that is a quintessential T cell 
activation marker) (data not shown and (304)), suggests that Tregs may not need to be 
primed or activated in traditional lymphoid structures in order to enter tissue sites.  
It is formally possible that our data suggests Tregs are primed in other lymphoid 
tissues such as the spleen, which has been observed in CD8+ T cell priming during 
influenza infection (305). However, we deem this to be unlikely considering T cell 
priming is usually associated with a burst in T cell proliferation and we see no increase in 
splenic Treg, Tcon or CD8+ T cell Ki67 expression either between naïve and infected 
mice or between circulating and splenic Tregs from EMCV-infected mice. To formally 
exclude this possibility, BrdU or EdU incorporation should be measured to determine if 
peripheral T cells demonstrate a burst in proliferation associated with priming. To 
conclusively demonstrate that CNS Tregs are not primed in the spleen, CNS Treg 
expansion could be evaluated in splenectomized mice infected with EMCV.  
It is also formally possible that CNS Treg accumulation relies on tertiary 
lymphoid tissues (TLTs) in the infected CNS, which would be unaffected by 
lymphotoxin alpha deficiency (306). TLT-dependent T cell accumulation in infected or 
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inflamed mucosal sites has been observed in multiple models (307). However, we believe 
that TLT-dependent T cell accumulation is unlikely in the EMCV-infected CNS 
considering 1) TLTs are leukocyte aggregates that form in chronically inflamed tissue, 
usually in the context of autoimmunity (307), whereas our disease model is acute and 
does not rely on immunization with self peptides and 2) TLTs generally involve a 
substantial B cell accumulation (308, 309) whereas we see little to no B cell participation 
in the EMCV-infected CNS. In fact, B cells decrease in the CNS during EMCV infection 
(Figure 3.2). Therefore, we consider that our data suggests an alternate, lymph-node 
independent mechanism of T cell entry into the infected CNS. 
 
4. CNS T cells share a gene signature with T cells entering inflamed tissue sites, but 
uniquely express the thyroxine binding protein, transthyretin 
Although CNS Tregs maintain their FoxP3 expression and core Treg gene 
signature, it was surprising to find global similarity between CNS Tregs and Tcons, a 
common gene signature that separates CNS T cells from their peripheral counterparts. 
This similarity was identified and supported by three independent analyses: PCA, 
unsupervised gene expression analysis, and supervised gene expression analysis. To our 
knowledge, this is the first published transcriptomic comparison of Tregs and Tcons 
entering the same infected or inflamed tissue. Other studies have indicated that Tregs can 
specialize into subsets analogous to Tcon subsets, and that the transcription factors 
critical to orchestrating Tcon differentiation also influence the polarization of Tregs. For 
example, the transcription factors T-bet, GATA3, STAT3, and Bcl6 mediate Tcon 
polarization into Th1, Th2, Th17 and Tfh subsets, respectively (310-313). These same 
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transcription factors can be utilized by Tregs and, in some cases, the deletion of these 
transcription factors impairs the capacity of Tregs to antagonize the corresponding Tcon 
counterparts (311-313). We observe a similar phenomenon in our gene expression data. 
That is, CNS Tregs and CNS Tcons adopt overlapping gene signatures upon entry into 
the same infected niche. In fact, both CNS Tregs and CNS Tcons appear to up-regulate 
Tbet and IRF8 compared to their peripheral counterparts, though only CNS Tcons 
express and produce IFN-γ. Therefore, the common gene signature of CNS Tregs and 
CNS Tcons may not only represent a common response to the infected CNS, but may 
also indicate the antagonism of CNS Tcon Th1 response by CNS Tregs. This could be 
determined conclusively by comparing CNS pathology and CNS immune response in 
EMCV-infected, Dtx-treated, Foxp3-DTR mice receiving adoptive transfer of Tbet-
deficient Tregs, to that of EMCV-infected, Dtx-treated, Foxp3-DTR mice receiving 
adoptive transfer of WT Tregs. 
By evaluating the genes differentially expressed between CNS T cells compared 
to peripheral T cells, we also assessed whether the tissue-specific modification of CNS T 
cell gene expression was due to infection, injury, or both. That is, by comparing the gene 
signature of CNS T cells to the top genes up-regulated by injured muscle T cells and 
VAT T cells, we determined that CNS T cells share a core signature with T cells isolated 
from inflamed sites, suggesting that these genes are induced commonly by inflammation 
even when mediated by distinct mechanisms in disparate mouse models. These shared 
genes unveil unappreciated response elements, including homing molecules, such as 
CCR5, corticosteroid response elements, and Type I and II IFN response genes. 
Interestingly, the induction of these pathways is specific to the infected CNS despite 
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systemic IFN production early during infection (data not shown), indicating that the 
signature is not consequence of systemic type I IFN response. Coupled with the fact that 
muscle T cells and VAT T cells share these IFN-stimulated genes, these data indicate that 
sterile injury and inflammation may drive a common gene signature in cells infiltrating 
inflamed sites.  
One glucocorticoid/hormone response gene that is highly up-regulated in CNS 
Tregs and CNS Tcons but not expressed in other tissue-specific T cells is transthyretin, a 
thyroxine binding protein. The functional relevance of the expression of this molecule 
within CNS T cells deserves further study for several reasons. Transthyretin is a serum 
and cerebrospinal fluid carrier of the thyroid hormone, thyroxine (T4), and of retinol 
binding protein bound to retinol. Ttr in serum is produced by the liver and kidney while 
Ttr in the CSF is produced by the choroid plexus, however there are no published studies 
showing Ttr production by lymphocytes. Interestingly, Ttr is responsible for trafficking 
the precursor to retinoic acid, retinol, into the CNS, which is crucial for induction of 
neurogenesis and control of neuronal patterning (314). To elaborate, Ttr-deficient mice 
exhibit learning and memory deficits that can be reversed by retinoic acid treatment 
(315). Retinoic acid, along with its role in neuronal development, is also anti-
inflammatory, suppressing inflammatory cytokine production in astrocytes (316). Not 
only is retinoic acid anti-inflammatory within the CNS, but it also plays important roles 
within the systemic immune system (317). Notably, retinoic acid enhances natural Treg 
recruitment to the gut (318). The other protein carried by Ttr, T4, also has important roles 
in neuronal health and the immune system. T4 mediates oligodendrocyte precursor 
differentiation into myelinating oligodendrocytes, enhancing remyelination after myelin 
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sheet damage (319). Together this implies and Ttr produced by CNS-infiltrating T cells 
during EMCV infection may help traffic anti-inflammatory and neuroprotective T4 and 
retinoic acid to the site of infection. For further study, Ttr-deficient T cells (Jackson, 
cryopreserved) could be transferred into Rag1-/- mice prior to infection and effects on 
CNS tissue pathology and survival could be monitored. Alternatively, to determine a 
Treg-specific role for Ttr production, CNS pathology and CNS immune response of 
EMCV-infected, Dtx-treated, Foxp3-DTR mice receiving adoptive transfer of Ttr-
deficient Tregs could be compared to those receiving adoptive transfer of WT Tregs. 
 
5. M/chDCs are a heterogeneous population with possible roles in mediating CNS 
Treg increase during infection, providing a tool for manipulating Tregs during CNS 
disease 
 We determined that the increase of both m/chDCs and CNS Tregs during EMCV 
infection can be artificially enhanced with injection of the DC-poietin, Flt3L. While 
Ftl3L treatment alone can promote the increase of m/chDCs, Flt3L treatment alone does 
not result in CNS Treg increase, indicating that infection is requisite the enhanced CNS 
Treg increase observed during Flt3L+EMCV treatment. The increase of CNS Tregs 
during EMCV and Flt3L co-treatment is independent of Flt3 expression on Tregs, 
strongly supporting the role of dendritic cells in augmenting CNS Treg increase during 
EMCV+Flt3L treatment. The ability to manipulate CNS Tregs through Flt3L provides a 
possible route for manipulating Treg populations during CNS pathology, a potential 
therapeutic that has not yet been tested.  
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In order to conclusively prove the link between m/chDCs and CNS Tregs, we 
attempted to ablate DCs using CD11c-Cre iDTA mice and determine the corresponding 
effect on CNS Tregs. However, m/chDCs were unaffected in infected CD11c-Cre iDTA 
mice, leading us to hypothesize that m/chDCs were a heterogeneous population. Indeed, 
m/chDCs consist of three subsets, separable by IRF8 and FcRγ. Many questions remain 
about the three m/chDCs subsets.  
 First, the identification of the progenitors to each of these three subsets is worth 
study. While m/chDCs have been shown to arise from pre-cDCs in the steady state (193), 
it is unclear if pre-cDCs equally give rise to each of these three subsets or if they only 
contribute to one subset. It is possible that the FcRγ+ IRF8lo m/chDCs derive from 
monocytes, or monocytic precursors, as has been postulated about lamina propria 
EsamloCD11b+ DCs (320). Analyzing the composition of m/chDCs after adoptive transfer 
of purified MDPs, CDPs, and pre-cDCs in congenic recipients would tell for certain. 
Moreover, it is unclear if the same progenitors replenish the m/chDC niche in naïve and 
EMCV infected mice. Similar adoptive transfer experiments into congenic recipients 
prior to infection would reveal whether EMCV infection drives alternate routes of 
hematopoiesis. These questions are relevant because they would allow more precise 
manipulations of each of these three m/chDC subsets. It is also possible that the FcRγ- 
IRF8- portion of m/chDCs precedes either, or both, of the FcRγ+ IRF8lo and FcRγ- IRF8+ 
m/chDC subsets. In order to test this, we would harvest the FcRγ- IRF8- m/chDCs, 




 Is it also of interest whether these distinct m/chDC subsets differentially mediate 
T cell responses, as is known about splenic cDC subsets. As a hint to the answer of this 
question, it is of interest whether these m/chDC subsets localize to distinct regions of the 
CNS, and whether their localization changes during infection. That is, do the FcRγ- IRF8+ 
m/chDCs preferentially localize to the choroid plexus while FcRγ+ IRF8lo m/chDCs 
localize in the lepto-meningeal space? Do any of the m/chDC subsets circulate through 
the CSF? Do they traffic into the brain parenchyma during infection? Discrete 
localization may indicate a preferential interaction with T cell subsets that localize to 
distinct compartments of the CNS, such as Tregs compartmentalized within the CSF. 
These questions could be answered with immunofluorescence microscopy and flow 
cytometry on CSF harvested directly from the cisterna magna, which is now a common 
technique for our lab. To further study the role of these three m/chDC subsets during 
CNS viral infection, mouse models deficient in characteristic DC-specific transcription 
factors could be evaluated with and without infection. For example, previous studies have 
made use of IRF4-/- mice, which lack CD11c+ DCs, Id2-/- mice, which lack CD8+ DCs, 
IRF8-/- mice, which also lack CD8+ DCs, and Batf3-/- mice, which lack CD8+ and CD103+ 
tissue DCs, to assess the function of each of these discrete DC subsets. One thing to note 
is that IRF8 deficiency affects a number of lineages, including Th1 T cells, so while this 
model is most applicable to our study of the IRF8+ m/chDCs, it may require adoptive 
transfer of WT, congenic T cells in order to evaluate natural T cell response.  
Additionally, in order to more conclusively determine the division of labor 
between these three subsets, it would be better to continue the study of m/chDCs in a 
disease model with known antigenic epitopes or known etiology. For example, it may be 
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better to use Theiler's Murine Encephalomyelitis Virus (TMEV), a relative of EMCV that 
is commonly used as a model of demyelinating disease, to study DC-dependent, CNS T 
cell response. The use of this model is preferable because there are tetramers and 
dextramers available, specific for the MHCI-restricted (CD8+ T cell) (321) and MHCII-
restricted (CD4+ T cell) antigenic viral epitopes (322).  Therefore, tetramer and dextramer 
staining could be used to evaluate antigen-specific T cell responses in TMEV-infected 
mice, deficient in stereotypical DC transcription factors (described above).   
 Lastly, it is worth studying whether MHCII expression is required for CNS Treg 
expansion during EMCV infection. Unfortunately, due to the heterogeneous expression 
of CD11c-Cre in m/chDCs, we cannot use CD11c-Cre MHCIIfl/fl mice to perform DC-
specific deletion of MHCII. However, we could start by assessing CNS Treg and CNS 
Tcon expansion in infected, H2-Ab1-/- (MHCII-deficient mice), which completely lack 
MHCII. These mice exhibit decreased numbers of CD4 T cells due to lack of selection on 
MHCII (323, 324), therefore, use of these mice would require adoptive transfer of bulk, 
congenic splenocytes into H2-Ab1-/- and H2-Ab1+/+ mice, one day prior to infection.  
In summary, our studies clarify the distinct compartmentalization, lymph node-
independent accumulation, and inflammation-associated gene signature of CNS Tregs. 
Most importantly, these findings have implications for neuro-immune cross-talk, 
particularly at the interface of the CSF and brain parenchyma. That is, neural progenitors 
extend their apical domains into the CSF of the ventricles, and therefore may be subject 
to regulation by CSF-borne Tregs. Further, while many studies have focused on the 
differences between tissue Treg subsets, we find a core set of genes expressed by CNS 
Tregs, injured muscle Tregs and VAT Tregs. These data suggest that common, 
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inflammation driven mechanisms may be used for therapeutic manipulation of these cells.  
Finally, we provide a foundation for the study of the origin, function, and localization of 
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Appendix: Generating a recombinant EMCV expressing a FLAG-tagged surrogate 
antigen 
1. Introduction and Approach 
EMCV represents a safe picornavirus model of CNS infection via natural route 
(239). However, two issues have hampered the thorough investigation of viral tropism 
and virus-specific immune response: a) the difficulty of inserting a traceable marker into 
EMCV because the small genome of EMCV resists genetic manipulation, and b) lack of 
defined antigenic EMCV epitope to allow study of antigen-specific T cell responses to 
EMCV. We attempted to overcome these problems by engineering a novel EMCV virus 
expressing a FLAG tag and surrogate antigen (FLAG-OVA1-OVA2).  
The EMCV genome is a small genome of 7.8kb, encoding a long polypeptide that 
is processed by viral proteases after translation (239). Unpublished data from our 
collaborator, Dr. Racaniello, and from the Palmenberg lab suggests that attempts to make 
significant modifications to EMCV have been thwarted by the virus “kicking out” large 
inserted fragments through an unknown mechanism. However, the EMCV genome has 
been found to tolerate insertion of short sequences up to 470 nucleotides (nts) at one site 
(234). This site, (VP1)-T3C-(2A), occurs between VP1 and 2A genes of EMCV (Figure 
6.1.A) and encodes VLMLESPNAL, which is a target of viral 3C protease (TC3), 
necessary for viral polypeptide processing after protein synthesis. We employed this site 
to introduce a 453 nt insertion encoding a FLAG-OVA1-OVA2 fusion protein. We 
designed this insertion with the following rationale: the FLAG tag is a short sequence that 
would allow detection of viral infection by staining with anti-FLAG antibody. OVA1 
encodes an 8-mer peptide, SIINFEKL, which is an antigenic epitope of ovalbumin that is 
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presented to CD8+ T cells in the context of H2-Kb MHC I (325, 326). As such, expression 
of OVA1 would allow monitoring of OVA-specific CD8+ T cell response using T cells 
from OT-I T cell receptor transgenic (TCR-Tg) mice (327). OVA2 encodes a 17-mer 
peptide, ISQAVHAAHAEINEAGR (328, 329), which is the antigenic epitope of 
ovalbumin that is presented  to CD4+ T cells in the context of I-Ab and I-Ad MHC II 
molecules. Therefore, we aimed to use expression of OVA2 to monitor of OVA-specific 
CD4+ T cell response using T cells from OT-II or DO11.10 TCR-Tg mice (330). To 
ensure viral processing of the surrogate antigens, we added a 24-nt sequence encoding 




We engineered EMCV-FLAG-OVA (EFO) using a cloning scheme adapted from 
the Racaniello lab (J. Morrison, thesis). Broadly, first we subcloned the segment of the 
EMCV genome between SpeI and SacI (Figure 6.1.A) into pBluescript SK II (+) and 
called this pBS-EMCV (Figure 6.1.B). Then we engineered our desired FLAG-tagged, 
T3c-flanked OVA insert using an OVA1-OVA2-containing plasmid (Nussenzweig lab) 
as template and synthetic oligos containing N-terminal FLAG tag and N- and C-terminal 
T3c sites as primers. Next, we flanked our T3c-FLAG-OVA-T3c insert with regions of 
homology to EMCV using primer extension and overlap PCR, from AccI to T3c on the 5’ 
end of the insert and from T3c to SacI on the 3’ end of the insert (Figure 6.1.C). We 
digested the resultant AccI—T3c-FLAG-OVA-T3c—SacI insert with AccI and SacI and 
ligated the purified insert with pBS-EMCV that had been digested with the same 
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enzymes. We called the resultant vector pBS-EMCV-FLAG-OVA. Finally, we digested 
pBS-EMCV-FLAG-OVA with SpeI and SacI and ligated the purified insert with pEC9 
that had been digested with the same enzymes (Figure 6.2). The faithful construction of 
pEMCV-FLAG-OVA (pEFO) was confirmed by Sanger sequencing.  
Generating virus  
In order to generate virus, we linearized 10μg pEFO and 10μg pEC9 (pEMCV) 
with SalI (Figure 6.3), ethanol precipitated the linearized DNA, and in vitro-transcribed 
2μg DNA using a T7 RNA polymerase kit (NEB, E2040S). In vitro-transcribed RNA was 
confirmed on an agarose gel (not shown), and the entire reaction containing both RNA 
and DNA was transfected into two wells of a 6-well plate of 70-80% confluent HeLa 
cells using DEAE-dextran, as described by Dr. Racaniello and in (331).  
During transfection, we observed that cytopathic effect (CPE) was visible in 
EMCV and EFO-transfected cells, 48 hours post-transfection, suggesting virus was 
generated (not shown). To confirm, we collected cells and cell supernatants from 
transfected cells at various times after transfection, frozen and thawed collection tubes 
three times to lyse cells and release virions, pelleted cell debris, and either submitted the 
supernatant to plaque assays, or used the supernatant to harvest RNA by TRIZol and 
generate cDNA. Plaque assays demonstrated that productive EMCV and EFO viruses 
were generated, however, the viral titer of EFO was significantly lower than that of the 
unmodified virus (Figure 6.4). That is, viral titer of EFO generated by transfection was 
1X105 pfu/mL (Figure 6.4). In contrast, transfection with EC9 RNA prepared the same 
way yielded 9X109 pfu/mL (Figure 6.4). These data suggest that EMCV virulence is 
dramatically affected by insertion of exogenous sequences, such as FLAG-OVA. 
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Evaluating EFO stability 
To test the stability of EFO, we collected RNA, synthesized cDNA and performed 
PCR on viral sequences. Using primers that flank the insertion (Figure 6.5.A), we were 
surprised to find that the FLAG-OVA insert was lost sporadically, as early 24 hours after 
transfection (Figure 6.5.B). This phenomenon has been documented in bacterial hosts 
transformed with EMCV plasmids and is attributed to the G-C rich regions of the EMCV 
genome (221). During transfection, this would likely occur during RNA synthesis. The 
full mechanism of EMCV RNA synthesis is not well understood and is controversial, so 
it is not clear how EFO would lose the FLAG-OVA insert. This effect was carried over in 
virus passaged through cells (Figure 6.5.B, lanes 8-11), indicating that the FLAG-OVA 
insert is unstable after passage. 
To determine if the FLAG-OVA insert was present in any of viruses after 
transfection and reinfection, we performed PCR on viral cDNA using a primer pair 
within the FLAG-OVA insertion (Figure 6.5.A). We reasoned that there would be no 
competition for this binding site between EFO and EFO that had lost the FLAG-OVA 
insert, so even rare EFO sequences would be detected by this reaction. We found that the 
insert could be detected, at least at a low level, even after passage (Figure 6.5.C). This 
suggests that EMCV-FLAG-OVA could be maintained but that there is competition 
between EFO and EFO that had lost the insert. Unfortunately, if one copy of EFO was to 
lose the FLAG-OVA insert, the reverted virus would easily out-compete virus that 
continued to express the FLAG-OVA due to the 105-fold increase in virulence in the 
unmodified virus compared to EFO.  
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In sum, we generated productive EFO virus but virulence is impaired by the 




Because EFO appears to lose our desired insert during passaging, further use of 
this virus will require some adaption. It is possible that virus could be generated fresh by 
transfection, prior to each experiment. However, this task is not trivial for the following 
reasons. First, transfection yields low volume and low titer of EFO. We perform our in 
vivo infections with 107 pfu EMCV in order to observe a robust immune response. 
Therefore, in order to generate enough virus for one infection, we would have to scale up 
the transfection considerably, starting with large volumes and high concentrations of 
pEFO. Generating large quantities of pEFO DNA is difficult, however, because 
competent bacteria must be freshly transformed and grown for only short periods of time 
in order to maintain genomic stability of pEFO. Each new transformation generates very 
little plasmid DNA, preventing production of pEFO at high concentrations. Second, the 
cost of generating enough virus by transfection to infect one mouse is significant, due to 
the costs of the SalI enzyme needed for linearization and the T7 polymerase kit needed 
for in vitro transcription. Lastly, the feasibility of generating virus freshly from in vitro 
transfection for in vivo inoculation is based on the assumption that we will observe a 
robust CNS immune response after inoculation with 107 pfu EFO. However, EFO will 
likely be less virulent in vivo, judging by its diminished capacity to replicate in vitro. In 
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conclusion, while we generated DNA containing EFO, in vivo infections with this virus 
in its current form are unfeasible.  
 There are several alternatives that allow us to continue our proposed idea to 
generate EFO. First, pEFO can be grown in Stbl2 competent cells (Invitrogen), which are 
specifically designed to clone unstable, retroviral inserts due to a mutation in DNA 
gyrase. Alternatively, pEFO can be directly transfected into OST7-1 cells (332), which 
constitutively express T7 RNA polymerase and allow for immediate production of virus 
without the intermediate step of synthesizing viral RNA. These alternatives would allow 
us to increase our yields of pEFO, however, they would not necessarily increase the 
stability or the virulence of the resulting virus. In order to increase the stability or 
virulence of our recombinant virus, EFO can be redesigned so that it expresses only one 
antigenic epitope of ovalbumin at a time. That is, two viruses could be generated: 
EMCV-FLAG-OVA1 and an EMCV-FLAG-OVA2. This may prove more effective, as 












Figure 6.1: Schematic of pEC9 subcloning and generation of FLAG-OVA insert. (A) 
Intact pEC9 (EMCV) was used to subclone a segment of the EMCV genome between 
SpeI and SacI into pBluescript SK II (+). (B) We called this pBS-EMCV (C). The FLAG-
OVA insert was generated, digested with AccI and SacI, gel-purified and ligated with 
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Figure 6.2: Schematic representation illustrates how ligation of SalI- and SacI-
digested pBS-EMCV-FLAG-OVA with SalI- and SacI-digested pEC9 generates 
pEMCV-FLAG-OVA. Schematic of FLAG-OVA insertion into pEC9 after double 
digestion with SalI and SacI and ligation with pEC9  that had been digested with the 




































Figure 6.3: Single digest with SalI linearizes pEMCV and pEFO. Agarose gel 
showing lane 2: undigested pEMCV; lane 3: undigested pEFO; lane 4: pEMCV digested 
with SalI, expected length 10.9k; lane 5: pEFO digested with SalI, expected length 
11.4kb; lane 6: pEMCV double digested with SalI and SacI, expected lengths 4116bp 
and 6768bp, and lane 7: pEFO double digested with SalI and SacI, expected lengths 













































Figure 6.4: While productive EFO virus is generated after transfection, it is far less 
virulent than unmodified EMCV. Plaque assays showing viral titers in EMCV- and 
EFO-transfected HeLa cells (same supernatant as used for Figure 6.5, lane 7). Numbers 
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Figure 6.5: EFO loses FLAG-OVA insert after as early as 24 hours post-
transfection. (A) Schematic of PCR reactions designed to detect FLAG-OVA insert in 
EFO after transfection and infection. Primer Pair 1 flanks the insertion (expected lengths: 
766bp and 1244bp for EMCV and EFO, respectively), whereas Primer Pair 2 amplifies a 
region within the insert (expected length: 213bp for EFO only). (B) Agarose gel showing 
PCR products from PCR reaction using Primer Pair 1 on the following templates: (lanes 
2 and 3) EMCV and EFO cDNA generated from in vitro transcribed RNA, (lanes 4-7) 
separate wells of HeLa cells transfected with EFO whose entire contents were collected 
at various times after transfection and used to generate viral cDNA, and (lanes 8-11) 
separate wells of HeLa cells infected with EFO (MOI 1) whose entire contents were 
collected at various times after infection and used to generate viral cDNA. (C) As in B 
but using Primer Pair 2. Representative of one of two experiments.  
 
 
 
 
 
 
 
 
 
 214 
 
